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Abstract
Oxidative stress and inflammatory stress have been implicated as a cause of tissue
damage in multiple organ systems, leading to the development of chronic diseases such as
obesity, diabetes, hypertony and atherosclerosis. They are also recognized as major factors
contributing to the physiological process of aging. Previous studies have demonstrated that
dietary calcium regulates reactive oxygen species production (ROS) production in adipocytes in
vitro and in vivo, and inhibits adipocyte-derived inflammatory cytokine expression by
suppression of calcitriol. In addition, high calcium diets modulate energy metabolism and
partitioning between adipose tissue and muscle resulting in a decrease in fat storage and an
increase in fat oxidation in muscle. Providing calcium in form of dairy appears to cause greater
effects than supplemental calcium in both mice and humans, most likely mediated by additional
components in dairy products such as branched-chain amino acids (BCAA) and angiotensin
converting enzyme inhibitor (ACEi) peptides. In consideration of the multiple effects of dietary
calcium and other components of dairy on adipocyte and muscle metabolism, a high density
oligonucleotide microarray approach was used to identify common and differential pathways
related to energy metabolism, inflammation and oxidative stress in adipose and muscle tissue in
response to milk and milk components. In addition, considering the protective role of dietary
calcium against oxidative and inflammatory stress, which otherwise accelerate the process of
aging, a lifespan study in a mouse model of diet- induced obesity was conducted to evaluate the
effects of dietary calcium from both non-dairy and dairy sources on mouse lifespan and on
lifespan-related biomarkers. The results of this research confirm that calcium and BCAA
contribute to the alteration of energy partitioning between adipose tissue and muscle and provide
v

new evidence for calcium independent effects of BCAA and ACEi in energy metabolism and
inflammation. Further, present data demonstrate that milk diet attenuates adiposity, protects
against muscle loss and reduces oxidative and inflammatory stress. Although these did not alter
maximum lifespan, they significantly suppressed early mortality.
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Part One
Introduction

1

Elderly individuals (defined as the number of people over age 65) have been
increasing worldwide, both as an absolute number and as a proportion of the total, for the
past century. In the United States the number increased from 3.1 million in 1900 to 35.0
million in 2000, and according to the U.S. census Bureau projections this trend will continue
as the first Baby Boomers turning 65 in 2011. It is projected that the older population will
increase up to 72 million in 2030 and represent up to 20 percent of the total U.S. population.
This increase is also accompanied by changes in the age composition of the population. The
median population age, increased from 22.9 years in 1900 to 35.3 years in 2000, and
projected 39 years in 2030 (1). However, the changes in age structure of the population have
tremendous impact on families and society as it changes the number of working-age people
and creates challenges to provide long-term care for the elderly. Therefore, aging research
became an important and expanding area of science, with the goal not only to increase life
expectancy but also to understand the biological process of aging in order to optimize
„successful aging‟, defined as avoidance of disease and disability, maintenance of mental
and physical function, and continued engagement with life (2).
Oxidative stress and inflammatory stress have been implicated as major factors
causing the physiological process of aging as well as playing a role in the pathogenesis of
numerous chronic diseases which contribute to morbidity, disability and mortality of the
older population (3, 4). Accordingly, diverse lifespan models either reducing or increasing
their production have been developed to investigate the underlying molecular mechanisms
(5-8).
Over the past decade, the view of the adipose tissue has changed from a passive
storage site for energy to an active endocrine organ that secretes multiple hormones and
2

cytokines regulating energy, glucose and lipid metabolism (9-11). Adipose tissue is an
important contributor to reactive oxygen species (ROS) and inflammatory cytokine
production (12). Consequently, obesity, and particularly visceral obesity, is associated with a
chronic low-grade inflammation status, a principal causative factor to the development of
metabolic diseases (13-16).
Dietary calcium and other dairy components have been demonstrated to significantly
alter adipose metabolism and overall energy partitioning between muscle and adipose tissue
(17). Multiple studies, both in vitro and in vivo, have confirmed that dietary calcium reduces
adiposity, promotes lean tissue mass and decreases oxidative and inflammatory stress,
thereby reducing obesity risk and improving metabolic status (18-23). In addition, dairy
products have been shown to exert greater effects than supplemental calcium due to
additional components in dairy such as branched-chain amino acids (BCAA) and
angiotensin-converting enzyme inhibitory (ACEi) peptides (24, 25).
Therefore, considering the role of dietary calcium in modulating oxidative and
inflammatory stress and considering the role of additional dairy components on these
effects, the purpose of this research was as follows: a) to elucidate the common and
differential pathways related to energy metabolism, inflammation and oxidative stress in
adipose tissue and muscle in response to milk and milk components by using a high-density
oligonucleotide microarray approach; and b) to evaluate the effects of dietary calcium and
dairy on lifespan and on lifespan related biomarkers in an animal model of diet-induced
obesity.
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Part Two
Literature Review

7

2.1

Aging and lifespan

2.1.1 Overview
Aging is a diverse and complex process associated with variable phenotypes and
different rates of progression across species as well as within the same species. Accordingly,
to find a universal definition and a distinct cause is nearly impossible, and today‟s view that
aging is a multifactorial process has replaced earlier attempts to find a single explanation. In
general, aging causes a loss of efficiency of physiological functions and of the capacity to
maintain internal homeostasis. As a consequence the organism is less resistant to stress and
more susceptible to diseases, infections and cancer leading to death. Factors that influence
the individual‟s lifespan can be genetically or environmentally (1).
The term „senescence‟ is often interchangeably used with aging. Senescence refers to
the biological process resulting in death of the individual but is also used as „cellular
senescence‟ to describe the aging process at the cellular level (2).
Longevity is often used as synonym for life expectancy and includes two different
concepts; the maximal and mean lifespan (3).

2.1.2 Theories of aging
In order to understand the phenomenon of aging many theories have evolved to give
explanations for origin, occurrence, progression and consequences. With advances in
technology and new experimental methods, new ideas developed either replacing or
improving older theories or giving rise to new ideas. Today, there are more than 300 theories
counted and their classification can vary widely. While some authors group them on the
8

basis of history, others divide them into stochastic vs. programmed and evolutionary
theories (4). Further they can be grouped depending on the level of biological organization,
which is as evolutionary, molecular, cellular and systemic (1).
Meanwhile well accepted, theories should explain the four specific criteria of aging
suggested from Strehler in 1959 (5):
Universality: the phenomenon is part of a general aging process in all individuals of
a species
Intrinsicality: changes are due to the inherent instability of the system
Progressiveness: the onset of the changes is gradual and accumulative
Deleteriousness: the change should result in a decreased survival capacity of the old
organism
However, many of the older theories do not meet those criteria.
2.1.2.1

Evolutionary
Evolutionary theories focus on the force of natural selection which declines with age

(6). According to Darwin‟s theory that natural selection favors processes which increase
reproductive fitness, aging with increased rate of mortality and reduced capacity of
reproduction seems to be in contradiction to this theory (7).
Weissmann in 1891, was one of the first biologists shaping the evolutionary era of
aging. He believed that organisms must show a decline („wear and tear‟) analogous to that of
mechanical devices but also argued that there was a specific death mechanism designed by
natural selection to eliminate the old (8). However, he never indicated any precise
mechanisms and his ideas were criticized as illogical and inconsistent. Also the hypothesis
that aging and programmed death occurs to limit population size and to facilitate the
9

turnover of generations was confuted by the fact that natural death contributes only
negligibly to the mortality in a natural environment where extrinsic hazards such as famine
and predation predominates (9).
Further solutions to this enigma were suggested by Haldane in 1941, who proposed
that natural selection would have little force at late ages based on his observations of
Huntington Disease (10). Since this detrimental disease, caused by a single dominant gene
mutation, affects only individuals at later age (30-40 years old), carriers are able to
reproduce before death occurs and therefore are able to escape natural selection. Inspired by
this observation, Medawar expanded this idea to the „Mutation accumulation theory‟,
proposing that deleterious mutation with a late onset may accumulate in the population and,
since unopposed by natural selection, may cause pathology and senescence (1).
Williams focused specifically on the idea of trade-offs between reproductive fitness
and later survival which was later named as the „antagonistic pleiotropy‟ by Rose in 1982
(10). This idea suggests that genes that are beneficial during youth are actively favored by
natural selection, although they may have deleterious effect with age.
Related to the pleitropic gene hypothesis is also the „disposable soma theory‟,
originally proposed by Kirkwood 1977 (11). This theory predicts that the accumulation of
unrepaired somatic damage through life will cause senile degeneration and ultimately
deaths. Since somatic maintenance and reproduction are both energy-consuming processes
there must be a balance between both. Therefore, the optimal level of investment will
depend on the species‟ ecological niche. Species with high external mortality may benefit by
investing in rapid reproduction while species with low accidental mortality may profit by
investment in somatic repair and a longer life (8).
10

While evolutionary theories in general focus on the aging process of the whole
individual organism, the molecular and cellular theories take also different tissue specific
aging pattern into account (4). However, although the age-related decline of physiological
functions varies within an individual, many changes may not be important for longevity.
2.1.2.2

Molecular
Molecular theories provide mechanistic explanations for the pathological changes of

aging in tissues and cells by focusing on the damage occurring to macromolecules. The main
categories of molecular damage within a cell occurs to DNA, RNA , or proteins (12).
However, most of the theories have focused only on a single category of molecular damage.
For example, the „Somatic mutation theory‟ of Szilard in 1959 assumes that the elementary
step for the process of aging is an „aging hit‟ which destroys a chromosome of the somatic
cell with the consequence that all genes of that chromosome become inactive (13). These
„aging hits‟ are random events that accumulate with a constant rate throughout life. This will
result in a decreased number of functional somatic cells at a given age and the fraction of
surviving functional cells decreases with age at an accelerating rate. In addition, the rate of
hits is characteristic of the species and therefore responsible for the similar lifespan of
individuals within a species.
The „Gene regulation theory‟, proposed by Kanungo in 1970 (14), is based on the
concept of cellular differentiation due to regulation of gene activity. Kanungo postulated that
each organism undergoes phases of differentiation, growth, maturity and senescence, which
have a unique characteristic, duration and speed for each species. This linear order of phases
occurs due to sequential activation and repression of genes. Addition or deletion of one or
more genes in the sequence may also accelerate or decelerate the sequence in the new
11

species and thereby decrease or increase its life span. Thus this model offers an explanation
for the two important characteristic features of aging: the gradual decline in activity after
maturity and the specific life span of a species.
The „Dysdifferentiation hypothesis‟, based on work from Cutler (15), focuses on
impaired regulation of gene expression due to random molecular damage. This hypothesis
suggests that aging results from a natural instability of proper gene regulation with cells
drifting away from their proper state of differentiation towards dysdifferentiation. Thus,
longevity must result from mechanisms acting to stabilize the proper differentiated state of
cells. Cutler proposed that a common set of „longevity determinant genes‟ may exist in
mammalian species which control the expression and timing of the defense and protective
system acting against the unfavorable side reactions of normal and essential biological
processes. These regulatory processes, and not specific kinds of genes, would govern the
characteristic aging rate of species.
Other theories emphasize on the changes occurring in proteins. For instance, the
„error catastrophe theory‟, introduced 1963 by Orgel (16), suggested that errors leading to
reduced specificity of protein-synthesizing enzymes increase rapidly the error frequency of
proteins. These processes accumulate over the lifespan of the organism and may reach a
value at which necessary processes for the existence of cells becomes critical and therefore
may result in death. Accordingly, the ability of a cell to produce functional proteins depends
not only on the correct genetic background but also on the competence of the proteinsynthetic apparatus.
Strehler (5) developed his „Codon restriction theory‟ which is based on the principle
that the kinds of proteins synthesized by a cell are controlled by the set of code words a cell
12

can decode. The types of tRNA and aminoacyl-tRNA synthetases determine the kinds of
syntheses a cell will carry out and are different during cell growth, differentiation and aging.
They also vary in different tissues and therefore are responsible for the characteristic protein
profile of a tissue.
In constrast, the „membrane hypothesis‟ of aging, introduced by Zs.-Nagy in the late
1970s (17), explains aging as a consequence of the formation of damaging waste products
such as lipofuscin accumulating in the plasma membrane which are due to an imbalance
between the rates of protein synthesis and elimination. These alterations are due in part to
free radical attacks and residual heat formation, which induce molecular damage. Despite a
continuous replacement of the damaged components, a certain amount of residual damage
accumulates during life, which consequently leads to an increase in dry mass due to a
passive loss of permeability of the cell membrane for potassium and water. This dehydration
process causes a decrease in enzyme activities and a decline in physiological functions.
Since all types of cells have basically identical structure, these processes can be observed in
every cell, however, in different magnitude.
2.1.2.3

Cellular
Cellular theories concentrate on the characteristic changes of aging in cells and often

overlap with molecular theories, since these changes are often also caused by molecular
damage. The most important theories in this category are the „Free radical theory‟ from
Harman, the „Cellular senescence theory‟ from Hayflick, and the „Telomere shortening
theory‟.
The „Free radical theory of aging‟ from Harman in 1956 postulates that the common
aging process is the initiation of free radical reactions (FRR) in cells and tissues which lead
13

to the progressive deterioration of biological systems over time due to their innate ability to
produce random changes (18). Therefore, measures to decrease the chain lengths of FRR or
their rates of initiation can, in turn, decrease the rate of aging and of disease pathogenesis.
Since most FRR take place in the mitochondria and life span is determined by the free
radical damage to mitochondria, this theory was extended to the „mitochondrial aging
theory‟ in 1972 (19).
The „cellular senescence theory‟ or also called the „Hayflick Limit theory‟, named
after its discoverer Dr. L. Hayflick in 1965, proposes that senescence is caused by a limit in
replicative capacity of normal cells (1). In his experiments, Hayflick demonstrated that
normal diploid cells could undergo only a certain number of cell divisions (50-100 times)
under in vitro conditions. Conversely, cells which don‟t have a finite lifetime share
properties of cancer cells (20).
One of the explanations for this „replicative senescence‟ was given by the idea of
„telomere shortening‟ in 1971 (21). Telomeres, which are repeated terminal DNA sequences
of eukaryotic chromosomes, are synthesized by the polymerase „telomerase‟, a
ribonucleoprotein reverse transcriptase. The function of the telomeres is to stabilize the ends
of chromosomes (22). Subsequent research indicated that these telomeres shorten every time
a cell divides because of a loss of telomerase activity, eventually leading to the cessation of
cellular proliferation (23) . In contrast, immortal cells such as cancer cells and embryonic
stem cells maintain telomerase activity and, consequently, a stable telomere length (24).
2.1.2.4

Systemic
Systemic theories are system-based views of aging with the concept that the

homeostatic network which integrates functions of different cells and tissues and gives the
14

organism the ability to communicate and to adapt to the environment, declines with age
(25). This approach combines evolutionary aspects with molecular and cellular models of
aging rather than providing an alternative (26); however, it considers the alterations of single
cells as secondary effects and as irrelevant for the whole organism. Key players in this
coordinating network are the neuroendocrine and the immune system (25).
The „neuroendocrine theory‟ proposes that aging is due to changes in neural and
endocrine function. It considers the hypothalamo-pituitary-adrenal axis as the master
regulator which regulates to a greater or lesser extend all body functions. Progressive
deterioration of this system leads to changes of hormones and neurons leading to secondary
alterations in other tissues and organs. Overall, the organism‟s ability to survive to stress
decreases and it becomes more susceptible to diseases and death (1, 25).
The „immunologic theory‟ emphasizes on the decline of the immune function
resulting in decreased resistance to infectious diseases and cancer, and increased incidence
of autoimmune responses (1). This model is based on the assumption that the immune
system is the leading apparatus to maintain body integrity because it must control and
eliminate foreign particles invading the host while at the same time protect it from selfdestruction. A progressive deterioration of the immune system with age such as seen in the
thymus in humans, which undergoes a continuous decline starting from puberty, leads to a
global reduction in the capacity to deal with a variety of stressors. This immunosenescence
will lead to an increase in the pro-inflammatory status which is one of the characteristics
seen with aging (27).
Since the immune system is also regulated by signals from the neuro-endocrine
system and, on the other hand, the neuro-endocrine system is modulated by signals derived
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from the immune system such as lymphokines and cytokines, there are new attempts to
integrate changes to both networks into one model (25).
Another systemic theory, however, in contrast to the above theories not focusing on a
network system, is the „rate of living theory‟ which originally was developed by Pearl in
1928 (28). In essence, this hypothesis assumes that any organism has a fixed amount of life
or energy expenditure. Animals that choose to utilize this amount fast will live shorter while
individuals, who use this amount slowly, will live longer. In many aspects this theory is
similar to the evolutionary „wear and tear‟ idea assuming that a living organism deteriorates
with higher usage similar to malfunctioning of mechanical objects (28).

2.1.3 Focus on ROS
Reactive oxygen species (ROS) are one of the most important free radicals in
biological systems. Superoxide Anion (O2˙ ) is considered the primary ROS and can further
interact with other molecules to generate secondary ROS such as the hydroxyl radical (˙OH)
and peroxyl radicals (ROO˙) (29). ROS are products of normal cellular metabolism and exist
at low but measurable concentrations in living systems. The balance between ROS
production and their elimination by the anti-oxidant defense system determines the effects in
cells which may be beneficial or harmful (30).
2.1.3.1

ROS production
ROS can be generated either as a byproduct of other biological reactions or can be

generated as a primary function of an enzyme system. Locations where ROS is produced as
a byproduct are the mitochondria, peroxisomes, and cytochrome P-450; the major ROS
producing enzyme are NADPH oxidases (31).
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Approximately 2% of the total oxygen consumption in isolated mitochondria are
converted to ROS under physiological conditions (32). This is caused by „electron-leakage‟
preferentially in complex I and III of the electron transport chain, which generates
superoxide instead of contributing the electrons to the reduction of oxygen to water (29).
Most of the produced superoxide is converted to the non-radical hydrogen peroxide (H2O2)
by Superoxide dismutase. However, extra-mitochondrial escaped superoxide can participate
in further reactions (e.g. Fenton reaction, Haber-Weiss reaction) to produce the highly
reactive hydroxyl radical.
The first identified system producing ROS as a primary function was the phagocytic
enzyme NADPH oxidase (31). The phagocytic form as well as the other nonphagocytic
isoforms belongs to a family of transmembrane heme-containing proteins which function to
transport electrons across the membrane from a cytosolic donor such as NADPH to an
electron acceptor such as oxygen. In this process superoxide can be generated which has
physiological relevance as a first line defense against environmental pathogens as well as in
cellular signaling and regulation of gene expression (33). There are seven family members
of NOX oxidases with a wide tissue distribution. NOX2 is the most abundant isoform in
phagocytes and NOX4 is most widely expressed (34). Other enzymes producing ROS
include 5-lipooxygenase and cyclooxygenase; however, the evidence for a physiological role
in ROS generation is still scarce (30).
2.1.3.2

Antioxidant defense system
To maintain a low concentration of ROS in the cell, different defense mechanisms

have evolved; these include preventive mechanisms, repair mechanisms, physical defenses
and antioxidant defenses (29). The antioxidant system includes the enzymatic defense by the
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enzymes Superoxide Dismutase (SOD), Catalase, and Glutathione Peroxidase (GPx), and
non-enzymatic defense involving antioxidants such as ascorbic acid (Vit C), α-tocopherol
(Vit E), carotenoids, flavonoids and glutathione (GSH) (29).
2.1.3.3

‘Redox signaling’, ‘Redox homeostasis’ and ‘Oxidative stress’
Under normal physiological conditions the concentration of ROS in a cell is low.

This „steady state‟ concentration is determined by the balance between the rate of ROS
production and the rate of ROS removal (29). During „redox signaling‟ this balance is
shifted temporarily towards more oxidative conditions, which will induce redox-sensitive
signal cascades. Direct feedback regulatory processes will inhibit further ROS production
and stimulate the antioxidant defense mechanisms to reset the original state. This
reestablishment of the original redox state after a temporary exposure to increased ROS
concentration is called „redox homeostasis‟ (30). However, under certain conditions the
oxidative event may be more strongly or persistently, and the defense mechanisms are not
sufficient to reach baseline levels. If this pro-oxidative shift is severe enough, it may result
in oxidative stress for the cell and may lead to the development of pathological conditions
(30).
2.1.3.4

Redox signaling under physiological conditions
The increased ROS production as an „oxidative burst‟ by the phagocytic NADPH

oxidase is one of the best studied redox-responsive signaling pathways. In an inflammatory
environment, activated macrophages and neutrophils can produce large quantities of
superoxide and hydrogen peroxide, and the latter can reach concentrations of 10-100 μM
(30). These antimicrobial and tumoricidal ROS act as a first line defense against the
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invading pathogens. In addition, the increased levels of ROS enhance the activation of Tlymphocytes further stimulating the immune response (35).
Another role of redox signaling is the regulation of cell adhesion of leukocytes to
endothelial cells and cell adhesion molecules, such as intercellular adhesion molecule-1
(ICAM-1), CD11b/CD18, and L-selectin, which play an important role in chronic
inflammation, cell growth and differentiation, and wound repair. It has been shown that
ROS induces the adherence of leukocytes to endothelial cells and induces the production of
adhesion molecules via activation of transcription factors such as AP-1, nuclear factor (NF)kB and hypoxida inducible factor (HIF) -1 (36).
In addition, there are multiple positive bidirectional interactions between signal
transduction pathways and ROS production. For example, multiple growth factors,
hormones and cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin- 3
(IL-3), tumor necrosis factor-α (TNF-α), angiotensin II (ANGII), platelet derived growth
factor (PGDF), nerve growth factor (NGF), transforming growth factor-β1 (TGF-β1),
granulocyte-macrophage colony-stimulating factor (GM-CSF), and fibroblast growth factor
(FGF-2) activate NADPH oxidase. The generated ROS, in turn, will induce positive
feedback effects on the signal transduction from the corresponding membrane receptor or
act as second messenger to activate tyrosine kinases, protein tyrosine phosphatases or
serine/threonine kinases involved in other signal transduction pathways such as mitogenactivated protein kinase (MAPK) and PI3K/AKT pathway (29, 30) .
Furthermore, an increase in intracellular ROS can activate intracellular Ca2+ stores as
well as stimulate the influx of extracellular calcium, resulting in increased intracellular Ca2+
concentration (37, 38). However, [Ca]i2+ as an ubiquitious intracellular second messenger is
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tightly regulated and involved in regulation of many different cellular functions such as
contraction, metabolism, gene expression and cell survival/death. In addition, there is a
bidirectional connection between [Ca]i2+ and ROS with [Ca2+]i also stimulating ROS
production in mitochondria and by NADPH oxidase (38). Therefore, the cross-talk of both
important signaling systems can be stimulatory or inhibitory, depending on cell type and
extent of exposure.
2.1.3.5

Redox signaling under pathological conditions
The response to ROS at the cellular level depends on the duration and intensity of the

oxidative insult. While low concentrations stimulate proliferative and survival pathways,
higher concentrations contribute to cell arrest and apoptosis (39). The harmful effects of
prolonged and intense ROS production (oxidative stress) are caused by different
mechanisms. First, the increase in ROS can damage other molecules such as DNA, proteins
and lipids (40-42). This can result in DNA mutation and breakage, loss of protein and
enzyme function, and rupture of membranes. On the other hand, chronic stimulation of
above mentioned signaling pathways contributes to chronic inflammation, proliferation and
cell death. Accordingly, oxidative stress has been implicated in a number of chronic diseases
including diabetes, cardiovascular diseases and cancer (43-46).
2.1.3.6

ROS and Aging
Harman (1956) was the first proposing the hypothesis that the accumulation of free

radicals in cells and tissues is responsible for the progressive deterioration and the process of
aging of biological systems (47). Later this idea was incorporated in other theories of aging
such as „protein error theory‟ and the „membrane hypothesis‟. Chen et al. also demonstrated
that „replicative senescence‟ could be induced by H2O2 (48).
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A growing body of evidence suggests that aging involves free radical induced
changes of molecules and of regulatory processes. For example, it was shown that shorterlived species produce relatively higher amounts of ROS than longer-lived species (49).
Other studies revealed that aging is associated with an accumulation of oxidized
biomolecules such as 8-oxo-2‟-deoxy Guanosine (8-oxo-dG) in DNA and oxidized proteins
in tissues (50-54). Further support is given by the fact that oxidative damage can result in
age-characteristic phenotypes (55); for instance, oxidative damage to brain cortex correlated
with impairment in memory and cognitive function (52). However, most evidence comes
from transgenic studies that show that decreasing ROS by over-expression of antioxidant
enzymes such as SOD and catalase can increase resistance to oxidative stress and prolong
lifespan (56-58). Also pharmacological treatment with antioxidants resulted in longevity
extension in some studies (59-61).

2.1.4 Mitochondrial aging
More than 90% of the oxygen used by aerobic cells is consumed by mitochondria in
the process of oxidative phosphorylation. As a byproduct, 1-2 % of the consumed oxygen is
converted to superoxide in the respiratory chain which will mainly be dismutated to H2O2
by the mitochondrial SOD (32). This continuously spontaneous production can contribute
immensely to the total ROS amount in cells, since hundreds to thousands of mitochondria
are within each cell, depending on cell type.
The „rate of living theory‟, proposed by Pearl, was the first theory to consider an
inverse relationship between the rate of oxygen consumption and maximum life span of
species (28). However, there were some exceptions to this theory, as seen in some species of
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birds, which show a high oxygen consumption and long lifespan. Later in 1972, Harman
focused his work on mitochondria and described them as „biological clock‟ since as a major
source of endogenous free radical production they would determine the lifespan (18, 19).
Miquel further developed the idea of „mitochondrial aging‟ which was based on studies of
insects and mammals (62). While insects showed consistently many age-related changes in
mitochondria of flight muscles in association with increased H2O2 production, such as
reduction of total mitochondrial volume, decrease in total amount of mtDNA, structural
changes as a loss of cristae as well as a decline in activity of key enzymes involved in
respiration and energy production, results of studies in mammals were conflicting depending
of the methodology and experimental design used. Similar age-related changes were found
in fixed postmitotic cells and cells with a low replication rate such as skeletal and heart
muscle, while cells with a high replication rate, such as gastro-intestinal cells, appeared to be
free of age-related changes. Thus, Miquel concluded that due to the increased free radical
production with age damage mainly to the inner mitochondrial membrane and DNA
accumulates because of lipid oxidation and cross-linking which makes the cell unable to
divide; however, the degree of damage is more evident in postmitotic cells and cells with a
low replication rate.
A large body of evidence supports this idea. Mitochondrial DNA (mtDNA) is more
susceptible to oxidative damage and mutation than nuclear DNA because of the close
proximity of ROS production and the characteristics of mtDNA. The lack of protective
histones and an effective repair system makes them more vulnerable to oxidative damage. In
addition, mtDNA has no introns. Consequently random mutations will usually strike a
coding sequence. Furthermore, mtDNA is inherited maternally and do not recombine so that
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normal and mutant DNA can coexist within the same cell. This heteroplasmy allows
otherwise lethal mutation to persist and to accumulate (63). As a result the transcription of
mitochondrial genes may be impaired, resulting in mitochondrial dysfunction which can
lead to a further increase of ROS production due to damage to the electron transport chain
(45). In addition, oxidative damage of mitochondrial proteins and membrane lipids further
contributes to morphological and functional changes (64). Accordingly, mitochondrial
dysfunction has been linked to the pathogenesis of a wide range of pathologies as well as to
aging (45, 63, 65).
Numerous studies conducted in multiple species support the relationship between
mitochondrial dysfunction and aging, although some have yielded inconsistent results. Some
investigators focused on the damage to the mtDNA; for example, Melov et al. found a
substantial increase in the number and variety of mtDNA rearrangement in muscle from
older humans compared to muscle from younger individuals (66). Others, such as Short et
al. (63), investigated structural and functional changes in human skeletal muscle and found
that there was a continuous decline in mitochondrial protein and DNA content which was
associated with a decrease in mitochondrial ATP production rate (67). Barja et al. also
examined the relationship of mtDNA damage of heart and brain to the lifespan in mammals
and compared it to the damage found in nuclear DNA. He identified an inverse relationship
between oxidative damage to mtDNA and maximum lifespan, while no such correlation was
found for nuclear DNA (68). In another study the causative link between mtDNA mutations
and aging was examined in knock-in mice expressing a proofreading-deficient DNA
polymerase (69). These knock-in mice developed a phenotype with 3 to 5 fold increase in
mtDNA mutations and deletions which was associated with reduced lifespan and premature
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onset of aging-related phenotypes such as weight loss, alopecia and osteoporosis. However,
in a follow-up study the authors showed that these age-related phenotypes in the mtDNA
mutator mice were not related to increased ROS production or a decrease in antioxidant
enzyme activities since the increase in oxidative damage was only minor despite profound
respiratory chain deficiency (70). Therefore, the authors proposed that the respiratory chain
dysfunction per se, and not oxidative stress, was the primary inducer of the premature aging.
Further conflicting data came from a study, in which life-long reduction of mitochondrial
SOD activity resulted in increased DNA damage but did not accelerate aging (71). On the
other hand, other studies demonstrated that decreasing mitochondrial ROS production by
over-expressing mitochondria targeting enzymes or by administration of antioxidants could
prolong lifespan and prevent age-related phenotypes (58, 72, 73). Despite some conflicting
data, the overall consensus seems to support the concept that mitochondrial oxidative stress
and dysfunction are important contributors to the process of aging, although detailed
mechanisms still needs to be fully elucidated.

2.1.5 Lifespan
The term „lifespan‟ can be applied to an individual or to a population of a species.
The individual lifespan specifies the period between birth and death for that individual (74).
In contrast, the population lifespan can be characterized by the maximum lifespan, which is
the highest verified age at death in a specified time period or ever recorded, or it can be
measured by the mean life expectancy, which is the statistically calculated estimate of
number of years of an individual to live at a given time. Other measures include the median
lifespan and range, all of them are always dependent on the number of individuals sampled
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(75). While the maximum lifespan seems to be relatively constant and mainly genetically
determined, the mean life-expectancy depends more on environmental conditions and
external mortality (9).
The lifespan between species varies widely from days in flies up to 200 years in
whales, but there is also substantial variation within the same species. Evolutionary biology
suggests that this variation is caused by adaptation processes resulting from selection due to
demographic circumstances, duration of infantile period and the species‟ ecological niche
(76). Despite some exceptions, there is generally a positive correlation between body size,
relative brain size, possession of armor and lifespan (75). However, growth seems to
negatively impact the life span within mammalian species (77).
In humans, there was a major increase in mean life expectancy over the past century;
this was associated with decreased early mortality due to improved nutrition, housing,
sanitation and health care. In contrast, there is no evidence for an increase in maximum
lifespan over that time period, with the highest recorded age of 122 years (74). There are
some indications for sex differences, with females living longer than males, possibly due to
factors such as men having riskier behavior, larger body size and different hormone levels
(78). In general, longevity shows a clear heritable component but also non-genetic factors
and gene-environment interactions are very important in determining the lifespan (74).
2.1.5.1

Models of lifespan
As the mean life expectancy dramatically increased over the last century due to

socio-economic factors it became also more evident that both lifespan and aging is under
moderate genetic control (79). Therefore, aging research over the last several decades has
focused on understanding the aging process at the molecular level with the inevitably
25

consequence of an intensive search for models of lifespan (80). Models of lifespan can be a
helpful tool to study pathways influencing metabolism and mechanisms of maintenance and
repair, and may also contribute to finding molecular candidates to extend health and
longevity. Since aging is a diverse and complex process associated with various phenotypes,
dissecting it into components and studying each component separately in experimentally
suitable models may be necessary; however, the results need to be interpreted in light of the
broad context of the process which is a complex network of inter-related pathways often
controlled by diverse mechanisms (80). Validity of findings are further complicated as they
critically depend on laboratory conditions and settings which often are very dissimilar to the
normal environment (79). Therefore, depending on the complexity and research questions
suitable models can reach from single cells to whole organisms.
2.1.5.1.1

Cellular models

According to Hayflick who discovered first that normal human fibroblasts have a
limited number of cell divisions and then enter into a state of cell senescence, the
accumulation of senescent cells may contribute to the process of aging in the whole
organism (81). In support of this hypothesis, single gene alterations such as loss of
telomerase or over-expression of p53 which alter the amount of cell divisions, are also
associated with overall changes in longevity of the whole organisms (82). In addition, many
mouse models of accelerated aging are caused by gene alterations affecting DNA repair, cell
cycle and apoptosis (82).
Technical advances in cell culturing and subcultivation in the 1960s and the
development of reliable biomarker for cell senescence such as the senescence associated β26

galactosidase (SA-β-gal) assay, flow cytometry and green fluorescent protein (GFP)expressing reporter constructs for gene expression, revolutionized biological aging research
(83). In cell culture the number of possible cell divisions until reaching a state of replicative
senescence seems to be cell type and species specific (84). Although most cell types
undergo cell senescence, there are some exceptions, such as transformed cells and postmitotic cells as neurons. Studying the pathways which enable immortal cells to escape
senescence has significantly contributed to the identification of signaling cascades important
for human aging and age-associated diseases; these include the telomerase pathway, the
IGF-Akt pathway and the mitochondrial/oxidative stress pathway (84). Therefore, cells can
be an easy and good model for finding key mechanisms and studying genetic mutations.
2.1.5.1.2

Invertebrates

Invertebrates such as S. cerevisiae, C. elegans and D. melanogaster have been
extensively used in aging research. Advantages of these models are in general their short
lifespan, easy maintenance and low costs, excellent background genetics, and the ready
availability of large numbers of genetically homogenous individuals (85, 86). Despite their
advantages, they also have some limitations that will be discussed below.
Saccharomyces cerevisiae, or baker‟s yeast, is a unicellular organisms belonging to
the ascomycete family. Aging in S. cerevisiae can refer to the „clonal‟, also called
„replicative‟ lifespan, or to the „chronological‟ age. The „replicative‟ lifespan is defined by
the finite number a mother cell can bud into smaller daughter cells, whereas the
„chronological‟ lifespan means the gradual loss of viability when grown to saturation. The
main difference between both is the reliance of mitochondrial respiration; under clonal
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conditions the energy derives from anaerobic glycolysis and mitochondrial respiration is
actively repressed, therefore it is an unsuitable model for studying energy metabolism (87).
Caenorhabditis elegans is a pseudo-coelomate nematode and very attractive as
model organism because of its large number of offspring, short generation time (around 20
days) and the ability to be stored frozen. However, an important difference in comparison to
mammals is the dependence of lifespan on the temperature. Lowering the ambient
temperature by 6oC can double the lifespan of either species. Aging studies are usually
centered on the „dauer stage‟, an alternative, dormant and stress resistant life stage induced
by food shortage and characterized by a very long lifespan (87, 88).
The fruit fly Drosophila melanogaster has been a favored model for aging.
Advantages to the others described above are the short time until reproduction/adulthood
and being essentially a postmitotic organism, therefore ideal to study accumulation of aging
changes. In addition, it represents a relatively complex organism because of its ability to fly
which requires engagement in various sensory and motor-driven behaviors that can be
followed with age in addition to its lifespan (85).
In contrast to cell studies, studies in invertebrates make it possible to examine
changes in a whole organism but still having the advantage of low cost and easy
maintenance. They can be easily genetically modified and used for targeted single gene
mutations. They also can be used for profile gene expression analysis to find age-related
gene expression differences and similarities between short-lived and long-lived animals
(89). Studies in invertebrates have contributed immensely to the identification of specific
genes and signaling pathways important for the aging process.
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2.1.5.1.3

Vertebrates

Findings in different invertebrate models support the possibility that these pathways
are highly conserved. Accordingly, vertebrate models are needed to test the key findings of
invertebrate models for relevance in mammals and eventually humans. Mice are mainly used
as vertebrate lifespan models because they still have a relatively short lifespan (2 to 3 years),
their basic biology and genomes are known, and they are relatively easy experimentally
manipulated.
Since there was a great body of evidence in C. elegans and D. melanogaster that the
insulin/IGF-1 pathways plays an important role in the aging process, there were several
genetic mouse models created with mutations in growth hormone (GH), IGF-1 or insulin
signaling. Examples are the following (90):
1) Dwarf mice: these mice have a mutation in the pituitary-specific transcription
factor 1 (Pit1) gene causing hereditary dwarfism. Depending on their mutation and
background, there are the „Snell‟, „Jackson‟, „Ames‟, and „Ames and Snell‟ dwarf mice.
Dwarf mice do not produce growth hormone (GH), thyroid stimulating hormone (TSH) and
prolactin (PRL); therefore they show severe growth retardation, infertility, and reduced
metabolism and metabolic rate. They also have alterations in insulin/IGF-1 signaling with
severely reduced circulating plasma insulin, IGF-1 and glucose levels. Some of these dwarf
mice also have an increased resistance to oxidative stress. Although reports on lifespan are
controversial, most investigators found an increase of up to 68% in these mice.
2) Growth hormone receptor/binding protein (GHR/BP) knockout mice: these mice
show severe growth retardation starting at 4 weeks of age and delayed sexual maturation in
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females. They have very high serum GH levels while IGF-1 levels are decreased by 90%.
Lifespan extension of up to 55% was reported compared to wild-type mice.
3) Insulin-like growth factor type I receptor (IGF-1R) knockout mice: while
homozygous knockout are not viable and die at birth, heterozygous (IGF1r+/-) animals look
normal. However, IGF-1R and IGF-1 signaling was reduced up to 50% in some tissues.
Most markers such as body weight, glucose levels and metabolic rate were normal or only
slightly different when compared to wild-type mice; however, they showed an increased
resistance to oxidative stress and an increase in mean lifespan up to 33%.
4) Fat-specific insulin receptor knockout (FIRKO) mice: in these mice the insulin
receptor (IR) gene is mutated in adipose tissue specifically leading to 90% reduction of
insulin-stimulated glucose uptake. These animals show a 15-25% reduction in total body
weight accompanied by a 50-70% reduction in fat mass despite higher food consumption. In
addition, FIRKO mice had lower fasted insulin plasma levels while maintaining normal
blood glucose level; however, they developed impaired glucose tolerance due to insulin
resistance with increasing age. Despite that, the median lifespan was increased 18%
compared to littermate controls.
Although these mouse models seem to support the link between GH/IGF-1 and
insulin axis and longevity, interpretation needs to be done with caution. Some of these
models represent rather multiple hormone deficiencies than single gene mutations; therefore
the precise role of GH and IGF-1 in regulation of lifespan remains equivocal. In addition,
these hormones have critical actions in development and early adulthood such as increasing
body weight, bolstering bone and muscle mass, enhancing immune function and increasing
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general reproductive fitness (91). Therefore, a balance between the beneficial and
deleterious consequences of these hormones needs to be found.
Another often-used mouse model with extended lifespan is the p66shc knockout
mouse. The p66shc gene encodes for a Src-homology2 (SHH2) domain protein with two
major functions: cytoplasmic signal transduction of mitogenic signals activated from
receptors to Ras, and the p53 stress activated induction of apoptosis and production of ROS.
Knockout mice show increased resistance to oxidative stress, lower plasma levels of
oxidative stress markers (isoprostane, LDL-oxidation) and mean survival was increased 40%
compared to wild-type mice (91)
Additional insight into the aging process may also be gained from models with
shortened lifespan. One of the oldest biogerontological resources is the senescence
accelerated mouse (SAM), which was developed by selective breeding in Jackson laboratory
in 1968 based on early onset of age-associated pathologies such as loss of activity, hair loss,
skin coarseness, osteoporosis and short lifespan. There exist 14 different senescence-prone
inbred strains (SAMP) and 4 senescence–resistant inbred strains (SAMR) with normal aging
which are used as controls. Additionally neurological age-related changes, including deficits
in learning and memory and hearing, as well as brain atrophy make them also a useful model
for studies of age-related neurodegenerative diseases (92).
Another model of shortened lifespan is the Telomerase knockout mouse. Since the
replicative senescence of human cells is caused, at least in part, by telomere shortening, it
was assumed that telomerase deficient animals would exhibit a shorter lifespan (93).
However, murine somatic cells have long telomeres and maintain telomerase activity, in
contrast to human somatic cells; therefore, telomerase-based replicative senescence is
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unlikely to occur during the normal aging process in mice. Consequently, a mouse model
was created by homologous recombination and successive intergenerational crosses that was
telomerase deficient and had undergone sufficient telomere shortening. These late
generation (mTerc-/-) animals demonstrated a shortened lifespan and premature aging
phenotypes such as alopecia, hair graying and reduced resistance to stress (93).
The Klotho mouse is an unintentionally created mouse model with shortened
lifespan. It was generated by incidental insertional mutation of a transgene in an unknown
gene that was later named klotho gene. The disruption of that gene contributes to an
accelerated aging process that is very similar to the normal aging in mammals. Animals
show calcification of small arteries, decreased bone mineral density, skin atrophy, and
cognitive impairment. Death usually occurs at 8 to 9 weeks of age. It is suggested that the
klotho gene inhibits the insulin/IGF-1 signaling pathway, since overexpression of klotho is
associated with moderate insensitivity to IGF-1 and insulin, and prolonged lifespan (94).
Since cancer suppression is an integral component of longevity, it was also expected
that increased activity of p53, a tumor suppressor gene, would cause an extension in
lifespan. However, hypermorphic p53 mutant mice with increased p53 activity exhibited
enhanced cancer resistance but reduced longevity and accelerated onset of aging-associated
phenotypes. In contrast, inactivation of p53 in mice resulted in drastically increased tumor
susceptibility but those animals in which tumor development could be prevented showed
increased longevity (95).
To determine the role of ROS production in mammalian longevity, many
manipulations of the antioxidant defense system have been studied. In general, potential
approaches can be divided into two categories: endogenous studies involving gene
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modifications or exogenous studies with exogenously administered toxicants or antioxidants
(96). Endogenous modifications involve complete knockouts to tissue specific disruption as
well as total and tissue targeted over-expression of antioxidant enzymes and proteins. For
example Sod2 (mitochondrial isoform) nullizygous mice die within the first week of life,
associated with severe pathologies such as dilated cardiomyopathy, hepatic lipid
accumulation, metablic defects and DNA oxidative damage. These symptoms were partly
rescued by administration of a catalytic antioxidant MnTBAP (97). In contrast, inactivation
of the other two isoforms of SOD (cytosolic and extracellular) resulted in a negligible
phenotypes and essentially normal lifespans (96). On the other hand, transgenic mice with
over-expression of catalase targeted to mitochondria, peroxisomes or nucleus were more
resistant to oxidative stress, had reduced mitochondrial deletions, delayed cardiac pathology
and cataract development, and had an increase in median and maximum lifespans (58).
Furthermore, over-expression of thioredoxin in mice resulted in median and maximum
lifespan extension compared to wild-type mice (98). However, some conflicting results
came from a newer study using transgenic mice over-expressing SOD and catalase either
alone or in combination, as none of these genotypes exhibit any effects on mean, median or
maximum survival (99).
To obtain results, which are physiologically more similar to humans, some studies
are performed in non-human primates. For instance, rhesus monkeys were used to
investigate the effects of adult-onset caloric restriction (30%) on disease pattern and
longevity (100). After 12 years of CR, the animals showed an expected reduction in body
weight, reduced adiposity, increased insulin sensitivity and reduced levels of oxidative
damage. Furthermore, middle-aged monkeys had reduced risk for cardiovascular disease and
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diabetes mellitus and an increased median survival (101). However, these animals have long
lifespans compared to rodent and other models; consequently, lifespan studies in this model
are quite resource intensive and, consequently, infrequently performed.
2.1.5.1.4

Relevance for humans

Although many of the lifespan regulating pathways identified in invertebrate model
organisms are highly conserved throughout evolution, they often have become more
complex and diverse in higher developed species (79). For example, the mammalian genome
often contains several homologues of a single invertebrate gene such as the forkhead
transcription factor (102). On the other hand, some genes have no homologues in
invertebrates (103). In addition, signaling pathways such as the insulin/IGF-1 have become
more complicated with different receptors and different functions for insulin and IGF (104).
Therefore, gene alterations prolonging the lifespan in invertebrates may lead to
paradoxically results in mammals, e.g. reduced p53 activity lead to lifespan extension in
flies (105) but is associated with increased tumor formation in mammals (106). In addition,
environmental conditions influence the expression patterns of genes and can result in gene
variations. Since laboratory conditions often poorly mimic the evolutionary niche, results
may affect genes, which have no relevance in the natural environment. Furthermore, geneenvironment interactions such as epigenetic modifications contribute to phenotypic
variations and can cause lifespan differences within species (79). Therefore, extrapolating
results from lifespan models to the human population should be done with caution. To
overcome these challenges, human diseases of premature aging are sometimes used to
examine the underlying mechanisms and to interpolate it to the normal aging process. One
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model of human aging is the Werner Syndrome, a rare autosomal recessive disorder.
Patients are normal until the second decade of life, and then they develop symptoms of
premature aging (alopecia, accelerated atherosclerosis, osteoporosis, cataracts, type II
diabetes, cancer) and usually die within the fourth decade (107). The gene mutation affects a
gene encoding for a DNA helicase that is important for maintenance of genome stability,
DNA replication and repair. However, the specific functional role of this protein and its
interaction with other proteins in human cells needs still to be fully elucidated.
Other human approaches include twin studies and studies in centenarians to look for
specific gene polymorphisms or longevity genes. Although all these models bring some
insight of understanding molecular genetic determinants and environmentally relevant
modulators, the multitude of mechanisms of the aging process remains a compelling area of
research.
2.1.5.2

Caloric restriction
Caloric restriction (CR) refers to a diet which is usually 20 to 40 % reduced in

calories compared to an ad libitum diet but contains all essential nutrients (108). While there
were some conflicting data if food or dietary restriction of various nutrients, e.g. proteins or
specific amino acids, without changing calorie intake can also prolong lifespan, it is now
well accepted that CR is the only dietary intervention able to extend lifespan and to delay
the onset of age-associated phenotypes (100, 109).
The idea of performing experiments on life extension by caloric restrictions is based
on the „rate of living‟ hypothesis, assuming that there is an inverse correlation between
energy expenditure and longevity (4). In the 1930s, Mc Cay et al. demonstrated first credible
evidence that the long-term reduction of caloric intake without malnutrition prolonged the
35

lifespan in rats (110). Since then multiple studies have been carried out in a wide variety of
organisms ranging from yeast to mammals giving further support that CR extends mean and
maximum lifespan (100, 111-113).
The physiological effects of CR depend on the duration and extent of restriction,
usually beginning with an acute phase followed by an adaptive phase of several weeks to
reach a stable, altered metabolic state. This state is characterized by lower body temperature,
lower blood glucose and insulin levels, reduced body fat and weight, and increased
resistance to external stressors such as heat and oxidative stress (114, 115).
Although the physiological changes of CR are well characterized, the underlying
molecular mechanisms to link CR to the extension of lifespan remain elusive. The first
mechanistic explanations were based on early findings that the metabolic rate was reduced.
This reduction in O2 consumption would consequently reduce ROS production during
respiration and therefore, fitting the free radical theory of Harman, would result in less
oxidative damage (116). However, this theory was refuted by the observation that the
metabolic rate was unchanged when normalized to body weight (117), and there was even
some evidence that respiration is increased by CR (118, 119). Many other hypotheses have
been proposed to explain the effects of CR on longevity, including alteration of glucoseinsulin system and growth-hormon/IGF axis (109). However, newer evidence points to the
nutrient-sensitive proteins such as sirtuins and forkhead transcription factors which are key
regulators of energy metabolism (100, 109).
Although the longevity effect of CR is still controversial in primates and humans, the
health benefits and the delay of age-associated diseases are well recognized. However,
lifelong caloric restriction is not very attractive to most humans and therefore in most cases
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unfeasible. Thus, a lot of research focuses on the development of drugs, which mimics the
effects of CR. One promising substance is resveratrol, a natural occurring polyphenolic
compound, mainly found in the skin of red grapes (120). In addition to its beneficial
cardiovascular effects, anti-cancer and anti-inflammatory effects, it also extended the
lifespan in some species including C. elegans, D. melanogaster, and mice, which seemed to
depend on the presence of the sirtuins Sir2 and Sirt1, respectively (121-124). However, in
another study the lifespan extending results could not be repeated (125). Overall, the
changes produced by resveratrol are similar to those produced by CR; these include
increased insulin sensitivity, increased AMP-activated protein kinase (AMPK) and
peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α activity, and increased
mitochondrial function (121). Although very promising, the application in humans is still
limited because of extremely low bioavailability, toxic effects at higher doses and
expensiveness of this compound (120, 122).
2.1.5.3

Role of Sirtuins
The silent information regulator (Sir) proteins, also called sirtuins, belong to a

conserved family of deacetylases and mono-ADP-ribosyltransferases that either deacetylase
histones and proteins or transfer ADP-ribose to an acceptor amino acid using NAD+ as a cosubstrate (126). Because of the NAD+-dependence they are linked to the metabolic activity
of cells regulating numerous metabolic pathways including adipogenesis, gluconeogenesis,
insulin and glucose homeostasis (127). Accordingly, they have been implicated in the
prevention of mitochondrial dysfunction, metabolic disorders and aging (128, 129).
Sir2 in yeast, the first of the sirtuins identified, is involved in the regulation of
transcriptional silencing and DNA damage responses (126) and has emerged as the major
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genetic determinant of replicative lifespan in yeast with and without CR (115). For example,
integration of an extra copy of Sir2 increased the lifespan in S. cerevisiae up to 30% whereas
deletion of Sir2 shortened it (130). Likewise, studies in different species such as C. elegans
and D. melanogaster with extra copies of Sir2 orthologs revealed similar results (131, 132).
In addition, CR did not extend the lifespan when Sir2 was deleted suggesting that CR
activates this pathway (132, 133); however, this finding was challenged by other reports
showing that CR prolonged lifespan in yeast independently from Sir2 (134).
There are seven sirtuins (Sirt1 to Sirt7) in mammals which are ubiquitously
expressed in different tissues (135). They can be classified into four classes according to
their conserved NAD-dependent core domain (136). In addition, they differ in their subcellular localization; Sirt1, 6 and 7 predominate in the nucleus while Sirt2 resides mainly in
the cytoplasm, and Sirt 3, 4 and 5 are predominantly found in the mitochondria (126).
Moreover, they vary in terms of activity with Sirt1 and Sirt5 having robust and weak
deactylase activity, respectively, Sirt4 and Sirt6 being mono-ADP-ribolsyl transferases, and
Sirt2 and 3 having both. The activity of Sirt7 is not yet fully understood (126).
The Sir2 ortholog in mammals is Sirt1 and is most extensively studied.

Sirt1

interacts with a large number of substrates including p53, nuclear factor (NF)-κB, forkhead
proteins,

peroxisome

proliferator-activated

receptor-γ

(PPAR-γ)

and

peroxisome

proliferator-activated receptor-γ coactivator (PGC)-1α, thereby influencing adipogenesis,
differentiation of muscle cells, glucose and fat metabolism, resistance to oxidative stress,
apoptosis and cell survival. These activities also connect them to the observed induction of
Sirt1 by CR (115, 127).
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2.1.5.3.1

Stress resistance, cell survival and apoptosis

The role of Sirt1 in cell survival and apoptosis is versatile and depends on tissue
localization and other stress factors. For instance, suppression of apoptosis in response to
DNA damage is promoted by deacetylation of lysine residues on p53 resulting in their
inhibition of transcriptional activity (137). Although this may not advantageous for all cells
and may promote cancer, it also stimulates survival of post-mitotic cells such as neurons and
may be beneficial in neurodegenerative diseases (127). On the other hand, p53 inhibition as
well as FOXO activation evoke cell-cycle dependend autophagocytosis, a catabolic process
which can degrade cellular proteins, membranes and organelles (138). It has been observed
that autophagic degradation declines during aging and efficient maintenance of autophagy
may have a significant role in regulation of longevity (138). Furthermore, FOXO activation
by Sirt2 under severe stress can promote cell death and reduce ROS production by activating
expression of manganese superoxide dismutase (139). In addition, Sirt1 can induce
apoptosis by inactivation of NF-κB, which plays not only an important role in regulating
inflammation but also in regulating cell survival. It has been demonstrated that deacetylation
of NF-κB in HEK 293 cells by SIRT1 sensitizes the cells to apoptosis in response to TNFα
in a p53-independent manner (140).
2.1.5.3.2

Regulation of insulin and glucose homeostasis

Sirt1 regulates insulin and glucose homeostasis in different ways. In pancreatic βcells it was shown that Sirt1 over-expression in BESTO mice positively promoted glucosestimulated insulin secretion and improves glucose tolerance (141); however, these effects
were lost with advanced age but could be restored by administration of nicotinamide
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mononucleotide, an important metabolite for the maintenance of normal NAD-biosynthesis
(142). These effects were also associated with a down-regulation of mitochondrial UCP-2
gene expression suggesting that Sirt1 promotes more efficient energy generation in
pancreatic β-cells. Interestingly, Bordone et al. demonstrated that overnight food deprivation
restored UCP2 levels via reduction in NAD resulting in down-regulation of Sirt1 (143).
In liver, Sirt1 stimulates gluconeogenesis via activation of FOXO and PGC-1α (127,
144). Sirtuin activation by resveratrol or by oxidative stress promoted FOXO1 mediated
transcription of gluconeogenic genes and glucose release from cultured hepatoma cells
(145). Sirt1 also deacetylates and activates the transcriptional coactivator PGC-1α, a master
regulator of energy homeostasis and mitochondrial biogenesis (146). While levels of PGC1α mRNA are very low under ad libitum conditions in liver, fasting and diabetic conditions
dramatically increased PGC-1α gene expression resulting in increased expression of
gluconeogenic genes and decreased expression of glycolytic genes (146). In addition, PGC1α contributes to improved insulin sensitivity in muscle by increasing simultaneously
mitochondrial respiration and glucose uptake by insulin-sensitive glucose transporter Glut-4
(146).
Sirt1 also improves insulin signaling in adipocytes. Studies in 3T3-L1 adipocytes
have demonstrated that Sirt1 knockdown inhibited insulin signaling events and glucose
uptake while treatment of these cells with an Sirt1 activator reversed the effects (147). In
addition, activation of FOXO by Sirt1 increases adiponectin levels which further improves
insulin sensitivity and regulates glucose and lipid metabolism (126).
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2.1.5.3.3

Regulation of adipogenesis and fat metabolism

The action of Sirt1 on adipogenesis and fat metabolism are mainly mediated by
repressing PPAR-γ via direct interaction and by activating the PPAR-γ negative cofactors NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoid and thyroid
receptors) (115). The nuclear receptor PPAR- γ is a ligand-activated transcription factor and
the master regulator of adipogenesis. It is induced during the differentiation of preadipocytes
in both white and brown adipose tissue but also regulates fat storage into adipocytes (148).
Repression of PPAR-γ by Sirt1 over-expression or activation resulted in inhibition of
adipogenesis, enhanced lipolysis and release of free fatty acids leading overall to decreased
adiposity (149).
2.1.5.3.4

Sirtuins, caloric restriction and longevity

It has been demonstrated that aging is associated with changes in glucose and fat
metabolism, such as increased adiposity and decreased insulin sensitivity. As described
above, CR and activation of Sirt1 can improve glucose metabolism, lower insulin levels,
increase insulin sensitivity and pancreatic β-cell function, and can reduce overall adiposity.
In addition, both have also neuroprotective effects and thus delay the onset of age-related
neurodegenerative diseases such as Alzheimer‟s disease, Parkinson‟s disease and stroke
(108). Although their effects on maximal lifespan in humans is controversial, they do appear
to have beneficial effects on overall health and may thereby contribute to a „healthy aging
process‟.
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2.1.5.4

Role of FOXO
The winged helix/forkhead class of transcription factors are important regulators of

stress resistance but are also, since regulated by insulin signaling pathway, an alternate
nutrient sensing pathway in cells linking caloric restriction, insulin signaling pathway and
longevity (150). Their function in the cell is versatile and reaches from regulation of cell
cycle arrest, DNA repair and apoptosis to cell differentiation, antioxidant defense, glucose
metabolism and energy homeostasis (102). There are over 100 members identified from
yeast to human, which are subdivided according to their phylogenetic basis. All have the
common characteristic 100-amino acid winged helix DNA-binding domain, giving them
their name (151).
In mammals, four FOXO genes are found (FOXO 1, 3a, 4 and 6); these are
vertebrate orthologs of DAF16 in C. elegans, the first identified forkhead protein. They are
tightly regulated by post-translational modification in response to environmental stimuli that
directs them either to the cytosol for proteasomal degradation or to the nucleus for specific
transcriptional activity (152, 153). One of the main regulatory mechanisms is the sequential
phosphorylation by Akt /PKB on serine and threonine residues (Ser 256 and 319, Thr 24)
which prevents their nuclear translocation, interferes with binding of the co-activators
p300/CBP and targets them for degradation thereby inhibiting their transcriptional activity
(153). Conversely, phosphorylation on threonine residues 447 and 451 by the stressactivated JNK (c-Jun N-terminal kinase) results in nuclear accumulation and enhanced
transcriptional activity to induce expression of antioxidants such as MnSOD (154).
Another modification is acetylation/deacetylation. In response to stress signals,
FOXO proteins transported to the nucleus associate with other proteins that have histone
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acetylase activity such as p300/CBP and PCAF (p300/CBP associated factor) to form the
initial transcriptional activation complex. However, paradoxically acetylation reduces their
transcriptional activity but recruits Sirt1 for deacetylation and consequently fully activation.
FOXO-Sirt1 interaction results in preferential activation of genes involved in cell-cycle
arrest/cell death and resistance to oxidative stress, and in reduction of pro-aptotic targets
(152).
The third layer of posttranslational modification involves ubiquitination. Aktdependent phosphorylation of serine 256 creates a binding site for the cytoplasmic ubiquitin
ligase Skp2. Ubiquitination targets them for proteasomal degradation which results in
reduction of total cellular levels of FOXO and therefore reduced activity (152).
This intricate interaction of posttranslational modifications in response to external
signals balances the functions of the FOXO proteins carefully and determines the fate of the
cell either to proliferation and survival, or to cell arrest and death, or to survival, stress
defense and longevity (153).
2.1.5.4.1

Insulin/IGF-1/FOXO axis and longevity

As discussed earlier the FOXO transcription factors are nutrient sensing signaling
regulators linking caloric restriction, insulin signaling pathway and longevity. Studies
demonstrate that FOXOs are positively regulated by oxidative and nutrient stress stimuli and
negatively regulated by growth factors and insulin (154-156). In addition to insulin, nutrient
status is also signalized by the energy sensor AMP-activated protein kinase (AMPK) which
directly phophorylates FOXO on sites distinct from the Akt phosphorylation sites, resulting
in its activation (157). FOXO target genes include the anti-oxidant enzyme MnSOD, the
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glycolytic gene Glucose-6-phosphatase, and the gluconeogenic genes phosphoenolpyruvate
carboxykinase 1 (Pck1) and PGC-1α (158). In addition, it regulates the hypothalamus by
inducing the expression of agouti-related protein (Agrp) and neuropeptide Y (Npy) to
increase food intake. In energy-utilizing tissues such as skeletal muscle it induces autophagy
and muscle atrophy in response to nutrient deprivation. Thus, FOXO activation acts in
concert to increase systemic glucose levels, to increase oxidative stress resistance, and to set
the whole organism in a self-preservation state to survive harsh environmental conditions in
anticipation of improved nutrient availability (158). These alterations of cellular metabolism
may contribute to an extended lifespan.
The first evidence for a role of FOXO in regulating longevity was demonstrated by
the identification of DAF-16 in C. elegans (159-161). DAF-16 is a downstream target of
DAF-2 pathway, the ortholog to the mammalian insulin/IGF-1 signaling cascade, and the
effects of DAF-2 mutants on longevity, metabolism and development are suppressed by
DAF-16 mutations. (161). Since the insulin/IGF-1 pathway is a highly conserved signaling
mechanism, it was assumed that alteration in this signaling pathway may also affect disease
development and longevity in higher eukaryotes including mammals. However, data in
mammals are conflicting since the mammalian insulin/IGF pathway is much more
complicated than in nematodes and flies with different functions for IGF and insulin, and
early disruption is associated with increased risk of age-related diseases and increased
mortality due to decreased insulin-sensitivity (104). Nonetheless, some evidence is provided
by studies in mice that both inactivation of IGF-1 receptor and insulin receptor substrate
(IRS) 1 extended the lifespan (162, 163). In addition, CR has been demonstrated to interfere
with the insulin/IGF-1/FOXO pathway as an underlying mechanism to prolong lifespan
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(150, 164), and sirtuins are also activators of FOXO, as described above. In humans,
evidence for the involvement of the insulin/IGF-1 pathway in controlling longevity is still
scarce. However, it has been reported that centenarians showed increased insulin sensitivity
but lower IGF-1 levels compared with aged subjects (165, 166). Moreover, polymorphic
variants of the IGF-1 receptor and phosphatidylinositol 3 kinase genes have been identified.
These variants were associated with lower plasma IGF-1 levels and more often found in
long-lived individuals (167).

2.1.6 Changes in body composition in aging
Changes in body composition with aging are mainly caused by a decline in bone and
skeletal muscle mass, and by changes in fat mass resulting in altered tissue functions and fat
to muscle ratio. These changes typically begin in the fourth decade of life and contribute to
impaired physical functioning, metabolic diseases, disability and frailty of the elderly (168).
2.1.6.1

Loss of bone densitiy and osteoporosis
Osteoporosis is characterized by a low bone mass and microarchitectural

deterioration of bone tissue, resulting in increased bone fragility and susceptibility to
fracture (169). Diagnosis is based on a WHO set of criteria comparing the bone mineral
content (BMC) or bone mineral density (BMD) of an individual to the young healthy adult
mean of the population (T-SCORE): values within 1 SD are regarded as normal, values
between -1 and -2.5 SD are defined as osteopenia, and values more than -2.5 SD below the
mean are labeled as osteoporosis. However, in clinical practice the T-score may not always
be relevant and the -score may be more important. The -score compares a person‟s bone
mass with the mean bone density of adults of the same age and gender and also is used to
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determine between primary and secondary osteoporosis (170). Osteoporosis can also be
diagnosed based on the presence of a fragility fracture regardless of the T-score or Z-score
(171). Primary fracture sites are locations with larger proportions of trabecular bone such as
hip, vertebrae and forearm. The incidence of fractures is higher in women and increases
exponentially with age (172).
Osteoporosis can occur primary due to age-related bone loss, or secondary as a result
of other diseases or conditions e.g. hyperparathyroidism, medication or poor nutrition (172).
In general, it is a multifactorial process caused by genetic, nutritional and environmental
factors, and occurs in both sexes. Risk factors include female sex, increased age, low weight,
and estrogen deficiency contributing to a negative balance in bone remodeling (173).
Bone remodeling is a lifelong process and is thought to support calcium homeostasis
as well as to maintain the load-bearing capacity and to prevent accumulation of old bone.
From infancy to adulthood BMD increases progressively to reach the „peak bone mass‟
around 25 years, then remains stable until the age of 45 to 55 and starts declining thereafter
in both men and women. In women, the decline occurs abruptly due to estrogen withdrawal
after the onset of menopause and causes a loss of 25 to 30 % of the skeletal mass over a
period of 5 to 10 years while in men the loss occurs more gradually at a rate of up to 1 % per
year (172, 174). Regulation of bone remodeling involves several endocrine hormones,
including estrogen, Vitamin D, parathyroid hormone (PTH), and insulin growth factor
(IGF)-1, as well as locally produced factors such as interleukin (IL) 6, receptor activator of
nuclear factor kappa B (RANK), its ligand RANKL, and macrophage colony-stimulating
factor (M-CSF) (172).
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Estrogen has a very important role in bone homeostasis because it is responsible for
the increase of BMD during puberty and also controls maintenance of bone mass later in life
in both men and women. The suggested underlying mechanism involves suppression of bone
resorbing cytokines such as IL6, IL1, tumor necrosis factor (TNF)-

and M-CSF, which

otherwise increase osteoclast formation and differentiation. In addition, estrogen upregulates
transforming growth factor (TGF)- , an inhibitor of bone resorption, and may positively
influence intestinal calcium absorption. Accordingly, estrogen deficiency increases bone
resorption and contributes to a negative calcium balance due to impaired calcium absorption
(172). Estrogen loss is not only one of the main contributors to the risk of osteoporosis in
postmenopausal women, but also in older men since testosterone and free estradiol levels
significantly decline with age while sex hormone binding globulin (SHBG) increases,
further reducing bioavailability of sex steroids (174).
2.1.6.2

Loss of muscle mass and sarcopenia
Age-related progressive muscle loss is called sarcopenia and is characterized by

quantitative and qualitative deterioration of muscle cells, resulting in gradual slowing of
movement and decline in strength (175). Sarcopenia affects both genders similarly. Multiple
contributing factors have been identified such as neuronal and hormonal changes,
inadequate nutrition, low-grade inflammation and physical inactivity (176). Histologically,
there is a decrease in fiber size and number, an associated loss of motor units as well as an
infiltration of fat and other non-contractile material with preferential impact on type II (fast
twitch) muscle fibers (175).
The age-related decline in hormones such as sex hormones (testosterone, estrogen)
and other anabolic hormones such as growth hormone (GH) and IGF-1 contribute not only
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to the development of osteoporosis but also to the progressive loss of muscle mass.
Androgens have been shown to increase satellite cell numbers in animals and humans (177,
178), and testosterone levels have been positively correlated to muscle strength in older men
whereas no association of sex hormones with muscle strength was found in women (179).
Growth hormones promote directly muscle growth and regulates mitochondrial function
(180). In addition, it stimulates IGF-1 secretion in liver and muscle further promoting
muscle growth but also motor neuron survival (175).
Many studies have linked an increase in proinflammatory cytokines to sarcopenia,
and elevations in IL6 and CRP are associated with greater risk of losing muscle mass and
strength (181), while low levels of IL6 can act as a muscle growth factor (182).
Furthermore, there is evidence that elevated levels of TNF- contribute to muscle loss by
activation of apoptosis (183).
Age-related changes in muscle are also associated with a decline in mitochondrial
function. Conley et al. measured key mitochondrial fluxes, ATP synthesis and O2 uptake in
vivo to determine mitochondrial coupling efficiency. They found that there was a significant
difference of mitochondrial dysfunction between muscles within the same individual, with
more damage in muscles high in type II muscle fiber content (184). Oxidative stress may
play a role for mitochondrial dysfunction since level of oxidative DNA lesions were
increased in older people which was associated with a reduction of protein content and key
oxidative enzyme activity as well as a decline in mitochondrial capacity for ATP production
(67).
Muscle loss in elderly may be further facilitated by inadequate nutritional status and
decreased physical activity. Anorexia and malnutrition secondary to decreased appetite, poor
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dentition, disease co-morbidities and/or isolation are well known problems in older people
(185). As a consequence, protein intake may become insufficient for optimal muscle protein
metabolism, although it remains unclear to what extent this contributes to sarcopenia (186).
Moreover, physical activity declines with age, further promoting the decline in muscle mass
and strength, and it has been demonstrated that exercise training (especially resistance
training) can maintain and reverse muscle strength (187).
2.1.6.3

Loss of fat mass and central adiposity
Changes in fat mass and redistribution occur throughout the lifespan. The peak in fat

mass is reached in middle or early old age, followed by a substantial decline in total body fat
in advanced old age, while the percent body fat remains basically constant due to
concomitant loss of body weight and fat free mass (188). In addition, fat depots are
redistributed from subcutaneous fat depots to visceral locations as well as to other non-fat
tissues such as bone marrow, muscle and liver. These changes may contribute to systemic
lipotoxicity and increased prevalence of metabolic syndrome in older populations (189).
Aging has a substantial effect on fat cell dynamics. Fat depot size increases with
middle age due to an increase in adipocyte number and size. However, there is a decrease in
fat depot size in old age; this is mainly related to a decrease in fat cell size whereas
accompanied by an increase in both preadipocyte and adipocyte number. However,
preadipocytes of old individuals have a reduced capacity to differentiate into fat cells and to
accumulate lipid compared to those from younger individuals. This is associated with a
decline in several differentiation dependent genes (188). For example, the expression of
C/EBP , one of the key regulators of adipogenesis and fat cell function, declines
substantially with aging (190). Since C/EBP
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augments PPAR- expression, a decline in

C/EBP

and PPAR- may contribute to the decrease in fat cell size and altered fat cell

functioning resulting in decreased lipid accumulation in fat cells (188). In addition, aging is
associated with increased levels of pro-inflammatory cytokines such as TNF- , released
from preadipocytes (191, 192). TNF-

inhibits C/EBP

and PPAR- expression and

activity, thereby further enhancing the above mentioned effects and contributing to reduced
insulin responsiveness in fat cells (193).
Ectopic fat accumulation is increased with aging. There are several mechanisms
suggested to explain this phenomenon (188). First, diminished adipose tissue function
increases the likelihood that lipids are stored in non-fat tissues. For example, lipodystrophic
syndromes are associated with a lack of fat tissue and accumulation of ectopic fat depots
(194). Another cause may be the dysdifferentiation of non-adipose mesenchymal cells such
as muscle satellite cells, osteoblasts and macrophages, into adipocyte-like cells. These cells
can acquire features of adipocytes, including the ability to express aP2 and PPAR- 2 and
can accumulate lipids (195). However, lipid accumulation in non-adipose tissues has
deleterious effects and can result in metabolic dysfunction and cellular damage due to
increased lipid peroxidation (188).
Loss of fat mass with age is found primarily in subcutaneous fat depots, with
substantial retention of fat in visceral depots (196). Since visceral adiposity is associated
with a higher production of pro-inflammatory cytokines, this increase in the ratio of visceral
to subcutaneous fat storage tends to decrease insulin sensitivity, and increase the risk of
atherosclerosis and diabetes (197) and may thereby contribute to the development of agerelated metabolic disorders.
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2.1.6.4

Consequences
Epidemiological studies in humans have demonstrated positive correlation of

changes in body composition with age to risk of metabolic disease, physical disability and
frailty in the elderly population. For example, a 5.5 longitudinal study in healthy older
people (mean baseline age 71 years found that both genders showed a significant decline of
appendicular and leg free fat mass (FFM) while waist circumference and total fat mass (FM)
increased despite overall weight stability over the study period. This was associated with
reduced ability to perform activities of daily living (198). In another prospective study
performed in men aged 60 to 79, muscle mass was inversely associated with mortality while
high waist circumference was positively correlated to mortality (199).
Some studies have demonstrated an age-related decline in resting energy expenditure
due to the loss of fat-free mass and alterations in metabolically active components (200,
201), and a decrease of total energy expenditure due to decreased physical activity (202).
This may lead to a positive energy balance contributing to the development of obesity and
central adiposity, often observed in middle and early old age.
The increase in central obesity with age causes a higher production of proinflammatory cytokines that contributes to a low-grade inflammatory state. As previously
discussed, inflammatory cytokines are implicated in the development of both, osteoporosis
and sarcopenia, and thus may further enhance the age-related changes in these tissues.
Furthermore, the pro-inflammatory cytokines are involved in the development of insulin
insensitivity (184), which is then exacerbated by the decreased metabolic functioning and
wasting of muscle tissue (175).
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2.1.7 Inflammatory stress
Aging is associated with an imbalance between the adaptive and innate immunity
leading to a pro-inflammatory phenotype; this phenomenon has been termed „inflammaging‟ (27). While the adaptive immune system declines with age (immunosenescence),
innate immunity seems to be activated. Epidemiological studies indicate that serum levels of
inflammatory markers are 2-4 fold elevated in aged people compared to their younger
counterparts (203). The most important cytokines in this process appear to be TNF- , IL-6,
IL-1 , TGF- and IL-10, and studies show that high levels of these markers are correlated
with greater morbidity, disability and mortality (204). Accordingly, inflammatory stress has
been implicated as one of the most important factors in the development of chronic diseases
of aging (204).
Various stimuli and factors are involved in the cytokine production, including
immunological stimuli, the renin-angiotensin system (RAS), ROS, adipose tissue
metabolism and PPARs (204). Most of these pathways converge on modulating the
transcription factor NF- B (nuclear factor kappa-light-chain-enhancer of activated B cells),
which is key player in activating the expression of pro-inflammatory genes such as those for
TNF- , IL-6 and IL-1 . Genetic polymorphisms may also influence the individual level of
produced cytokines and therefore the intensity of the inflammatory response (204).
The transcription factor NF- B has a crucial role in regulating the inflammatory
response in multiple cell types. In the resting state, NF- B is associated with inhibitory
proteins I Bs and thereby sequestered in the cytoplasm. However, I Bs are rapidly
phosphorylated and degraded by the proteasomes in response to various stimuli, resulting in
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free NF- B that translocates to the nucleus to regulate gene expression of its target genes
(205). In addition to the I B-kinase (IKK)-dependent regulation, NF-KB can be
posttranslationally modified independently of I B by ubiquitination, acetylation and
isomerization of specific amino acid residues (206); e.g. deacetylation by Sirt1 leads to its
inactivation (140).
There is a bidirectional interaction between oxidative stress and inflammation. H2O2
produced from the mitochondria leads to NF- B activation in the cytosol and consecutively
to the production of pro-inflammatory cytokines. Although the response to oxidative stimuli
is short-lived under normal conditions, it can lead to chronic inflammatory responses when
the oxidative stimuli are not well controlled (207). On the other hand, induction of TNFcan increase cellular ROS production, mainly by activation of NADPH oxidase. Because of
a positive feedback loop, this results in further activation of NF- B and production of TNF(208, 209). The interaction between oxidative stress and inflammation appears to play an
important role in vascular inflammation and the development of atherosclerosis even in the
absence of other traditional risk factors. For instance, it was demonstrated that TNF-

in

isolated carotid arteries from young rats can promote an atherosclerotic phenotype by
increasing superoxide production and NF- B activation, and treatment with an anti-TNFagent exerted vasculoprotective effects in aged rats (210).
The local renin-angiotensin system (RAS) plays also a role in NF- B stimulated
inflammation, particularly in endothelial cells (209). Most of these effects are mediated by
angiotensin II (Ang II). The classical mechanism involves the phosphorylation of I B;
however, binding to its AT1 receptor can also activate NADPH oxidase resulting in
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increased ROS production and NF- B activation (211). In addition, there is evidence for a
Ras/MEK/ERK1/2 signaling pathway dependent activation of NF- B (212)
Adipose tissue is a key source of pro-inflammatory cytokines, including IL-6, TNF, C-reactive protein, plasminogen activator inhibitor-1 (PAI-I) and angiotensin (213).
Therefore, the increase of visceral adipose tissue with age is a major contributor to the proinflammatory state of older people. In support of this concept, obese people show increased
levels of pro-inflammatory markers and a greater incidence of inflammation-based diseases
than lean people (214).
Newer evidence from genetic analysis of candidate genes in centenarians and
patients with age-related diseases indicates that some genes related to inflammation are
implicated in human longevity. There are positive associations between polymorphic
markers of IL-6, IL-10 and TGF- 1 and longevity. Moreover, additive effects of gene
variants of cytokines with other genes involved in metabolic pathways such as PPAR were
reported to influence the lifespan (215, 216). Thus, genetic polymorphism may influence the
individual level of circulating cytokines and consequently determine overall survival.

2.1.8 Insulin sensitivity
Aging is associated with a high prevalence of type 2 diabetes and impaired glucose
tolerance, which contributes to a substantial risk for cardiovascular disease, and
consecutively to early morbidity and mortality. Although the interaction of many factors
associated with aging such as the development of central adiposity, the decrease in physical
activity, the decrease in muscle mass, medications and coexisting illness contribute to the
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age-related insulin resistance, the influence of the aging process per se on this impairment is
still not fully understood (217).
Although obesity is clearly a major contributor to the development of insulinresistance, there is also a slight age-related increase in fasting glucose levels and a reduction
in insulin sensitivity in healthy older and lean people (218). The impairment of insulin
action can appear at all levels of the insulin signaling pathway and affects glucose
metabolism as well as lipid synthesis, protein synthesis and other insulin signaling
pathways. While the insulin signaling system is highly conserved and practically expressed
in all cell types, the major insulin responsive tissues are muscle, liver and adipose tissue
(217).
A great body of evidence suggests that the increased production of adipocytokines is
the underlying link between central adiposity and insulin resistance (193). The most
important cytokine in this process is TNF- . Studies have shown that TNF- can inhibit the
tyrosine kinase activity of the insulin receptor (IR) and induces serine phosphorylation of
IRS-1 in adipocytes and hepatoma cells resulting in reduced autophosphorylation and
activity of the IR (219, 220). In addition, TNF- decreased Glut-4 mediated glucose uptake
and stimulates the mobilization of stored trigylcerides in human adipocytes in cell culture
(221). However, the increased release of free fatty acids can result in insulin resistance of
muscle and liver (222, 223). In addition, TNF- , released into the systemic circulation by
adipose tissue can have direct effects on other tissues, such as muscle and liver. For
example, chronic TNF-

exposure impaired both insulin-stimulated glucose uptake and

Glut4 translocation in primary myotubes (224), and it inhibited insulin signaling and insulininduced glucose production in liver (225, 226). Furthermore, TNF- exerts indirect effects
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on insulin signaling by suppressing the transcription of adiponectin in adipocytes.
Adiponectin has a wide range of actions, including increasing whole body insulin sensitivity
by reducing endogenous hepatic glucose production and promoting glucose uptake and
oxidation in muscle. However, in contrast to other adipokines, circulating plasma levels are
reduced in individuals with visceral obesity and insulin resistance (227). Since TNF- levels
rise with age even in non-obese people, it may also play a role in the development of insulin
resistance in healthy older people (228).
A cross-talk between Insulin/IGF- and ROS-redox pathways may suggest a link
between oxidative stress and insulin resistance (229). It has been shown that activation of
the insulin receptor activates NADPH-oxidase to generate H2O2. This endogenous burst of
low-level H2O2 reversibly inhibits the protein tyrosine phophatase (PTB) activity that
negatively regulates the autophosphorylation of the insulin receptor (IR) (230). Thus, the IR
mediated ROS production implicates a positive autoregulatory mechanism in early insulin
signal transduction. In addition, it has an essential role in the downstream insulin cascade by
enhancing phosphoinositide 3 kinase (PI3K) and Akt activity (231). On the other hand, longterm exposure and/or higher concentration of H2O2 exert inhibitory effects on insulin action
by multiple molecular mechanisms. These include direct oxidant-induced protein
modifications of insulin signaling molecules, changes in gene regulation as well as impaired
signal transduction due to enhanced serine phosphorylation of IR and IRS by activated
Serine/Threonine-kinases such as ERK, JNK and IKK (232). Therefore, the increase of
endogenous oxidative stress with age leading to impaired insulin signal transmission may be
part of the mechanisms of the age-related insulin resistance.
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The renin-angiotensin-system (RAS) is mainly responsible for adverse structural
changes of arteries leading to endothelial dysfunction and cardiovascular disease seen in
patients with hypertension and diabetes (233). However, multiple studies suggest also an
involvement of the RAS in the pathogenesis of insulin resistance and diabetes. This
hypothesis is based on the observation that inhibition of RAS, either by angiotensinconverting enzyme (ACE) inhibitors or by angiotensin receptor blockade (ARB) reduced the
incidence of type II diabetes in patients with and without hypertension in these clinical trials
(234). Proposed underlying mechanisms are mainly mediated by angiotensin II (ANG II)
stimulation of the AT 1 receptor. This can lead to increased ROS production by activation of
NADPH oxidase and increased expression of cytokines such as TNF- , IL-6 and NF- B
leading to impairment of insulin signaling and glucose uptake in muscle and other tissues.
Moreover, ANG II increases the serine phosphorylation of IR -subunit, IRS-1, and the p85
regulatory subunit of PI-3-kinase via activation of the serine/threonine kinases JNK and
ERK 1/2 (234). Additionally, it was proposed that RAS blockade increases the number of
small insulin-sensitive adipocytes and inhibits lipid storage in muscle and other tissues, thus
improving insulin sensitivity (235). Since adipocytes contain all components of RAS, and
RAS is up-regulated in obese patients, the RAS induced insulin resistance may be a further
link between obesity and insulin resistance (236).
Insulin levels are generally decreased in older people due to insulin secretory defects,
suggesting pancreatic -cell dysfunction. Thus, the compensatory hyperinsulinemia, needed
to maintain normal glucose metabolism during a state of decreased insulin sensitivity can
not occur. Consequently, the age-related insulin secretory dysfunction contributes to the
glucose intolerance and the prevalence of type 2 diabetes in the elderly (237).
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2.2

Adipose tissue

2.2.1 Background
Adipose tissue has been intensively studied over the last decades as it transformed
from an energy storage depot to an active endocrine organ participating in energy
homeostasis, glucose metabolism and immune function. It differs from many other tissues as
it is distributed around the body and forms clusters around other organs such as heart and
kidneys (238). Dispersed fat cells can also occur within other tissues such as bone and
muscle and are more often found in elderly and under lipodystrophic conditions (188, 194).
Adipose tissue in mammals can be distinguished into white adipose tissue (WAT)
and brown adipose tissue (BAT) with almost opposed physiological roles. In contrast to
WAT, BAT serves primarily in thermogenesis by dissipating energy in form of heat
established by increased mitochondrial biogenesis and increased expression of the
uncoupling protein (UCP)-1 (239). Despite their different functions, they are most likely
derived from common precursor cells and maintain the ability to transform into each other
depending from the metabolic needs and stimuli (240).
In humans, the WAT can be distinguished into subcutaneous and visceral WAT,
which have different gene expression profiles of several genes, specific functional
characteristics and gender specific distribution. The visceral fat is found in the
intraperitoneal and retroperitoneal compartments. Intraperitoneal fat can be further divided
into omental, mesenteric and in rodents perigonadal/epididymal fat. The retroperitoneal fat
is located along the ventral surface of the kidney and dorsal from of the intestines, and
represents only a minor part in humans. The subcutaneous can be subdivided into superficial
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and deep layers and is found to a greater extent around the hip, gluteal and femoral region
(241). Premenopausal females appear to accumulate a greater proportion of their body fat in
the gluteal and femoral region (gynoid type), whereas men tend to store their excess fat in
the abdominal cavity (android type) (242). Visceral fat is unique compared to other adipose
regions because of its close proximity and direct connection to the liver by the portal vein. In
addition, visceral adipocytes are smaller than subcutaneous cells, accumulate fewer lipids,
show a greater response to -adrenergic agonists and glucocorticoids, have a higher lipolytic
rate, and are metabolically more active by secreting higher amounts of adipocytokines (243).
All these different characteristics contribute to the greater impact of visceral adiposity to the
development of insulin resistance and metabolic diseases.
Adipose tissue growth can appear by an increase in both adipocyte size
(hypertrophy) and number (hyperplasia), and is controlled by interactions of multiple factors
including hormones, transcription factors, autonomic nervous system and diet (244, 245).
While studies suggest that hyperplasia is highest during the first years of life and at puberty,
hypertrophy seems to be more responsible for fat mass expansion in adulthood. However,
the capacity to increase the adipocyte number remains throughout life, although it is
hypothesized that a critical fat cell size is necessary before hyperplasia takes place and that
the mature adipocyte stimulates the proliferation of preadipocytes in an autocrine/paracrine
manner (246-248).
The cell dividing capacity of mature adipocytes is very limited, thus hyperplasia
involves the differentiation of precursor cells to new adipocytes. Differentiation to
adipocytes can be induced from embryonic stem cells (249), and it has been reported that
mulitpotent adipose derived stem cells (MADS) have been isolated from human adipose
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tissue harvested by liposuction, which can differentiate into mesenchymal cells giving rise to
adipogenic, osteogenic, chondrogenic and myogenic precursor cells (250). However,
molecular and cellular differentiation events have been best studied in in vitro culture
systems

using

undifferentiated

fibroblast-like

preadipocytes

(251).

To

undergo

differentiation, committed preadipocytes have to withdraw from the cell cycle (growth
arrest) and receive a combination of mitogenic and adipogenic signals, which may vary
depending on the specific cell culture model used. In general, the adipogenic induction
cocktail includes supraphysiological concentrations of insulin, dexamethason (DEX), and
isobuthylmethylxanthine

(IBMX),

indicating

the

involvement

of

insulin/IGF-1,

glucocorticoid and c-AMP signaling pathway as required signals for differentiation.
Adipogenesis is accompanied by characteristic morphological and gene transcription
changes. Morphological hallmark is the alteration of the cell shape from a fibroblastic to a
spherical shape. Transcriptionally gene expression changes can be divided into early,
intermediate and late mRNA/protein markers. Key regulators include the transcription factor
families CCAT/enhancer binding protein factor (C/EBP
proliferator activated receptor (PPAR)-

,

and

) and peroxisome

as well as the adipocyte determination and

differentiation factor (ADD)-1 and the sterol regulatory-element binding protein (SREBP)1c. Activation of the transcriptional cascade leads finally to increased activity and mRNA
levels for enzymes involved in lipid metabolism, insulin sensitivity and glucose uptake, and
adipocyte-specific production of hormones and cytokines (251, 252).
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2.2.2 Cell composition
In addition to adipocytes, adipose tissue consists of a variety of other cell types.
These include stromal/vascular cells, immune cells and nerve fibres of the autonomic
nervous tissue (213, 245).
Studies have demonstrated that there is a dynamic interplay between adipogenesis
and angiogenesis (253-255). Adipocyte differentiation took place in adipogenic/angiogenic
cell clusters and depended significantly on the secretion of the vascular endothelial growth
factor (VEGF) of the non-fat cells in these clusters. On the other hand, VEGF antibodies
could inhibit angiogenesis and decrease the formation of adipogenic/angiogenic cell clusters
(255). Similarly in the other study, preadipocytes induced angiogenesis in a vivo-model
while PPAR- inhibition reduced preadipocyte-induced angiogenesis and VEGF-receptor
antibodies inhibited angiogenesis and subsequent further predadipocyte differentiation
suggesting a paracrine interaction between adipocytes and stromal/vascular cells (253).
The stromal/vascular fraction of adipose tissue constitutes also an important
residence for macrophages that could originate from either preadipocytes or blood
monocytes. Cousin et al. provided evidence that preadipocytes could function as macrophage like cells and that this ability was lost with differentiation into adipocytes (256). In
addition, studies indicate that the macrophage population in adipose tissue resulted from
recruitment of blood monocytes. Adipocyte-derived proteins such as monocyte
chemoattractant protein (MCP)-1, IL-8 and leptin in mature adipocyte-conditioned medium
were capable to activate endothelial cells to secrete soluble adhesion molecules such as
intercellular adhesion molecule (ICAM)-1 and platelet endothelial cell adhesion molecule
(PECAM)-1 that stimulated the adhesion and diapedesis of blood monocytes (257). In
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support of this concept, obesity is positively correlated with higher levels of adhesion
molecules such as ICAM-1, vascular cellular adhesion molecule (VCAM)-1, E- and Pselectin (258, 259) and fat tissue from adipose individuals shows a greater infiltration of
macrophages (257). The latter was also confirmed in a gene expression profile study in mice
demonstrating that adiposity up-regulated a large proportion of transcripts encoding for
proteins characteristic for macrophages (260). In addition, visceral fat was associated with
increased expression of adhesion molecules mRNA compared to subcutaneous fat,
supporting the link between visceral adiposity, inflammation and increased risk of
cardiovascular disease (258).
It has been reported that the adipose tissue is regulated by the autonomous nervous
system directly and indirectly as a result of its effect on insulin secretion (261). While
sympathetic activation in white adipose tissue led to an increase in lipolysis and release of
free fatty acids, and inhibited adipocyte proliferation in vivo (262, 263), it increased
thermogenesis and proliferation of brown adipose tissue (239). Furthermore, adipose siterelated differences were suggested with a weaker catecholamine-induced lipolytic response
in subcutaneous fat than in visceral fat, which was more evident in women than in men. This
effect could be explained by the different distribution of

2-adreno

and

1,2-adrenoreceptors,

which is not only sex-specific but also depend on the extent of fat mass and fat cell
hypertrophy (261). In contrast, the evidence for parasympathetic innervation is scarce and
controversial. However, Kreier et al. reported an overall anabolic role for the vagal input to
white adipose tissue (264).
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2.2.3 Endocrine function
The view of the adipose tissue as a passive energy-storing tissue has changed with
the discovery of leptin. Since then, many new hormones and factors secreted from
adipocytes or by other cell types within the adipose tissue such as macrophages have been
identified, and its active endocrine role is meanwhile well recognized (213). In addition to
regulating energy and nutrient homeostasis locally, adipose derived hormones such as leptin
and adiponectin (discussed below) are involved in modulating energy balance, lipid and
glucose metabolism in other tissues, and cytokines such as TNF-

and Il-6 (discussed

below) play a central role in the pathogenesis of inflammation and metabolic diseases (265).
Furthermore, adipose tissue expresses enzymes influencing glucocorticoid conversion such
as 11 -hydroxysteroid dehydrogenase (11

HSD) that converts inactive cortisone to the

active form cortisol, and sex hormone production promoting the formation of estrogen from
androgenic precursors (266). Particularly increased 11 -HSD activities may contribute to
visceral adiposity and metabolic syndrome (267, 268). In addition, adipose tissue expresses
all enzymes of the renin-angiotensin-system (RAS) that contributes locally and systemically
to inflammation and oxidative stress production (269, 270).
2.2.3.1

Leptin
The hormone leptin, a 167 amino acids long protein product of the obesity (ob) gene,

is derived almost exclusively from the adipose tissue. Its main function is to regulate energy
homeostasis by repressing food intake and promoting energy expenditure; however, it also
modulates neuroendocrine and immune function (271).
The main action of leptin is mediated by interaction with leptin receptors in the CNS.
Highest expression of these receptors is found on neurons in the hypothalamus. Binding to
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its receptor causes rapid activation of Janus activating kinase (JAK) 2 leading to tyrosine
phophorylation of the receptor and consecutively to binding of src homology 2 (SH2)domain containing proteins such as STAT3 and SH-2-domain phosphotyrosine phosphatase
(SHP-2). Downstream targets of this signaling cascade include activation of the extracellular
signal-regulated kinase (ERK1/2), c-FOS and PI3K (272).
Serum leptin levels are proportional to the amount of adipose tissue and abdominal
obesity is generally correlated with higher circulating leptin concentrations. However,
despite higher levels, obese individuals seem to develop a state of leptin-resistance in the
CNS either caused by decreased uptake by the brain blood barrier or by overexpression of
negative regulators of the leptin signaling cascade such as suppressor of cytokine signaling
(SOCS) 3 protein and protein phosphatase 1B (PTP-1B) (227, 272).
In addition to its central action, leptin receptors are present in peripheral tissues such
as adipose tissue, liver, skeletal muscle and pancreatic -cells. Leptin signaling in these
tissues regulate glucose homeostasis, improve insulin sensitivity and inhibit accumulation of
triglycerides in liver and muscle (265). Moreover, anti-immunosuppressive effects by
interacting with T lymphocytes were reported, which may activate the innate immune
system. While this activation may have beneficial effects under acute conditions and
starvation, chronically activation may be deleterious and may contribute to the proinflammatory state associated with obesity (213, 272).
2.2.3.2

Adiponectin
Adiponectin, also known as adipocyte complement-related protein 30 (Arcp30),

adipose most abundant gene transcript 1 (apM1) and adipoQ, is a 30 kDA protein and
mainly synthesized by adipocytes (273). It circulates in high concentration in the plasma
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with circulating levels in females two to three times higher than in males. In contrast to most
other adipocytokines, adiponectin levels decrease with increasing fat mass, particularly
visceral obesity, and are negatively correlated with insulin resistance and type II diabetes
(273, 274).
The adiponectin monomer consists of three domains, which are a variable aminoterminal signal peptide, a collagen-triple helix formation, and a globular head at the
carboxyl-terminus. In serum adiponectin exist in form of homotrimers, which can further
combine to multimeric complexes. These complexes can be classified into two major
groups: low molecular weight (LMW) oligomers which include trimers and hexamers, and
high molecular weight (HMW) multimers consisting of four to six trimers or more (12-, 18mers and larger). Furthermore, adiponectin can undergo several kinds of post-translational
modification including hydroxylation and disulphide bond formation, which play a role for
oligmerization (273).
There are two adiponectin receptors identified. AdipoR1 is ubiquitously expressed
but most abundant in skeletal muscle, AdipoR2 is most abundantly expressed in liver. In
addition to lower circulating adiponectin levels during hyperinsulinemia, the expression of
both receptors is also decreased by insulin (265, 273).
Adiponectin is a multifunctional protein with potent insulin-sensitizing effects. It
increases fatty acid oxidation and glucose uptake in skeletal muscle, and it reduces glucose
production in liver; most of these effects are mediated by activation of AMPK (275). It also
suppresses TNF-

expression thereby exerting anti-atherosclerotic, anti-atherogenic and

anti-inflammatory effects which are beneficial in protection against vascular disesase (276).
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2.2.3.3

Tumor necrosis factor (TNF) One of the most potent pro-inflammatory cytokines is TNF-

that is mainly

produced by activated macrophages within the adipose tissue rather than by adipocytes
(213). It is a 26 kDa plasma membrane protein which is cleaved in the extracellular domain
by matrix metalloproteinases to release a 17 kDa soluble form. Responses to TNF-

are

mediated by binding to one of two distinct cell surface receptors, TNFR1 and TNFR2,
which differ in their cellular and tissue distribtion and show both distinct and overlapping
activities (277). In addition, soluble forms of TNF- receptors are known and it is suggested
that these compete for binding with the cell surface receptors to inhibit TNF-

activity

(271). Binding of TNF- to its cell-surface receptors results in subsequent signaling events,
which include activation of NF- B, JNK and p38 MAPK. Overall, these signaling cascades
may lead to wide range of cellular responses such as death, survival, proliferation,
differentiation and migration (277).
Similarly to the other cytokines, higher levels of TNF- are found in visceral adipose
fat depots than in subcutaneous fat (278). Circulating TNF-

concentrations rises with

increasing obesity and are positively correlated with insulin resistance (213). In addition,
TNF-

plays a pivotal role in the pathogenesis of vascular inflammation and endothelial

dysfunction (279), providing an important link between visceral adiposity, insulin resistance
and vascular diseases.
2.2.3.4

Interleukin 6 (IL-6)
IL-6 is an important regulator of inflammation and immune response. It is produced

by a number of cells such as endothelial cells, fibroblasts, osteoblasts, myocytes and
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macrophages; however, the adipose tissue is recognized as one of the major production sites
and contributes 10 to 35 % of circulating plasma levels in resting, healthy humans. Within
the adipose tissue, the adipocytes release only a fraction of the total IL-6; non-fat cells in the
adipose matrix such as macrophages and stromavascular cells produce the remaining
amount. Hypertrophic enlargement of adipocytes is correlated with increased IL-6
production, and visceral fat contribution is greater than subcutaneous fat production.
Accordingly, circulating levels are slightly but significantly elevated with visceral adiposity
and contribute to a chronic low-grade inflammation state in obese people (213, 280).
The IL-6 receptor consists of two forms: a membrane bound form and a soluble form
(IL-6Rs) generated by alternative splicing or proteolytic cleavage of the membrane-bound
receptor. In addition, IL-6 in form of IL-6/IL-6Rs, can bind to gp130, a common signal
transducer unit for IL-6 type cytokines including IL-11, leukemia inhibitory factor and
oncostatin M. After binding to the receptors, the IL-6/receptor complex leads to activation of
the JAK/STAT pathway and MAPK signaling cascade (271, 280).
IL-6 has auto-, para-, and endocrine regulatory function. While in muscle insulin
sensitizing effects with increased insulin-stimulated glucose uptake are reported, it
suppresses insulin-signal transduction in liver and adipocytes resulting in reduced glucose
uptake and increased release of free fatty acid from the adipose tissue (280). Similarly,
double-sided actions are found in terms of inflammation. Some evidence points to antiinflammatory functions because it inhibits TNF- production and stimulates the production
of anti-inflammatory IL-1 receptor antagonist and IL-10. On the other hand, it promotes the
release of C-reactive protein and other acute phase proteins from the liver, promotes the
migration of polymorphnuclear leukocytes and increased expression of adhesion molecules
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in endothelial cells, and leads to activation of local RAS thereby favoring chronic
inflammation and vascular damage (213, 281)

2.2.4 Energy metabolism
The adipose tissue plays a major role in total body lipid and energy homeostasis.
First, it is the most important site of energy storage and manages the release or uptake of
free fatty acids and triglycerides according to the body‟s supply and demand. Secondly, it
acts as an endocrine organ in a hormonal and neuronal network by integrating signals from
other part of the body and by secreting adipocytokines that regulate food and energy balance
locally and peripherally.
Lipid storage in adipocytes is regulated by fatty acid uptake, lipogenesis and
lipolysis, and reflects the balance or imbalance between energy intake and expenditure.
Triglyceride synthesis can start as de novo lipogenesis from acetyl-CoA that involves the
key enzymes acyl-CoA carboxilase (ACC) and fatty acid synthase (FAS), or from the uptake
of circulating free fatty acids (FFA). In humans, de novo lipogenesis seems to be of minor
importance in adipocytes and plays mainly a role under high caloric, low-fat highcarbohydrate-diets (282). Under normal condition, most triglycerides derive from the uptake
of FFA, which are released from circulating lipoprotein-triglycerides by lipoprotein lipase.
In the adipocytes, the FFA will be esterified to glycerol-3-phophate and stored in the lipid
droplets (276).
Under fasting or enhanced energy demand adipose tissue fat stores are used to supply
the body‟s energy requirements. The generation of FFA (lipolysis) involves the hydrolysis
of the esterbonds from the glycerol backbone, which is mediated by the three lipases:
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adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and monoglyceride
lipase (MGL) (283). Although HSL shows broad substrate specificity, it preferentially
hydrolyzes diglycerides, whereas ATGL prefers triglycerides over diglycerides.
Adipose tissue is also involved in regulation of glucose homeostasis. It participates
in postprandial insulin-mediated glucose uptake and disposal, and both obesity and
lipodystrophy are associated with hyperglycemia and insulin-resistance. In addition, the
secretion of several hormones such as leptin, adiponectin, resistin, and visfatin can modulate
insulin sensitivity and glucose metabolism (284). Furthermore, circulating non-esterified
fatty acids, primarily released from the adipose tissue during fasting, may reduce glucose
uptake in muscle and adipose tissue, promote hepatic glucose production, and stimulate
pancreatic insulin secretion (222, 285). These effects are most likely caused to spare glucose
utilization for the CNS. However, prolonged exposure as seen under insulin-resistant and
diabetic conditions may lead to -cell apoptosis and lipotoxicity of other tissues such as
muscle and liver, thus producing a vicious cycle by further increasing insulin resistance
(286, 287)
Glucose and lipid metabolism is controlled by hormonal and neuronal stimuli, which
also depend on other conditions such as age, gender, physical activity and nutritional factors.
The most potent stimulators of lipolysis are catecholamines acting on 1 and 2 adrenergic
receptors in human adipose tissue. Binding to the receptor stimulates Gs proteins to activate
adenylate cyclase, which results in increase in c-AMP and subsequently to activation of cAMP-dependent protein kinase-A (PKA). Other hormones that act via Gs protein-couple
receptors and stimulate PKA are glucagon, parathyroid hormone, thyrotropin,

-

melanocyte-stimulating hormone, and adrenocorticotropin (283). PKA phophorylates a
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number of target proteins including lipolytic enzymes such as HSL and lipid droplet
associated proteins. On the other hand, there are several anti-lipolytic factors acting through
inhibitory Gi protein-coupled receptors. Examples are 2-adrenergic receptor catechomines,
prostaglandins, adenosine and nicotinic acid. However, the most potent inhibitors of
lipolysis are insulin and IGF, which interact with the insulin signaling cascade and leads to
activation of several protein kinases such as 3-phosphoinositide-dependent protein kinases
(PDK1 and 2) and protein kinase C (PKC). Inhibition of lipolysis includes the
phosphorylation of phophodiesterase 3B resulting in degradation of c-AMP and decreased
PKA activity.
Insulin, released in the fed state, is also one of most important hormones influencing
lipogenesis. The stimulating effect is caused by several mechanisms, these include increased
uptake of glucose in the adipose cell, activation of lipogenic and glycolytic enzymes via
covalent modification, and activation of the transcription factors sterol regulatory element
binding protein (SREBP)-1 and PPAR- (288).
Lipogenesis is also stimulated in an endocrine/autocrine manner by the acylation
stimulating protein (ASP), a small peptide produced by the adipose tissue. In vitro and in
vivo studies indicate that ASP stimulates triglyceride clearance from the plasma and
accumaltion in the adipocytes while simultaneously decreasing lipolysis. However, the
specific underlying molecular mechanisms are still not known (275).

2.2.5 Source of ROS
Adipose tissue is a significant source of ROS production, and obesity can lead to an
increase in systemic oxidative stress. Supporting evidence is provided by studies, which
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show that BMI and fat accumulation correlates with systemic oxidative stress markers in
rodents and humans (289, 290). Furthermore, abdominal fat and weight loss after bariatric
surgery was correlated with decreases of plasma derivatives of reactive oxidative
metabolites (291).
The major source of ROS production in adipocytes is NADPH oxidase, and two
isoforms, NOX2 and NOX4, have been identified (31). Furukawa et al. showed that adipose
tissue NOX4 is up-regulated in obese mice (290). They also indicated that NOX4 mediated
ROS production seemed to be stimulated by fatty acids, since ROS production was
increased concomitantly with the accumulation of fat into the differentiating 3T3-L1
adipocytes, and was also elevated in differentiated adipocytes after incubation with free fatty
acids in the medium. Inhibitors of NADPH oxidase suppressed both effects. In addition,
adipose tissue plays a pivotal role in the production of TNFTNF-

and other cytokines, and

appears to be an important activator of ROS production. Most of this effect is

mediated by inducing NADPH oxidase gene expression and activity as demonstrated in
multiple tissues such as cerebral vascular endothelial cells, colon epithelial cells and
vascular smooth muscle cells (292-294). However, since ROS stimulates the NF- Bdependent activation of pro-inflammatory cytokine expression including TNF- (295), this
bidirectional interaction may act as a vicious cycle under conditions of either enhanced ROS
or cytokine production as seen in obesity.
Mitochondrial ROS production is dependent on the mitochondrial potential, which is
determined by the backflow of H+ across the mitochondrial membrane. The uncoupling
proteins (UCP) are a family of proteins in the inner mitochondrial membrane, which
uncouple the proton flux from ATP-synthesis, thereby reducing the mitochondrial potential
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and ROS formation (296). UCP 2 and 3 are ubiquitously expressed and played an important
role in modulating mitochondrial ROS production in several tissues and cells including
macrophages and endothelial cells (297). For example, over-expression of recombinant
UCP-2 in primary cultured human vascular smooth muscle cells reversed high glucose and
Angiotensin II stimulated ROS production (298), whereas defective UCP2 expression in
endothelial cells increased intracellular and extracellular oxidative stress markers (299).
Since UCP2 is also highly expressed in adipose tissue and tissues rich in macrophages (300),
it is very likely to play a major role in adipocyte ROS production. In addition, UCP2
expression appears to function as a free fatty acid transporter that support the fatty acid (FA)
cycling to the mitochondria for oxidation (296), Accordingly, it has been postulated that free
fatty acids up-regulate UCP expression by mechanisms that may involve the PPARtranscription factors (301, 302). They also seem to be up-regulated in obese animals and
humans (303, 304), suggesting a protective and compensatory role of UCP2; although, some
evidence indicates decreased levels in obese subjects, which is compatible with reduced
energy expenditure in obesity (305).

2.3

Dietary calcium and dairy modulation of adipose tissue
function
Studies over the last decade indicate that dietary calcium has not only health

promoting effects on bone and mineral metabolism but also on adipose tissue function by
modulating adiposity, fat metabolism and endocrine activity. Dairy products are the major
contributors to dietary calcium and are often used to study the effects of calcium; however,
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effects are often augmented when dairy products are compared to supplemental calcium,
which is due to additional components in dairy as discussed in the next chapter.

2.3.1 Energy storage and adiposity
Epidemiological and experimental evidence pointed to an inverse relationship
between calcium intake and body weight and adiposity in multiple studies (306). Although
these effects are usually seen in all population groups, some studies show gender and ethnic
differences such as a cross-sectional survey in 3246 Israelis aged 25 to 60 years, which
showed a significant inverse association between daily calcium intake and waist
circumference for women but not for men (307), and a cross-sectional study constructed
among US adults from the National Health and Nutrition Examination Survey 1999-2004
data, in which the effects of a variety of dairy products and their related nutrients on obesity,
central obesity and metabolic syndrome were assessed. Ethnic differences in metabolic
outcomes were found, with higher BMI for Non-Hispanic Blacks and Mexican Americans,
which could be at least in part explained by variations in dairy-related nutrients (308).
Lower weight, BMI and body fat mass and higher lean body mass were also found for the
highest calcium intake group in a study conducted in 96 normal weight and obese
adolescents providing further support for the importance of an adequate calcium intake
during childhood and early adulthood (309).
Calcium and dairy appear to have augmenting effects on weight and fat loss under
caloric restriction and decreases adiposity under eucaloric conditions in individuals with low
calcium intake. For example, Zemel et al. conducted a randomized, placebo-controlled
weight loss trial over 24 weeks in 32 obese adults with habitual low calcium intake, in which
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patients were maintained on a standard hypocaloric diet either supplemented with placebo,
800 mg of calcium or 1200 to 1300 mg of calcium in form of dairy. The high calcium and
dairy group increased their weight loss by 26% and 70%, respectively, compared to the
placebo group; calcium and dairy also significantly augmented fat loss from the trunk region
(310). This effect seems to be diminished in individuals whose calcium intake is adequate or
only moderately low (311). Although no weight loss effects of high calcium treatment is
seen under eucaloric conditions, it still significantly modulates body composition by
reducing fat mass and increasing lean tissue mass (312).
Mechanistic explanations are suggested by multiple animal and cell studies. Low
calcium intake causes an increase in parathyroid hormone secretion and 1, 25-dihydroxyvitamin D (calcitriol) production. Calcitriol stimulates rapid calcium influx into the cells by
acting on the membrane-associated rapid response to steroid receptor (MARRS), which
results, paradoxically, in an increased intracellular calcium concentration ([Ca2+]i) (313,
314). The calcitriol-stimulated increase in [Ca2+]i promotes energy storage in adipocytes by
activating key enzymes of lipogenesis such as fatty acid synthase (FAS) and inhibiting
lipolytic genes (315, 316). Accordingly, dietary calcium suppresses circulating calcitriol that
leads to a decrease of [Ca2+]i and to a reversal of calcitriol action. In addition, calcitriol acts
via the classical nuclear vitamin D receptors to inhibit UCP2 expression in adipocytes,
leading to inhibition of apoptotic pathways at physiological calcitriol concentration;
consequently, suppression of calcitriol with high calcium diets results in up-regulation of
UCP2 and apoptosis in adipose tissue further enhancing the anti-obesity effect of high
calcium diets (317, 318). Additionally, UCP2 is involved in fatty acid transport to the
mitochondria, and its up-regulation increases fatty acid oxidation; that together with
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increased uncoupling leads to increased energy expenditure (319, 320). These concepts are
confirmed by experimental studies in mice. After induction of obesity by feeding a low
calcium high sucrose diet in aP2-agouti transgenic mice, a weight loss phase was
implemented with either a low-calcium hypo-caloric diet or different high calcium hypocaloric diets. The high calcium groups showed significantly greater weight and fat pad loss
and an increase in core temperature, which was associated with a decrease in FAS activity
and increase in lipolysis as well as an up-regulation of UCP2 expression in WAT (321). In
another study, the calcium effects on refeeding were examined after a weight loss period.
The high calcium groups demonstrated less weight gain, stimulated adipocyte lipolysis,
inhibited lipogenesis and adipogenesis, and were associated with higher UCP2 expression in
WAT and UCP3 expression in muscle indicating a repartioning of energy from adipose
tissue to muscle (320).
Studies have shown that the anti-obesity effect induced by high calcium diets
resulted in greater reduction of visceral fat depots (322). This effects is most likely
attributable to a decreased activity of 11 -hydroxysteroid dehydrogenase type 1 (11 HSD1), which converts inactive cortisone to active cortisol in adipose tissue (319). In fact,
calcitriol has been shown to stimulate cortisol production in human adipocytes (323), and
selective over-expression of 11 -HSD in white adipose tissue in mice resulted in central
obesity (268). In addition, results of a microarray study demonstrated suppression of 11 HSD1 expressions in adipose tissue by dietary calcium in diet-induced obese mice (324).
Thus, it seems very plausible that the reduced cortisol production due to suppression of
calcitriol caused the preferential loss of visceral adipose tissue.
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2.3.2 Adipose tissue – muscle crosstalk
Adipose tissue funtions as a large energy reserve that provides fuel for metabolic
processes in other tissues in form of fatty acids during fasting or during periods of high
activity. This energy is primarily used in muscle. In addition, adipose tissue secretes factors
that regulate energy balance and may alter substrate utilization in muscle (252). For
example, adiponectin secreted from the adipocytes is a potent activator of AMPK in muscle,
which results in increased fatty oxidation and glucose uptake, thus improving hypergycemia
and insulin sensitivity. Leptin also stimulates repartitioning of fatty acids towards oxidation
via activation of AMPK and enhances the insulin response in muscle (325). In addition, proand anti-inflammatory cytokines play a role in the interaction between adipose tissue and
muscle. Culture of human skeletal muscle cells with conditioned media from mature human
adipocytes derived from subjects with a wide range of BMI demonstrated an inverse
correlation between insulin-stimulated Akt/PKB and BMI and fat cell size (326). The
selected adipokine concentration in the conditioned media also revealed an inhibitory effect
TNF- on Akt/PKB phosphorylation. Likewise, chronic exposure to TNF- induced insulin
resistance in rodents (220, 226), and TNF-

expression was significantly increased in

skeletal muscle of insulin resistant humans (327). Furthermore, TNF- appeared to impair
mitochondrial biogenesis in vitro in white and brown adipocytes, and muscle satellite cells
as well as in vivo in fat and muscle tissue of genetically and environmentally obese mice
(328), which may contribute to the altered lipid metabolism observed in insulin resistant
individuals. Conversely, the cytokine IL-6 seems to have insulin-sensitizing effects and
catabolic effects on lipid metabolism; IL-6 infusion in diabetic patients decreased plasma
insulin concentration and increased fatty acid utilization in muscle (329). Further, Il-15, a
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cytokine highly expressed in skeletal muscle, appeared to have anabolic action on muscle
fiber growth in cell culture, and administration to adult rats decreased white adipose tissue
mass and circulating triacylglycerols levels, indicating significant effects on both adipose
and muscle tissue (330).
Dietary calcium, particularly in form of dairy products, has been demonstrated to
reduce adiposity and to promote lean tissue mass in multiple studies (310, 321, 331),
indicating a role of calcium and calcitriol on energy partitioning between adipose tissue and
skeletal muscle. Thus, in a follow-up cell study the effects of calcitriol and calcium
antagonism in regulation of adipose-muscle cross-talk were investigated in an adipocyteskeletal myocyte coculture system (332). Calcitriol significantly decreased fatty acid
oxidation in muscle cells and concurrently increased FAS gene expression in adipocytes,
while the calcium channel blocker nifedipine partially inhibited these effects. Additionally,
it was found that calcitriol inhibited adiponectin production in adipocytes, which was
reversed by addition of nifedipin. Calcitriol also regulated the interaction of macrophages
and adipocytes, which resulted in enhanced pro-inflammatory cytokine production, as
demonstrated in an adipocyte-macrophage coculture system (333), which may further
contribute to alteration in energy metabolism as discussed earlier.

2.3.3 ROS
As described before, adipose tissue is major site of ROS production and oxidative
stress is increased in obesity and associated disorders (290). It has been demonstrated that
calcitriol stimulates ROS production in adipose tissue via both genomic and non-genomic
actions, as follows (319). The calcitriol induced increase in [Ca2+]i resulted in an increased
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expression of NADPH oxidase, the major contributor to cytosolic ROS production, in
human and murine adipocytes (334), while suppression of calcitriol by dietary calcium
inhibited adipocyte NADPH oxidase expression and ROS production in aP2-transgenic mice
(335). Further, calcitriol suppressed adipocyte UCP2 expression via interaction with nVDR,
resulting in increased mitochondrial potential and, consequently, enhanced mitochondrial
ROS production (334). This effect was augmented by addition of a mitochondrial uncoupler
inhibitor and reversed by over-expression of UCP2. Moreover, the calcitriol induced an
increase in adipocyte cortisol production via activation of 11 -HSD1, thereby promoting
visceral adiposity, as described above, and visceral fat appeared to be associated with a
higher ROS production than subcutaneous fat (336). Accordingly, suppression of calcitriol
by dietary calcium resulted in a greater reduction of ROS in visceral fat than in
subcutaneous fat. Overall, all these effects support a role of dietary calcium in modulating
oxidative stress, and is supported by both in vitro and in vivo studies (335-337).

2.3.4 Inflammation
Dietary calcium has been shown to attenuate obesity-associated inflammatory stress
in mouse models of obesity by inhibiting the expression of pro-inflammatory factors, such
as TNF- and IL-6, in visceral fat, and stimulating the expression of the anti-inflammatory
factors such as IL-15 and adiponectin. Conversely, calcitriol stimulated the expression of
TNF- , IL-6 and Il-8 in differentiated adipocytes (338). Further it was demonstrated that
calcitriol induced the production of an array of other inflammatory cytokines in adipocytes
and/or adipose tissue derived macrophages, which include macrophage surface specific
protein CD14, macrophage inhibitory factor (MIF), macrophage colony-stimulating factor
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(M-CSF), macrophage inflammatory protein (MIP) and monocyte chemoattractant protein-1
(MCP-1). In addition, it regulated the cross-talk between adipocytes and macrophages,
resulting in an augmentation of inflammatory cytokine production (333). Both the calciumchannel antagonist nifedipine and the mitochondrial uncoupler dinitrophenol were able to
block these effects, suggesting that the calcitriol induced inflammatory cytokine production
involves both calcium-dependent and mitochondrial uncoupling-dependent mechanisms.

2.4

Role of additional bioactive components in dairy in
modulating adipose tissue function
Beneficial effects of milk on health are known for centuries; however, more recently

physiologically active compounds in dairy products have gained major interest. Milk
consists of various components and cow milk contains approximately 5% lactose, 3.2%
protein, 4% lipids and 0.7% mineral salts (339). The major proteins of cow milk are a
micellar casein fraction (about 80%) and a soluble whey protein fraction (about 20%) that
includes -lactose, -Lactalbumin, and immunoglobulins. Both, caseins and whey proteins,
may act as precursor for many peptides produced by enzymatic proteolyses with bioactive
functions such as opiate agonist/antagonist and ACE inhibitory activities (339). In addition,
milk proteins have a high nutritional quality score and contain a high proportion of the
branched chain amino acids (BCAA) leucine, isoleucine and valine (340).
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2.4.1 BCAA and Leucine
Dairy proteins, and particularly whey protein, provide a rich source of essential
amino acids and BCAAs. Although the recommended daily allowance (RDA) guidelines for
protein intake is based on maintaining short-term nitrogen balance under conditions of
controlled energy intake, which is 0.8 g protein/kg body weight/day (341), higher intake
levels of BCAAs are required for fulfilling other metabolic functions than serving as
substrate for protein synthesis (342). Recommended intake levels also depend on the kind of
method used, thus measurements based on nitrogen balance revealed lower levels than
newer methodologies measuring direct amino acid oxidation and direct amino acid balance
(343). Therefore, some investigators recommend protein and amino acid intake levels of up
to three times the RDAs, reaching over 8g/day for leucine (342).
In contrast to the other amino acids, BCAAs are not degraded in the liver; therefore
plasma and peripheral tissue levels are proportional to dietary intake (344). Their primary
function is to serve as substrates for protein synthesis; additional roles are to function as
precursors for alanine and glutamine synthesis and to participate in signaling pathways
(342). Leucine, in particular, has a unique role in regulating muscle protein synthesis.
Administration of leucine, alone or in combination with the other amino acids, stimulates
muscle protein synthesis after exercise and inhibits muscle degradation during catabolic
periods such as food deprivation and prolonged endurance training (345-347). In addition,
leucine supplementation stimulated protein synthesis rate to the same amount in older men
compared to younger men after fulfilling activities of daily living suggesting that it may be
beneficial in preventing the age-related muscle loss in the elderly (348). Supplementation
with whey (rich in leucine) led to greater fat loss and less reduction of lean tissue during a
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weight loss period in obese people when compared to the control diet with equal energy
value (349). Similarly, dairy administration exerted greater effects on weight loss, fat loss
and prevention of fat regain after refeeding in obese mice and humans compared to
supplemental high calcium diets (310, 320). Although these effects may be attributable to
several dairy components, recent data demonstrate that leucine alters energy partitioning
between adipose tissue and muscle by stimulating skeletal muscle fatty acid oxidation and
suppressing lipid accumulation in adipocytes (332).
The underlying molecular mechanism for leucine‟s unique role in regulating protein
synthesis is mainly mediated by stimulation of the mTOR complex 1 (TORC1) in skeletal
muscle, which results in activation of eukaryotic initiation factor-4E (eIF4E) and S6
ribosomal protein. Leucine also activates the eukaryotic initiation factor-4G (eIF4G) through
a mTOR-independent mechanism. Although these effects are largely insulin-independent,
baseline fasting levels of insulin seem to be necessary for optimal effects (350).

2.4.2 Angiotensin-converting enzyme inhibitor (ACEi) peptides
Bioactive peptides with ACE inhibitory activity in the casein and whey fraction of
dairy have been demonstrated to play a role in modulating adipose tissue function. ACE is
one of the enzymes necessary for the successive enzymatic cleavage of angiotensinogen to
the major active form angiotensin (ANG) II, and it is well documented that in addition to the
classical endocrine pathway of ANG II synthesis, multiple tissues, including adipose tissue,
contain all the enzymes to produce locally ANG II (270, 351).
The action of ANG II is initiated through interaction with the angiotensin receptor 1
or 2 (AT1 and AT2), which mediate partly counteracting actions. AT1 mediated effects are
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mainly responsible for vascular, renal and adrenal actions of ANG II resulting in arterial
vasoconstriction, renal sodium absorption and sympathetic nervous system stimulation. AT2
expression is much lower in these tissues and results in vasodilation by stimulation of
endothelial nitric oxide synthase (eNOS) and bradykinin release, and in antiproliferation
(234).
Adipose-derived angiotensinogen (AGT) may not only exert its effects locally at the
adipose tissue but also contribute to systemic circulating levels, as numerous studies have
demonstrated that circulating RAS components are increased in obesity and reduced with
weight loss in both animals and humans (269, 352-354). In addition, the amount of visceral
fat correlates with higher levels of RAS components than subcutaneous fat (355).
A role of RAS in adiposity is suggested by studies that demonstrated that ANG II
regulates both adipogenesis and lipogenesis. For example, ANG II increased triglyceride
content and activities of two key lipogenic enzymes (fatty acid synthase

(FAS) and

glycerol-3-phosphate dehydrogenase (GPDH)) in 3T3-L1 and human adipocytes (356).
Regulation of adipogenesis is more complex and seems to be different for mesenchymal
stem sells and preadipocytes. While stimulation of AT1 receptor on mesenchymal stem cells
promoted differentiation to adipocytes, AT2 receptor activation inhibited adipogenesis
(357). In primary cultured human preadipocytes, stimulation of AT1 receptor, which is the
major expressed receptor in preadipocytes, inhibited differentiation resulting in poorly
differentiated adipocytes. Accordingly, blockade of RAS, either by ACEi or angiotensin
receptor blockers, promotes recruitment of preadipocytes and an increase in small insulinsensitive adipocytes (235, 358). Furthermore, co-culture with mature adipocytes inhibited
adipogenic differentiation, and this effect was abolished by AT1 receptor blockade (359)
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The beneficial effects of RAS blockade also results in improvement of metabolic
abnormalities. Since poorly differentiated insulin resistant adipocytes promote lipid
deposition in other tissues such as muscle and bone with consecutively cell damage,
blockade of RAS prevented ectopic fat deposition (360). In addition, blockade of RAS by
ARB reduced the production of ROS, TNF- and other cytokines in adipose tissue of obese
mice which otherwise may exaggerate the inflammatory response (361). Moreover, adiposederived RAS components contribute to systemic levels causing vasoconstriction and
impairing the insulin signaling cascade in muscle and liver promoting overall hypertension,
and insulin resistance (362). Accordingly, blockade of RAS either, by ACEi and/or ARB,
resulted in significant improvement of insulin resistance and metabolic disorders in both
humans and rodents (360, 363-365).

83

Literature Cited:
1.

Weinert B, Timiras P. Invited review: Theories of aging. J Appl Physiol. 2003 2003

Oct;95:1706-16.
2.

van Doorn WG, Woltering EJ. Senescence and programmed cell death: substance or

semantics? J Exp Bot. 2004 Oct;55:2147-53.
3.

Vina J, Borras C, Miquel J. Theories of ageing. IUBMB Life. 2007 Apr-

May;59:249-54.
4.

Medvedev ZA. An attempt at a rational classification of theories of ageing. Biol Rev

Camb Philos Soc. 1990 Aug;65:375-98.
5.

Strehler B, Hirsch G, Gusseck D, Johnson R, Bick M. Codon-restriction theory by

aging and development. J Theor Biol. 1971 Dec;33:429-74.
6.

Hughes KA, Reynolds RM. Evolutionary and mechanistic theories of aging. Annu

Rev Entomol. 2005;50:421-45.
7.

Kirkwood TB, Austad SN. Why do we age? Nature. 2000 Nov 9;408:233-8.

8.

Kirkwood TB, Cremer T. Cytogerontology since 1881: a reappraisal of August

Weismann and a review of modern progress. Hum Genet. 1982;60:101-21.
9.

Kirkwood TB. Evolution of ageing. Mech Ageing Dev. 2002 Apr;123:737-45.

10.

Rose MR, Burke MK, Shahrestani P, Mueller LD. Evolution of ageing since Darwin.

J Genet. 2008 Dec;87:363-71.
11.

Kirkwood TB. Evolution of ageing. Nature. 1977 Nov 24;270:301-4.

12.

Rattan SI. Theories of biological aging: genes, proteins, and free radicals. Free Radic

Res. 2006 Dec;40:1230-8.
84

13.

Szilard L. On the Nature of the Aging Process. Proc Natl Acad Sci U S A. 1959

Jan;45:30-45.
14.

Kanungo MS. A model for ageing. J Theor Biol. 1975 Sep;53:253-61.

15.

Cutler

RG.

Recent

progress

in

testing

the

longevity

determinant

and

dysdifferentiation hypotheses of aging. Arch Gerontol Geriatr. 1991 Mar-Jun;12:75-98.
16.

Orgel LE. The maintenance of the accuracy of protein synthesis and its relevance to

ageing. Proc Natl Acad Sci U S A. 1963 Apr;49:517-21.
17.

Zs-Nagy I. The biological waste product formation in the light of the membrane

hypothesis of aging. Arch Gerontol Geriatr. 2002 May-Jun;34:329-41.
18.

Harman D. Aging: overview. Ann N Y Acad Sci. 2001 2001 Apr;928:1-21.

19.

Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972

Apr;20:145-7.
20.

Hayflick L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. Exp Cell

Res. 1965 Mar;37:614-36.
21.

Olovnikov AM. Telomeres, telomerase, and aging: origin of the theory. Exp

Gerontol. 1996 Jul-Aug;31:443-8.
22.

Ahmed A, Tollefsbol T. Telomeres and telomerase: basic science implications for

aging. J Am Geriatr Soc. 2001 Aug;49:1105-9.
23.

Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human

fibroblasts. Nature. 1990 May 31;345:458-60.
24.

Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S,

Hirte HW, Counter CM, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb
Symp Quant Biol. 1994;59:307-15.
85

25.

Fabris N. Neuroendocrine-immune interactions: a theoretical approach to aging.

Arch Gerontol Geriatr. 1991 Mar-Jun;12:219-30.
26.

Franceschi C, Valensin S, Bonafe M, Paolisso G, Yashin AI, Monti D, De Benedictis

G. The network and the remodeling theories of aging: historical background and new
perspectives. Exp Gerontol. 2000 Sep;35:879-96.
27.

Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De

Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y
Acad Sci. 2000 Jun;908:244-54.
28.

Speakman JR, Selman C, McLaren JS, Harper EJ. Living fast, dying when? The link

between aging and energetics. J Nutr. 2002 Jun;132:1583S-97S.
29.

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and

antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol.
2007;39:44-84.
30.

Droge W. Free radicals in the physiological control of cell function. Physiol Rev.

2002 Jan;82:47-95.
31.

Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases:

physiology and pathophysiology. Physiol Rev. 2007 Jan;87:245-313.
32.

Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs.

Physiol Rev. 1979 Jul;59:527-605.
33.

Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases: not just in

mammals. Biochimie. 2007 Sep;89:1107-12.
34.

Krause KH. Aging: a revisited theory based on free radicals generated by NOX

family NADPH oxidases. Exp Gerontol. 2007 Apr;42:256-62.
86

35.

Los M, Droge W, Stricker K, Baeuerle PA, Schulze-Osthoff K. Hydrogen peroxide

as a potent activator of T lymphocyte functions. Eur J Immunol. 1995 Jan;25:159-65.
36.

Rojas A, Figueroa H, Re L, Morales MA. Oxidative stress at the vascular wall.

Mechanistic and pharmacological aspects. Arch Med Res. 2006 May;37:436-48.
37.

Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Mitochondrial

reactive oxygen species and Ca2+ signaling. Am J Physiol Cell Physiol. 2006
Nov;291:C1082-8.
38.

Yan Y, Wei CL, Zhang WR, Cheng HP, Liu J. Cross-talk between calcium and

reactive oxygen species signaling. Acta Pharmacol Sin. 2006 Jul;27:821-6.
39.

Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for

suicide and survival. J Cell Physiol. 2002 Jul;192:1-15.
40.

Frisard M, Ravussin E. Energy metabolism and oxidative stress: impact on the

metabolic syndrome and the aging process. Endocrine. 2006 Feb;29:27-32.
41.

Shringarpure R, Davies KJ. Protein turnover by the proteasome in aging and disease.

Free Radic Biol Med. 2002 Jun 1;32:1084-9.
42.

Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem. 1997 Aug

8;272:19633-6.
43.

Touyz R. Reactive oxygen species, vascular oxidative stress, and redox signaling in

hypertension: what is the clinical significance? Hypertension. 2004 2004 Sep;44:248-52.
44.

Touyz R, Schiffrin E. Reactive oxygen species in vascular biology: implications in

hypertension. Histochem Cell Biol. 2004 2004 Oct;122:339-52.
45.

Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of

disease. Exp Mol Pathol. 2007 Aug;83:84-92.
87

46.

Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in

the management of diabetes and its complications. Biomed Pharmacother. 2005 2005
Aug;59:365-73.
47.

Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol.

1956 Jul;11:298-300.
48.

Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in

human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A. 1994 May 10;91:4130-4.
49.

Ku HH, Brunk UT, Sohal RS. Relationship between mitochondrial superoxide and

hydrogen peroxide production and longevity of mammalian species. Free Radic Biol Med.
1993 Dec;15:621-7.
50.

Jung T, Hohn A, Catalgol B, Grune T. Age-related differences in oxidative protein-

damage in young and senescent fibroblasts. Arch Biochem Biophys. 2009 Mar 1;483:12735.
51.

Kaneko T, Tahara S, Taguchi T, Kondo H. Accumulation of oxidative DNA damage,

8-oxo-2'-deoxyguanosine, and change of repair systems during in vitro cellular aging of
cultured human skin fibroblasts. Mutat Res. 2001 Nov 1;487:19-30.
52.

Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS. Age-related losses

of cognitive function and motor skills in mice are associated with oxidative protein damage
in the brain. Proc Natl Acad Sci U S A. 1996 May 14;93:4765-9.
53.

Sitte N, Merker K, Von Zglinicki T, Grune T, Davies KJ. Protein oxidation and

degradation during cellular senescence of human BJ fibroblasts: part I--effects of
proliferative senescence. FASEB J. 2000 Dec;14:2495-502.

88

54.

Sitte N, Merker K, von Zglinicki T, Grune T. Protein oxidation and degradation

during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med. 2000
Mar 1;28:701-8.
55.

Martin I, Grotewiel MS. Oxidative damage and age-related functional declines.

Mech Ageing Dev. 2006 May;127:411-23.
56.

Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide

dismutase and catalase in Drosophila melanogaster. Science. 1994 Feb 25;263:1128-30.
57.

Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. Extension

of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet.
1998 Jun;19:171-4.
58.

Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun

PE, Ladiges W, Wolf N, et al. Extension of murine life span by overexpression of catalase
targeted to mitochondria. Science. 2005 Jun 24;308:1909-11.
59.

Comfort A, Youhotsky-Gore I, Pathmanathan K. Effect of ethoxyquin on the

longevity of C3H mice. Nature. 1971 Jan 22;229:254-5.
60.

Melov S, Ravenscroft J, Malik S, Gill MS, Walker DW, Clayton PE, Wallace DC,

Malfroy B, Doctrow SR, Lithgow GJ. Extension of life-span with superoxide
dismutase/catalase mimetics. Science. 2000 Sep 1;289:1567-9.
61.

Harman D. Free radical theory of aging: dietary implications. Am J Clin Nutr. 1972

Aug;25:839-43.
62.

Miquel J, Economos AC, Fleming J, Johnson JE, Jr. Mitochondrial role in cell aging.

Exp Gerontol. 1980;15:575-91.

89

63.

Johns DR. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial

DNA and disease. N Engl J Med. 1995 Sep 7;333:638-44.
64.

Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in

aging and apoptosis. IUBMB Life. 2000 May;49:427-35.
65.

Lee HC, Wei YH. Oxidative stress, mitochondrial DNA mutation, and apoptosis in

aging. Exp Biol Med (Maywood). 2007 May;232:592-606.
66.

Melov S, Shoffner JM, Kaufman A, Wallace DC. Marked increase in the number and

variety of mitochondrial DNA rearrangements in aging human skeletal muscle. Nucleic
Acids Res. 1995 Oct 25;23:4122-6.
67.

Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, Nair

KS. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl
Acad Sci U S A. 2005 Apr 12;102:5618-23.
68.

Barja G, Herrero A. Oxidative damage to mitochondrial DNA is inversely related to

maximum life span in the heart and brain of mammals. FASEB J. 2000 Feb;14:312-8.
69.

Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE,

Bohlooly YM, Gidlof S, Oldfors A, et al. Premature ageing in mice expressing defective
mitochondrial DNA polymerase. Nature. 2004 May 27;429:417-23.
70.

Trifunovic A, Hansson A, Wredenberg A, Rovio AT, Dufour E, Khvorostov I,

Spelbrink JN, Wibom R, Jacobs HT, Larsson NG. Somatic mtDNA mutations cause aging
phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci U S A.
2005 Dec 13;102:17993-8.
71.

Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson

NL, Baynes JW, Epstein CJ, et al. Life-long reduction in MnSOD activity results in
90

increased DNA damage and higher incidence of cancer but does not accelerate aging.
Physiol Genomics. 2003 Dec 16;16:29-37.
72.

Hayashi Y, Yoshida M, Yamato M, Ide T, Wu Z, Ochi-Shindou M, Kanki T, Kang

D, Sunagawa K, et al. Reverse of age-dependent memory impairment and mitochondrial
DNA damage in microglia by an overexpression of human mitochondrial transcription factor
a in mice. J Neurosci. 2008 Aug 20;28:8624-34.
73.

Pallardo FV, Asensi M, Garcia de la Asuncion J, Anton V, Lloret A, Sastre J, Vina J.

Late onset administration of oral antioxidants prevents age-related loss of motor coordination and brain mitochondrial DNA damage. Free Radic Res. 1998 Dec;29:617-23.
74.

Kirkwood TB. Human senescence. Bioessays. 1996 Dec;18:1009-16.

75.

Lee RD. Life Span: Evolutionary, Ecological, and Demographic Perspectives.

Population and Development Review (Suppl). 2003;29:183-207.
76.

Bonsall MB. Longevity and ageing: appraising the evolutionary consequences of

growing old. Philos Trans R Soc Lond B Biol Sci. 2006 Jan 29;361:119-35.
77.

Rollo CD. Growth negatively impacts the life span of mammals. Evol Dev. 2002

Jan-Feb;4:55-61.
78.

May RC. Gender, immunity and the regulation of longevity. Bioessays. 2007

Aug;29:795-802.
79.

Kuningas M, Mooijaart SP, van Heemst D, Zwaan BJ, Slagboom PE, Westendorp

RG. Genes encoding longevity: from model organisms to humans. Aging Cell. 2008
Mar;7:270-80.
80.

Gershon H, Gershon D. Paradigms in aging research: a critical review and

assessment. Mech Ageing Dev. 2000 Aug 15;117:21-8.
91

81.

Faragher RG. Cell senescence and human aging: where's the link? Biochem Soc

Trans. 2000 Feb;28:221-6.
82.

de Magalhaes JP, Faragher RG. Cell divisions and mammalian aging: integrative

biology insights from genes that regulate longevity. Bioessays. 2008 Jun;30:567-78.
83.

Tollefsbol TO. Techniques for analysis of biological aging. Methods Mol Biol.

2007;371:1-7.
84.

Miura T, Mattson MP, Rao MS. Cellular lifespan and senescence signaling in

embryonic stem cells. Aging Cell. 2004 Dec;3:333-43.
85.

Helfand SL, Rogina B. Molecular genetics of aging in the fly: is this the end of the

beginning? Bioessays. 2003 Feb;25:134-41.
86.

Kammenga JE, Phillips PC, De Bono M, Doroszuk A. Beyond induced mutants:

using worms to study natural variation in genetic pathways. Trends Genet. 2008
Apr;24:178-85.
87.

Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H. Trends in

oxidative aging theories. Free Radic Biol Med. 2007 Aug 15;43:477-503.
88.

Hekimi S, Burgess J, Bussiere F, Meng Y, Benard C. Genetics of lifespan in C.

elegans: molecular diversity, physiological complexity, mechanistic simplicity. Trends
Genet. 2001 Dec;17:712-8.
89.

Kim SK. Common aging pathways in worms, flies, mice and humans. J Exp Biol.

2007 May;210:1607-12.
90.

Liang H, Masoro EJ, Nelson JF, Strong R, McMahan CA, Richardson A. Genetic

mouse models of extended lifespan. Exp Gerontol. 2003 Nov-Dec;38:1353-64.

92

91.

Carter CS, Ramsey MM, Ingram RL, Cashion AB, Cefalu WT, Wang ZQ, Sonntag

WE. Models of growth hormone and IGF-1 deficiency: applications to studies of aging
processes and life-span determination. J Gerontol A Biol Sci Med Sci. 2002 May;57:B17788.
92.

Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in

aging research. Neurobiol Aging. 1999 Mar-Apr;20:105-10.
93.

Chang S. Modeling premature aging syndromes with the telomerase knockout

mouse. Curr Mol Med. 2005 Mar;5:153-8.
94.

Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem.

2008 Mar;389:233-41.
95.

Dumble M, Gatza C, Tyner S, Venkatachalam S, Donehower LA. Insights into aging

obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun;1019:171-7.
96.

Melov S. Animal models of oxidative stress, aging, and therapeutic antioxidant

interventions. Int J Biochem Cell Biol. 2002 Nov;34:1395-400.
97.

Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K,

Wallace DC, Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in
superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase
mimetics. J Neurosci. 2001 Nov 1;21:8348-53.
98.

Mitsui A, Hamuro J, Nakamura H, Kondo N, Hirabayashi Y, Ishizaki-Koizumi S,

Hirakawa T, Inoue T, Yodoi J. Overexpression of human thioredoxin in transgenic mice
controls oxidative stress and life span. Antioxid Redox Signal. 2002 Aug;4:693-6.

93

99.

Perez VI, Van Remmen H, Bokov A, Epstein CJ, Vijg J, Richardson A. The

overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging
Cell. 2009 Feb;8:73-5.
100.

Anderson RM, Shanmuganayagam D, Weindruch R. Caloric restriction and aging:

studies in mice and monkeys. Toxicol Pathol. 2009;37:47-51.
101.

Everitt AV. Caloric restriction versus drug therapy to delay the onset of aging

diseases and extend life. Ageing Res Rev. 2005;27.
102.

Carter ME, Brunet A. FOXO transcription factors. Curr Biol. 2007 Feb 20;17:R113-

4.
103.

Copley RR. The animal in the genome: comparative genomics and evolution. Philos

Trans R Soc Lond B Biol Sci. 2008 Apr 27;363:1453-61.
104.

Rincon M, Muzumdar R, Atzmon G, Barzilai N. The paradox of the insulin/IGF-1

signaling pathway in longevity. Mech Ageing Dev. 2004 Jun;125:397-403.
105.

Bauer JH, Helfand SL. New tricks of an old molecule: lifespan regulation by p53.

Aging Cell. 2006 Oct;5:437-40.
106.

Campisi J. Cancer and ageing: rival demons? Nat Rev Cancer. 2003 May;3:339-49.

107.

Nehlin JO, Skovgaard GL, Bohr VA. The Werner syndrome. A model for the study

of human aging. Ann N Y Acad Sci. 2000 Jun;908:167-79.
108.

Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding

longevity. Nat Rev Mol Cell Biol. 2005 Apr;6:298-305.
109.

Masoro EJ. Overview of caloric restriction and ageing. Mech Ageing Dev. 2005

Sep;126:913-22.

94

110.

McCay CM. The effect of retarded growth upon the length of life and upon the the

ultimate body size. J Nutr. 1935;10:63-79.
111.

Holloszy JO, Schechtman KB. Interaction between exercise and food restriction:

effects on longevity of male rats. J Appl Physiol. 1991 Apr;70:1529-35.
112.

Smith DL, Jr., McClure JM, Matecic M, Smith JS. Calorie restriction extends the

chronological lifespan of Saccharomyces cerevisiae independently of the Sirtuins. Aging
Cell. 2007 Oct;6:649-62.
113.

Weindruch R, Walford RL, Fligiel S, Guthrie D. The retardation of aging in mice by

dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr. 1986
Apr;116:641-54.
114.

Weindruch R, Kayo T, Lee CK, Prolla TA. Effects of caloric restriction on gene

expression. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;6:17-28; discussion 32.
115.

Guarente L, Picard F. Calorie restriction--the SIR2 connection. Cell. 2005 Feb

25;120:473-82.
116.

Wolf G. Calorie restriction increases life span: a molecular mechanism. Nutr Rev.

2006 Feb;64:89-92.
117.

McCarter R, Masoro EJ, Yu BP. Does food restriction retard aging by reducing the

metabolic rate? Am J Physiol. 1985 Apr;248:E488-90.
118.

Houthoofd K, Braeckman BP, Lenaerts I, Brys K, De Vreese A, Van Eygen S,

Vanfleteren JR. No reduction of metabolic rate in food restricted Caenorhabditis elegans.
Exp Gerontol. 2002 Dec;37:1359-69.

95

119.

Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, Culotta VC, Fink GR,

Guarente L. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing
respiration. Nature. 2002 Jul 18;418:344-8.
120.

Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat

Rev Drug Discov. 2006 Jun;5:493-506.
121.

Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F,

Messadeq N, Milne J, Lambert P, et al. Resveratrol improves mitochondrial function and
protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006 Dec
15;127:1109-22.
122.

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard

JS, Lopez-Lluch G, et al. Resveratrol improves health and survival of mice on a high-calorie
diet. Nature. 2006 Nov 16;444:337-42.
123.

Gruber J, Tang SY, Halliwell B. Evidence for a trade-off between survival and

fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y Acad Sci. 2007
Apr;1100:530-42.
124.

Viswanathan M, Kim SK, Berdichevsky A, Guarente L. A role for SIR-2.1

regulation of ER stress response genes in determining C. elegans life span. Dev Cell. 2005
Nov;9:605-15.
125.

Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. Effects of resveratrol on

lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev. 2007
Oct;128:546-52.
126.

Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function.

Biochem J. 2007 May 15;404:1-13.
96

127.

Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging,

and calorie restriction. Genes Dev. 2006 Nov 1;20:2913-21.
128.

Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of

aging? Trends Biochem Sci. 2007 Dec;32:555-60.
129.

Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-

Pinto NC, Bohr VA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell
survival. Cell. 2007 Sep 21;130:1095-107.
130.

Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone

promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev.
1999 Oct 1;13:2570-80.
131.

Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in

Caenorhabditis elegans. Nature. 2001 Mar 8;410:227-30.
132.

Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related

to calorie restriction. Proc Natl Acad Sci U S A. 2004 Nov 9;101:15998-6003.
133.

Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span

extension by calorie restriction in Saccharomyces cerevisiae. Science. 2000 Sep
22;289:2126-8.
134.

Kaeberlein M, Kirkland KT, Fields S, Kennedy BK. Sir2-independent life span

extension by calorie restriction in yeast. PLoS Biol. 2004 Sep;2:E296.
135.

Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily

conserved and nonconserved cellular localizations and functions of human SIRT proteins.
Mol Biol Cell. 2005 Oct;16:4623-35.

97

136.

Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like

proteins. Biochem Biophys Res Commun. 2000 Jul 5;273:793-8.
137.

Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L,

Weinberg RA. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001
Oct 19;107:149-59.
138.

Salminen A, Kaarniranta K. SIRT1: Regulation of longevity via autophagy. Cell

Signal. 2009 Feb 26.
139.

Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to

oxidative stress and caloric restriction. Aging Cell. 2007 Aug;6:505-14.
140.

Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW.

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1
deacetylase. EMBO J. 2004 Jun 16;23:2369-80.
141.

Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur

C, Permutt MA, Imai S. Increased dosage of mammalian Sir2 in pancreatic beta cells
enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005 Aug;2:105-17.
142.

Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss of Sirt1-mediated

enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1overexpressing (BESTO) mice. Aging Cell. 2008 Jan;7:78-88.
143.

Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, McDonagh T,

Lemieux M, McBurney M, et al. Sirt1 regulates insulin secretion by repressing UCP2 in
pancreatic beta cells. PLoS Biol. 2006 Feb;4:e31.

98

144.

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient

control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005
Mar 3;434:113-8.
145.

Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor

FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol
Chem. 2005 May 27;280:20589-95.
146.

Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma

coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator.
Endocr Rev. 2003 Feb;24:78-90.
147.

Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, Lu JC,

Smith JJ, Jirousek MR, Olefsky JM. SIRT1 exerts anti-inflammatory effects and improves
insulin sensitivity in adipocytes. Mol Cell Biol. 2009 Mar;29:1363-74.
148.

Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma.

Annu Rev Biochem. 2008;77:289-312.
149.

Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira

R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat mobilization in white adipocytes
by repressing PPAR-gamma. Nature. 2004 Jun 17;429:771-6.
150.

Corton JC, Brown-Borg HM. Peroxisome proliferator-activated receptor gamma

coactivator 1 in caloric restriction and other models of longevity. J Gerontol A Biol Sci Med
Sci. 2005 Dec;60:1494-509.
151.

Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged

helix/forkhead transcription factors. Genes Dev. 2000 Jan 15;14:142-6.

99

152.

Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and

ubiquitination of FOXO proteins. Cell Cycle. 2005 Jul;4:908-13.
153.

Lam EW, Francis RE, Petkovic M. FOXO transcription factors: key regulators of

cell fate. Biochem Soc Trans. 2006 Nov;34:722-6.
154.

Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL,

Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the
small GTPase Ral and JNK. EMBO J. 2004 Dec 8;23:4802-12.
155.

Nakae J, Barr V, Accili D. Differential regulation of gene expression by insulin and

IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the
forkhead transcription factor FKHR. EMBO J. 2000 Mar 1;19:989-96.
156.

Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE,

Mostoslavsky R, et al. Stress-dependent regulation of FOXO transcription factors by the
SIRT1 deacetylase. Science. 2004 Mar 26;303:2011-5.
157.

Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The

energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3
transcription factor. J Biol Chem. 2007 Oct 12;282:30107-19.
158.

Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular

homeostasis during aging. Curr Opin Cell Biol. 2008 Apr;20:126-36.
159.

Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead family

member that can function to double the life-span of Caenorhabditis elegans. Science. 1997
Nov 14;278:1319-22.
160.

Larsen PL, Albert PS, Riddle DL. Genes that regulate both development and

longevity in Caenorhabditis elegans. Genetics. 1995 Apr;139:1567-83.
100

161.

Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G. The

Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity
signals in C. elegans. Nature. 1997 Oct 30;389:994-9.
162.

Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le

Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature.
2003 Jan 9;421:182-7.
163.

Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M,

Ramadani F, Okkenhaug K, Schuster E, et al. Evidence for lifespan extension and delayed
age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 2008
Mar;22:807-18.
164.

Giannakou ME, Goss M, Partridge L. Role of dFOXO in lifespan extension by

dietary restriction in Drosophila melanogaster: not required, but its activity modulates the
response. Aging Cell. 2008 Mar;7:187-98.
165.

Paolisso G, Ammendola S, Del Buono A, Gambardella A, Riondino M, Tagliamonte

MR, Rizzo MR, Carella C, Varricchio M. Serum levels of insulin-like growth factor-I (IGFI) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and
lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab. 1997
Jul;82:2204-9.
166.

Paolisso G, Barbieri M, Rizzo MR, Carella C, Rotondi M, Bonafe M, Franceschi C,

Rose G, De Benedictis G. Low insulin resistance and preserved beta-cell function contribute
to human longevity but are not associated with TH-INS genes. Exp Gerontol. 2001
Dec;37:149-56.

101

167.

Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C, Mugianesi

E, Centurelli M, Franceschi C, Paolisso G. Polymorphic variants of insulin-like growth
factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and
human longevity: cues for an evolutionarily conserved mechanism of life span control. J
Clin Endocrinol Metab. 2003 Jul;88:3299-304.
168.

Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G. Body composition

assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med. 2009 Mar 5.
169.

Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993.

Am J Med. 1993 Nov 30;95:1S-78S.
170.

Licata AA. Diagnosing primary osteoporosis: it's more than a T score. Cleve Clin J

Med. 2006 May;73:473-6.
171.

Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev

Endocr Metab Disord. 2006 Jun;7:75-89.
172.

Shen H, Recker RR, Deng HW. Molecular and genetic mechanisms of osteoporosis:

implication for treatment. Curr Mol Med. 2003 Dec;3:737-57.
173.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and

Therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001 Jun;94:569-73.
174.

Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008 Jun;29:441-64.

175.

Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying

age-related skeletal muscle wasting and weakness. Biogerontology. 2008 Aug;9:213-28.
176.

Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old

age. Exp Gerontol. 2006 Dec;41:1234-8.

102

177.

Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone

supplementation on skeletal muscle fiber hypertrophy and satellite cells in communitydwelling older men. J Clin Endocrinol Metab. 2006 Aug;91:3024-33.
178.

Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen

receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by
androgen treatment. J Clin Endocrinol Metab. 2004 Oct;89:5245-55.
179.

Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P. The

association of sex hormone levels with poor mobility, low muscle strength and incidence of
falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63:152-60.
180.

Short KR, Moller N, Bigelow ML, Coenen-Schimke J, Nair KS. Enhancement of

muscle mitochondrial function by growth hormone. J Clin Endocrinol Metab. 2008
Feb;93:597-604.
181.

Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of

muscle mass (sarcopenia) and strength. Am J Med. 2006 Jun;119:526 e9-17.
182.

Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6

is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab.
2008 Jan;7:33-44.
183.

Dirks AJ, Leeuwenburgh C. Tumor necrosis factor alpha signaling in skeletal

muscle: effects of age and caloric restriction. J Nutr Biochem. 2006 Aug;17:501-8.
184.

Conley KE, Amara CE, Jubrias SA, Marcinek DJ. Mitochondrial function, fibre

types and ageing: new insights from human muscle in vivo. Exp Physiol. 2007 Mar;92:3339.

103

185.

Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med

Sci. 2000 Dec;55:M716-24.
186.

Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol. 2003

Oct;95:1717-27.
187.

Koopman R, van Loon LJ. Aging, exercise and muscle protein metabolism. J Appl

Physiol. 2009 Jan 8.
188.

Kirkland JL, Tchkonia T, Pirtskhalava T, Han J, Karagiannides I. Adipogenesis and

aging: does aging make fat go MAD? Exp Gerontol. 2002 Jun;37:757-67.
189.

Cartwright MJ, Tchkonia T, Kirkland JL. Aging in adipocytes: potential impact of

inherent, depot-specific mechanisms. Exp Gerontol. 2007 Jun;42:463-71.
190.

Karagiannides I, Tchkonia T, Dobson DE, Steppan CM, Cummins P, Chan G,

Salvatori K, Hadzopoulou-Cladaras M, Kirkland JL. Altered expression of C/EBP family
members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp
Physiol. 2001 Jun;280:R1772-80.
191.

Wu D, Ren Z, Pae M, Guo W, Cui X, Merrill AH, Meydani SN. Aging up-regulates

expression of inflammatory mediators in mouse adipose tissue. J Immunol. 2007 Oct
1;179:4829-39.
192.

Tchkonia T, Pirtskhalava T, Thomou T, Cartwright MJ, Wise B, Karagiannides I,

Shpilman A, Lash TL, Becherer JD, Kirkland JL. Increased TNFalpha and
CCAAT/enhancer-binding protein homologous protein with aging predispose preadipocytes
to resist adipogenesis. Am J Physiol Endocrinol Metab. 2007 Dec;293:E1810-9.

104

193.

Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin

resistance and beta-cell function: potential role of adipocyte-derived cytokines in the
pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002 Jun;32 Suppl 3:24-34.
194.

Garg A. Lipodystrophies. Am J Med. 2000 Feb;108:143-52.

195.

Grimaldi PA, Teboul L, Inadera H, Gaillard D, Amri EZ. Trans-differentiation of

myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones.
Prostaglandins Leukot Essent Fatty Acids. 1997 Jul;57:71-5.
196.

Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Fiatarone Singh MA.

Anthropometric assessment of 10-y changes in body composition in the elderly. Am J Clin
Nutr. 2004 Aug;80:475-82.
197.

Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between

visceral and subcutaneous fat. Curr Diabetes Rev. 2006 Nov;2:367-73.
198.

Fantin F, Di Francesco V, Fontana G, Zivelonghi A, Bissoli L, Zoico E, Rossi A,

Micciolo R, Bosello O, Zamboni M. Longitudinal body composition changes in old men and
women: interrelationships with worsening disability. J Gerontol A Biol Sci Med Sci. 2007
Dec;62:1375-81.
199.

Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Decreased muscle mass and

increased central adiposity are independently related to mortality in older men. Am J Clin
Nutr. 2007 Nov;86:1339-46.
200.

Frisard MI, Broussard A, Davies SS, Roberts LJ, 2nd, Rood J, de Jonge L, Fang X,

Jazwinski SM, Deutsch WA, Ravussin E. Aging, resting metabolic rate, and oxidative
damage: results from the Louisiana Healthy Aging Study. J Gerontol A Biol Sci Med Sci.
2007 Jul;62:752-9.
105

201.

Bosy-Westphal A, Eichhorn C, Kutzner D, Illner K, Heller M, Muller MJ. The age-

related decline in resting energy expenditure in humans is due to the loss of fat-free mass
and to alterations in its metabolically active components. J Nutr. 2003 Jul;133:2356-62.
202.

Luhrmann PM, Bender R, Edelmann-Schafer B, Neuhauser-Berthold M.

Longitudinal changes in energy expenditure in an elderly German population: a 12-year
follow-up. Eur J Clin Nutr. 2009 Feb 4.
203.

Krabbe K, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp

Gerontol. 2004 2004 May;39:687-99.
204.

Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C.

Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of
mitochondria and new perspectives from systems biology. Curr Pharm Des. 2006;12:316171.
205.

Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen

species: fifteen years later. Biochem Pharmacol. 2006 Nov 30;72:1493-505.
206.

Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB

activity. FASEB J. 2007 Sep;21:2642-54.
207.

Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP,

Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases.
Ageing Res Rev. 2009 Jan;8:18-30.
208.

Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J. TNF-alpha-induced

mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase
mimetic Tempol. Am J Physiol Heart Circ Physiol. 2007 Nov;293:H2726-37.

106

209.

Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial

dysfunction during aging: role of NF-kappaB. J Appl Physiol. 2008 Oct;105:1333-41.
210.

Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z. Vasculoprotective

effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol. 2007
Jan;170:388-98.
211.

Min LJ, Mogi M, Iwai M, Horiuchi M. Signaling mechanisms of angiotensin II in

regulating vascular senescence. Ageing Res Rev. 2009 Apr;8:113-21.
212.

Zhang L, Ma Y, Zhang J, Cheng J, Du J. A new cellular signaling mechanism for

angiotensin II activation of NF-kappaB: An IkappaB-independent, RSK-mediated
phosphorylation of p65. Arterioscler Thromb Vasc Biol. 2005 Jun;25:1148-53.
213.

Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in

metabolic disorders linked to obesity. J Am Soc Nephrol. 2004 Nov;15:2792-800.
214.

Van Itallie TB. Health implications of overweight and obesity in the United States.

Ann Intern Med. 1985 Dec;103:983-8.
215.

Rea IM, Ross OA, Armstrong M, McNerlan S, Alexander DH, Curran MD,

Middleton D. Interleukin-6-gene C/G 174 polymorphism in nonagenarian and octogenarian
subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for
IL-10 in serum and monocyte supernatants. Mech Ageing Dev. 2003 Apr;124:555-61.
216.

Salvioli S, Olivieri F, Marchegiani F, Cardelli M, Santoro A, Bellavista E, Mishto

M, Invidia L, Capri M, et al. Genes, ageing and longevity in humans: problems, advantages
and perspectives. Free Radic Res. 2006 Dec;40:1303-23.
217.

Fulop T, Larbi A, Douziech N. Insulin receptor and ageing. Pathol Biol (Paris). 2003

Dec;51:574-80.
107

218.

Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in

aging. J Clin Invest. 1983 Jun;71:1523-35.
219.

Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin

resistance. J Intern Med. 1999 Jun;245:621-5.
220.

Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor

alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994 May
24;91:4854-8.
221.

Hauner H, Petruschke T, Russ M, Rohrig K, Eckel J. Effects of tumour necrosis

factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated
human fat cells in cell culture. Diabetologia. 1995 Jul;38:764-71.
222.

Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman

GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996
Jun 15;97:2859-65.
223.

Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008

Sep;37:635-46, viii-ix.
224.

de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha

produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a
p38 MAPK-dependent manner. J Biol Chem. 2004 Apr 23;279:17070-8.
225.

Qin B, Anderson RA, Adeli K. Tumor necrosis factor-alpha directly stimulates the

overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic
insulin signaling. Am J Physiol Gastrointest Liver Physiol. 2008 May;294:G1120-9.
226.

Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on

peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992 Jan;130:43-52.
108

227.

Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin

resistance. Mol Med. 2008 Mar-Apr;14:222-31.
228.

Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M,

Carella C, Giugliano D, Varricchio M, D'Onofrio F. Advancing age and insulin resistance:
role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998 Aug;275:E294-9.
229.

Papaconstantinou J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging

and longevity determination. Mol Cell Endocrinol. 2009 Feb 5;299:89-100.
230.

Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-stimulated hydrogen peroxide

reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin
action cascade. J Biol Chem. 2001 Jun 15;276:21938-42.
231.

Mahadev K, Wu X, Zilbering A, Zhu L, Lawrence JT, Goldstein BJ. Hydrogen

peroxide generated during cellular insulin stimulation is integral to activation of the distal
insulin signaling cascade in 3T3-L1 adipocytes. J Biol Chem. 2001 Dec 28;276:48662-9.
232.

Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative

regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev. 2009
Jan;89:27-71.
233.

Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance

arteries in hypertension: role of angiotensin II. Exp Physiol. 2005 Jul;90:449-55.
234.

Liu Z. The renin-angiotensin system and insulin resistance. Curr Diab Rep. 2007

Feb;7:34-42.
235.

Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade

prevents type 2 diabetes by formation of fat cells. Hypertension. 2002 Nov;40:609-11.

109

236.

Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system.

Public Health Nutr. 2007 Oct;10:1151-5.
237.

Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab.

2003 Jan;284:E7-12.
238.

Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell

Dev Biol. 2000;16:145-71.
239.

Lean ME. Brown adipose tissue in humans. Proc Nutr Soc. 1989 Jul;48:243-56.

240.

Cancello R, Zingaretti MC, Sarzani R, Ricquier D, Cinti S. Leptin and UCP1 genes

are reciprocally regulated in brown adipose tissue. Endocrinology. 1998 Nov;139:4747-50.
241.

Anghel SI, Wahli W. Fat poetry: a kingdom for PPAR gamma. Cell Res. 2007

Jun;17:486-511.
242.

Belanger C, Luu-The V, Dupont P, Tchernof A. Adipose tissue intracrinology:

potential importance of local androgen/estrogen metabolism in the regulation of adiposity.
Horm Metab Res. 2002 Nov-Dec;34:737-45.
243.

Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in

adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand. 2005
Jan;183:13-30.
244.

Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, Cushman SW, Periwal V.

Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLoS Comput Biol.
2009 Mar;5:e1000324.
245.

Fliers E, Kreier F, Voshol PJ, Havekes LM, Sauerwein HP, Kalsbeek A, Buijs RM,

Romijn JA. White adipose tissue: getting nervous. J Neuroendocrinol. 2003 Nov;15:100510.
110

246.

van Harmelen V, Skurk T, Rohrig K, Lee YM, Halbleib M, Aprath-Husmann I,

Hauner H. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in
women. Int J Obes Relat Metab Disord. 2003 Aug;27:889-95.
247.

Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O,

Blomqvist L, Hoffstedt J, Naslund E, et al. Dynamics of fat cell turnover in humans. Nature.
2008 Jun 5;453:783-7.
248.

Considine RV, Nyce MR, Morales LM, Magosin SA, Sinha MK, Bauer TL, Rosato

EL, Colberg J, Caro JF. Paracrine stimulation of preadipocyte-enriched cell cultures by
mature adipocytes. Am J Physiol. 1996 May;270:E895-9.
249.

Dani C, Smith AG, Dessolin S, Leroy P, Staccini L, Villageois P, Darimont C,

Ailhaud G. Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci. 1997
Jun;110 ( Pt 11):1279-85.
250.

Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is

a source of multipotent stem cells. Biochimie. 2005 Jan;87:125-8.
251.

Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol

Med (Maywood). 2001 Dec;226:997-1002.
252.

Kokta TA, Dodson MV, Gertler A, Hill RA. Intercellular signaling between adipose

tissue and muscle tissue. Domest Anim Endocrinol. 2004 Nov;27:303-31.
253.

Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K,

Garkavtsev I, Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation
during in vivo adipogenesis. Circ Res. 2003 Oct 31;93:e88-97.
254.

Neels JG, Thinnes T, Loskutoff DJ. Angiogenesis in an in vivo model of adipose

tissue development. FASEB J. 2004 Jun;18:983-5.
111

255.

Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, Ohsugi M,

Tobe K, Kadowaki T, et al. Adipogenesis in obesity requires close interplay between
differentiating adipocytes, stromal cells, and blood vessels. Diabetes. 2007 Jun;56:1517-26.
256.

Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P,

Casteilla L, Penicaud L. A role for preadipocytes as macrophage-like cells. FASEB J. 1999
Feb;13:305-12.
257.

Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A.

From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by
human mature adipocytes. Diabetes. 2004 May;53:1285-92.
258.

Bosanska L, Michalsky D, Lacinova Z, Dostalova I, Bartlova M, Haluzikova D,

Matoulek M, Kasalicky M, Haluzik M. The influence of obesity and different fat depots on
adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol Res.
2009 Feb 27.
259.

Targher G, Bonadonna RC, Alberiche M, Zenere MB, Muggeo M, Bonora E.

Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic
individuals: role of adipose tissue. Diabetes Care. 2001 Nov;24:1961-6.
260.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr.

Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003
Dec;112:1796-808.
261.

Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new

pathophysiological insights? Trends Pharmacol Sci. 2003 Jun;24:276-83.
262.

Bartness TJ, Song CK. Brain-adipose tissue neural crosstalk. Physiol Behav. 2007

Jul 24;91:343-51.
112

263.

Foster MT, Bartness TJ. Sympathetic but not sensory denervation stimulates white

adipocyte proliferation. Am J Physiol Regul Integr Comp Physiol. 2006 Dec;291:R1630-7.
264.

Kreier F, Fliers E, Voshol PJ, Van Eden CG, Havekes LM, Kalsbeek A, Van

Heijningen CL, Sluiter AA, Mettenleiter TC, et al. Selective parasympathetic innervation of
subcutaneous and intra-abdominal fat--functional implications. J Clin Invest. 2002
Nov;110:1243-50.
265.

Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol

Med. 2008 Nov-Dec;14:741-51.
266.

Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue

metabolism. Curr Med Chem. 2007;14:2918-24.
267.

Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR, Walker BR,

Morton NM. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size
independently of obesity. Obesity (Silver Spring). 2007 May;15:1155-63.
268.

Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A

transgenic model of visceral obesity and the metabolic syndrome. Science. 2001 Dec
7;294:2166-70.
269.

Kim S, Soltani-Bejnood M, Quignard-Boulange A, Massiera F, Teboul M, Ailhaud

G, Kim JH, Moustaid-Moussa N, Voy BH. The adipose Renin-Angiotensin system
modulates systemic markers of insulin sensitivity and activates the intrarenal ReninAngiotensin system. J Biomed Biotechnol. 2006;2006:27012.
270.

Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human

adipose tissue expresses angiotensinogen and enzymes required for its conversion to
angiotensin II. J Clin Endocrinol Metab. 1998 Nov;83:3925-9.
113

271.

Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and

paracrine organ. Int J Obes Relat Metab Disord. 1998 Dec;22:1145-58.
272.

Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the

periphery. Recent Prog Horm Res. 2004;59:305-31.
273.

Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin--a

key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006 May;8:264-80.
274.

Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy

homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003 Sep;144:3765-73.
275.

Ailhaud G. Adipose tissue as a secretory organ: from adipogenesis to the metabolic

syndrome. C R Biol. 2006 Aug;329:570-7; discussion 653-5.
276.

Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative

physiology of human adipose tissue. Int J Obes Relat Metab Disord. 2003 Aug;27:875-88.
277.

Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008 Jan;214:149-60.

278.

Winkler G, Kiss S, Keszthelyi L, Sapi Z, Ory I, Salamon F, Kovacs M, Vargha P,

Szekeres O, et al. Expression of tumor necrosis factor (TNF)-alpha protein in the
subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum
TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J
Endocrinol. 2003 Aug;149:129-35.
279.

Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C. Role of

TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009 Feb;116:219-30.
280.

Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat

distribution and energy balance. Obes Rev. 2008 Jan;9:20-9.

114

281.

Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance

with focus on IL-6. Horm Metab Res. 2008 Sep;40:635-9.
282.

Hudgins LC, Baday A, Hellerstein MK, Parker TS, Levine DM, Seidman CE, Neese

RA, Tremaroli JD, Hirsch J. The effect of dietary carbohydrate on genes for fatty acid
synthase and inflammatory cytokines in adipose tissues from lean and obese subjects. J Nutr
Biochem. 2008 Apr;19:237-45.
283.

Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose

triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res. 2009
Jan;50:3-21.
284.

Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose

homeostasis. Nature. 2006 Dec 14;444:847-53.
285.

Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR,

Nowotny P, Waldhausl W, Shulman GI. Effects of free fatty acid elevation on
postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes.
2000 May;49:701-7.
286.

Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell

apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A. 1998 Mar
3;95:2498-502.
287.

Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in

muscle, liver and vasculature. Diabetes Obes Metab. 2005 Nov;7:621-32.
288.

Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis.

EMBO Rep. 2001 Apr;2:282-6.

115

289.

Keaney JF, Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro

JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical
correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol.
2003 Mar 1;23:434-9.
290.

Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y,

Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity
and its impact on metabolic syndrome. J Clin Invest. 2004 2004 Dec;114:1752-61.
291.

Gletsu-Miller N, Hansen JM, Jones DP, Go YM, Torres WE, Ziegler TR, Lin E.

Loss of total and visceral adipose tissue mass predicts decreases in oxidative stress after
weight-loss surgery. Obesity (Silver Spring). 2009 Mar;17:439-46.
292.

Manea A, Manea SA, Gafencu AV, Raicu M, Simionescu M. AP-1-dependent

transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: role of
p22phox subunit. Arterioscler Thromb Vasc Biol. 2008 May;28:878-85.
293.

Basuroy S, Bhattacharya S, Leffler CW, Parfenova H. Nox4 NADPH oxidase

mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular
endothelial cells. Am J Physiol Cell Physiol. 2009 Mar;296:C422-32.
294.

Kuwano Y, Tominaga K, Kawahara T, Sasaki H, Takeo K, Nishida K, Masuda K,

Kawai T, Teshima-Kondo S, Rokutan K. Tumor necrosis factor alpha activates transcription
of the NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production
in colon epithelial cells. Free Radic Biol Med. 2008 Dec 15;45:1642-52.
295.

Janssen-Heininger YM, Macara I, Mossman BT. Cooperativity between oxidants and

tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of

116

Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Am J
Respir Cell Mol Biol. 1999 May;20:942-52.
296.

Jezek P, Zácková M, Růzicka M, Skobisová E, Jabůrek M. Mitochondrial

uncoupling proteins--facts and fantasies. Physiol Res. 2004;53 Suppl 1:S199-211.
297.

Kim HS, Park KG, Koo TB, Huh S, Lee IK. The modulating effects of the

overexpression of uncoupling protein 2 on the formation of reactive oxygen species in
vascular cells. Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S46-8.
298.

Park JY, Park KG, Kim HJ, Kang HG, Ahn JD, Kim HS, Kim YM, Son SM, Kim IJ,

et al. The effects of the overexpression of recombinant uncoupling protein 2 on proliferation,
migration and plasminogen activator inhibitor 1 expression in human vascular smooth
muscle cells. Diabetologia. 2005 May;48:1022-8.
299.

Duval C, Negre-Salvayre A, Dogilo A, Salvayre R, Penicaud L, Casteilla L.

Increased reactive oxygen species production with antisense oligonucleotides directed
against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol. 2002;80:75764.
300.

Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C,

Bouillaud F, Seldin MF, Surwit RS, et al. Uncoupling protein-2: a novel gene linked to
obesity and hyperinsulinemia. Nat Genet. 1997 Mar;15:269-72.
301.

Chevillotte E, Rieusset J, Roques M, Desage M, Vidal H. The regulation of

uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human
skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome
proliferator-activated receptor beta. J Biol Chem. 2001 Apr 6;276:10853-60.

117

302.

Surwit RS, Wang S, Petro AE, Sanchis D, Raimbault S, Ricquier D, Collins S. Diet-

induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of
mice. Proc Natl Acad Sci U S A. 1998 Mar 31;95:4061-5.
303.

Millet L, Vidal H, Andreelli F, Larrouy D, Riou JP, Ricquier D, Laville M, Langin

D. Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean
humans. J Clin Invest. 1997 Dec 1;100:2665-70.
304.

Gimeno RE, Dembski M, Weng X, Deng N, Shyjan AW, Gimeno CJ, Iris F, Ellis SJ,

Woolf EA, Tartaglia LA. Cloning and characterization of an uncoupling protein homolog: a
potential molecular mediator of human thermogenesis. Diabetes. 1997 May;46:900-6.
305.

Nordfors L, Hoffstedt J, Nyberg B, Thorne A, Arner P, Schalling M, Lonnqvist F.

Reduced gene expression of UCP2 but not UCP3 in skeletal muscle of human obese
subjects. Diabetologia. 1998 Aug;41:935-9.
306.

Parikh SJ, Yanovski JA. Calcium intake and adiposity. Am J Clin Nutr. 2003

Feb;77:281-7.
307.

Dicker D, Belnic Y, Goldsmith R, Kaluski DN. Relationship between dietary

calcium intake, body mass index, and waist circumference in MABAT--the Israeli National
Health and Nutrition Study. Isr Med Assoc J. 2008 Jul;10:512-5.
308.

Beydoun MA, Gary TL, Caballero BH, Lawrence RS, Cheskin LJ, Wang Y. Ethnic

differences in dairy and related nutrient consumption among US adults and their association
with obesity, central obesity, and the metabolic syndrome. Am J Clin Nutr. 2008
Jun;87:1914-25.

118

309.

dos Santos LC, de Padua Cintra I, Fisberg M, Martini LA. Calcium intake and its

relationship with adiposity and insulin resistance in post-pubertal adolescents. J Hum Nutr
Diet. 2008 Apr;21:109-16.
310.

Zemel M, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy

acceleration of weight and fat loss during energy restriction in obese adults. Obes Res. 2004
2004 Apr;12:582-90.
311.

Bowen J, Noakes M, Clifton PM. Effect of calcium and dairy foods in high protein,

energy-restricted diets on weight loss and metabolic parameters in overweight adults. Int J
Obes (Lond). 2005 Aug;29:957-65.
312.

Zemel M, Richards J, Milstead A, Campbell P. Effects of calcium and dairy on body

composition and weight loss in African-American adults. Obes Res. 2005 2005 Jul;13:121825.
313.

Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting

secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab.
2000;18:109-25.
314.

Shi H, Norman A, Okamura W, Sen A, Zemel M. 1alpha,25-Dihydroxyvitamin D3

modulates human adipocyte metabolism via nongenomic action. FASEB J. 2001 2001
Dec;15:2751-3.
315.

Zemel M. Regulation of adiposity and obesity risk by dietary calcium: mechanisms

and implications. J Am Coll Nutr. 2002 2002 Apr;21:146S-51S.
316.

Xue B, Greenberg A, Kraemer F, Zemel M. Mechanism of intracellular calcium

([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J. 2001 2001 Nov;15:2527-9.

119

317.

Sun X, Zemel M. Role of uncoupling protein 2 (UCP2) expression and 1alpha, 25-

dihydroxyvitamin D3 in modulating adipocyte apoptosis. FASEB J. 2004 2004
Sep;18:1430-2.
318.

Shi H, Norman A, Okamura W, Sen A, Zemel M. 1alpha,25-dihydroxyvitamin D3

inhibits uncoupling protein 2 expression in human adipocytes. FASEB J. 2002 2002
Nov;16:1808-10.
319.

Zemel MB, Sun X. Calcitriol and energy metabolism. Nutr Rev. 2008 Oct;66:S139-

46.
320.

Sun X, Zemel M. Calcium and dairy products inhibit weight and fat regain during ad

libitum consumption following energy restriction in Ap2-agouti transgenic mice. J Nutr.
2004 2004 Nov;134:3054-60.
321.

Shi H, Dirienzo D, Zemel M. Effects of dietary calcium on adipocyte lipid

metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice.
FASEB J. 2001 2001 Feb;15:291-3.
322.

Zemel M, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy

augmentation of total and central fat loss in obese subjects. Int J Obes (Lond). 2005 2005
Apr;29:391-7.
323.

Morris K, Zemel M. 1,25-dihydroxyvitamin D3 modulation of adipocyte

glucocorticoid function. Obes Res. 2005 2005 Apr;13:670-7.
324.

Sun XM, K.L.; Zemel, M.B. Role of calcitriol and cortisol on human adipocyte

proliferation and oxidative and inflammatory stress: a microarray study. J Nutrigenet
Nutrigenomics 2008;1
:30-48.
120

325.

Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of

skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006
Jan;186:5-16.
326.

Skurk T, Alberti-Huber C, Hauner H. Effect of conditioned media from mature

human adipocytes on insulin-stimulated Akt/PKB phosphorylation in human skeletal muscle
cells: role of BMI and fat cell size. Horm Metab Res. 2009 Mar;41:190-6.
327.

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF

alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996 Feb
15;97:1111-6.
328.

Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L,

Cantoni O, Clementi E, et al. TNF-alpha downregulates eNOS expression and mitochondrial
biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006 Oct;116:2791-8.
329.

Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA,

Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo
and in tissue culture in vitro. Am J Physiol Endocrinol Metab. 2005 Jan;288:E155-62.
330.

Carbo N, Lopez-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM, Quinn

LS, Lopez-Soriano FJ, Argiles JM. Interleukin-15 mediates reciprocal regulation of adipose
and muscle mass: a potential role in body weight control. Biochim Biophys Acta. 2001 Apr
3;1526:17-24.
331.

Zemel MB, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy

augmentation of total and central fat loss in obese subjects. Int J Obes (Lond). 2005
Apr;29:391-7.

121

332.

Sun X, Zemel M. Leucine and calcium regulate fat metabolism and energy

partitioning in murine adipocytes and muscle cells. Lipids. 2007 2007 Apr;42:297-305.
333.

Sun X, Zemel M. Calcitriol and calcium regulate cytokine production and adipocyte-

macrophage cross-talk. J Nutr Biochem. 2007 2007 Sep.
334.

Sun X, Zemel MB. 1Alpha,25-dihydroxyvitamin D3 modulation of adipocyte

reactive oxygen species production. Obesity (Silver Spring). 2007 Aug;15:1944-53.
335.

Zemel MB, Sun X. Dietary calcium and dairy products modulate oxidative and

inflammatory stress in mice and humans. J Nutr. 2008 Jun;138:1047-52.
336.

Sun X, Zemel M. Dietary calcium regulates ROS production in aP2-agouti

transgenic mice on high-fat/high-sucrose diets. Int J Obes (Lond). 2006 2006 Sep;30:13416.
337.

Sun X, Zemel M. 1Alpha,25-dihydroxyvitamin D3 modulation of adipocyte reactive

oxygen species production. Obesity (Silver Spring). 2007 2007 Aug;15:1944-53.
338.

Sun X, Zemel M. Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine

expression. Obesity (Silver Spring). 2007 2007 Feb;15:340-8.
339.

Shah N. Effects of milk-derived bioactives: an overview. Br J Nutr. 2000 2000

Nov;84 Suppl 1:S3-10.
340.

Bos C, Gaudichon C, Tome D. Nutritional and physiological criteria in the

assessment of milk protein quality for humans. J Am Coll Nutr. 2000 Apr;19:191S-205S.
341.

Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy,

carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc.
2002 Nov;102:1621-30.

122

342.

Layman DK. The role of leucine in weight loss diets and glucose homeostasis. J

Nutr. 2003 Jan;133:261S-7S.
343.

Kurpad AV, Regan MM, Raj T, Gnanou JV. Branched-chain amino acid

requirements in healthy adult human subjects. J Nutr. 2006 Jan;136:256S-63S.
344.

Layman DK, Walker DA. Potential importance of leucine in treatment of obesity and

the metabolic syndrome. J Nutr. 2006 Jan;136:319S-23S.
345.

Koopman R, Wagenmakers AJ, Manders RJ, Zorenc AH, Senden JM, Gorselink M,

Keizer HA, van Loon LJ. Combined ingestion of protein and free leucine with carbohydrate
increases postexercise muscle protein synthesis in vivo in male subjects. Am J Physiol
Endocrinol Metab. 2005 Apr;288:E645-53.
346.

Howarth KR, Moreau NA, Phillips SM, Gibala MJ. Coingestion of protein with

carbohydrate during recovery from endurance exercise stimulates skeletal muscle protein
synthesis in humans. J Appl Physiol. 2009 Apr;106:1394-402.
347.

Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS. Oral leucine

administration stimulates protein synthesis in rat skeletal muscle. J Nutr. 2005 Mar;135:37682.
348.

Koopman R, Verdijk L, Manders RJ, Gijsen AP, Gorselink M, Pijpers E,

Wagenmakers AJ, van Loon LJ. Co-ingestion of protein and leucine stimulates muscle
protein synthesis rates to the same extent in young and elderly lean men. Am J Clin Nutr.
2006 Sep;84:623-32.
349.

Frestedt JL, Zenk JL, Kuskowski MA, Ward LS, Bastian ED. A whey-protein

supplement increases fat loss and spares lean muscle in obese subjects: a randomized human
clinical study. Nutr Metab (Lond). 2008;5:8.
123

350.

Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through

which branched-chain amino acids mediate translational control of protein synthesis. J Nutr.
2006 Jan;136:227S-31S.
351.

Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin

system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord. 1999
Apr;23:336-41.
352.

Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma

AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005
Mar;45:356-62.
353.

Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D,

Ward R, Forrester T. ACE, angiotensinogen and obesity: a potential pathway leading to
hypertension. J Hum Hypertens. 1997 Feb;11:107-11.
354.

Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM,

Quignard-Boulange A, Negrel R, Ailhaud G, et al. Adipose angiotensinogen is involved in
adipose tissue growth and blood pressure regulation. FASEB J. 2001 Dec;15:2727-9.
355.

Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M,

Mantero F. Overexpression of the renin-angiotensin system in human visceral adipose tissue
in normal and overweight subjects. Am J Hypertens. 2002 May;15:381-8.
356.

Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-

L1 and human adipose cells. Endocrinology. 1997 Apr;138:1512-9.
357.

Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin

expression regulates human mesenchymal stem cell differentiation to adipocytes.
Hypertension. 2006 Dec;48:1095-102.
124

358.

Mogi M, Iwai M, Horiuchi M. Emerging concept of adipogenesis regulation by the

renin-angiotensin system. Hypertension. 2006 Dec;48:1020-2.
359.

Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in

vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002
Jun;51:1699-707.
360.

Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura

K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with
improvement in insulin sensitivity. J Hypertens. 2004 Oct;22:1977-82.
361.

Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse

T, Fujita K, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in
adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006 Nov;70:171724.
362.

Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and

the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol. 2009
Apr 29;302:128-39.
363.

White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L,

Racine N, Ducharme A, et al. Effects of combined candesartan and ACE inhibitors on BNP,
markers of inflammation and oxidative stress, and glucose regulation in patients with
symptomatic heart failure. J Card Fail. 2007 Mar;13:86-94.
364.

Vaccari CS, Rahman ST, Khan QA, Cheema FA, Khan BV. Effects of angiotensin-

converting enzyme inhibitor therapy on levels of inflammatory markers in response to
exercise-induced stress: studies in the metabolic syndrome. J Cardiometab Syndr. 2008
Winter;3:12-7.
125

365.

Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS,

Shin EK. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J
Am Coll Cardiol. 2003 Sep 3;42:905-10.

126

3
Part Three
The Effects of Dairy Components on Energy
Partitioning and Metabolic Risk in Mice:
A Microarray Study1

1
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3.1

Abstract
Background/Aim: High calcium diets modulate energy metabolism and suppress

inflammatory stress. These effects are primarily mediated by calcium suppression of
calcitriol. We have now investigated the contribution of additional components in dairy
(branched-chain amino acids [BCAA] and Angiotensin-Converting-Enzyme inhibitors
[ACEi]) on adipocyte and muscle metabolism in an animal model of diet-induced obesity.
Methods: aP2 agouti mice were fed four different 70% restricted diet groups (basal
(0.4% Ca), milk (1.2 % Ca), calcium depleted milk (0.4 % Ca), or basal (0.4 % Ca) with
supplemented BCAA/ACEi for 6 weeks.

A high density oligonucleotide microarray

approach was used to compare the effects on energy metabolism.
Results: Lipogenic genes in adipose tissue were downregulated in the milk group
while in muscle protein synthetic pathways were stimulated by the Ca depleted and low
Ca/BCAA/ACEi diet groups. Pathways involved in inflammation were altered in adipose
tissue and muscle by all three diet treatment groups.
Conclusions: The results support our previous findings that calcium and BCAA
contribute to the alteration of energy partitioning between adipose tissue and muscle. They
provide further evidence for a calcium independent effect of BCAA and ACEi in energy
metabolism and inflammation.
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3.2

Introduction
Dietary calcium appears to play a significant role in modulating energy metabolism

and obesity risk (1-3) Although these effects are mediated, in part, by calcium suppression
of circulating calcitriol, providing calcium in form of dairy products causes a greater effect
than supplemental calcium in both mice and humans (4-6). Additional components in dairy
products that appear to contribute to this effect include branched-chain amino acids (BCAA)
and angiotensin converting enzyme inhibitor (ACEi) peptides (7,8).
Dairy proteins contain a high proportion of the BCAA leucine, isoleucine and valine.
Of these, leucine plays an important role in metabolic signaling pathways regulating muscle
protein synthesis (9-11). Accordingly, leucine-stimulated protein synthesis may create a
metabolic demand for increased fatty acid oxidation to support the energetic requirements of
increased protein synthesis.

In support of this concept, we recently demonstrated

coordinated cross-talk between adipose tissue and skeletal muscle in response to leucine (8),
with leucine suppressing lipid accumulation in adipocytes while stimulating skeletal muscle
fatty acid oxidation.
ACEi lowers blood pressure by inhibiting the conversion of angiotensin I to
angiotensin II (12). However, the local renin-angiotensin system (RAS) also plays an
important role in adipogenesis and in the development of inflammation associated with
obesity. In humans, angiotensin II inhibits preadipocyte differentiation, resulting in poorly
differentiated adipocytes which may exhibit exaggerated inflammatory and metabolic
abnormalities (13,14). Accordingly, blockade of RAS, either by ACEi or angiotensin
receptor blockers, promotes recruitment of preadipocytes and an increase in small insulin129

sensitive adipocytes (15,16). Consequently, the ACEi peptides found in dairy foods may
contribute favorably to improvements in obesity and metabolic syndrome.
Increased production of reactive oxygen species (ROS) has been implicated as a
major factor in the development of chronic diseases associated with obesity (17-19). One of
the underlying mechanisms is the dysregulation of adipocytokines producing a low grade
systemic inflammation (20). Recent data demonstrate that calcitriol plays a role in the
regulation of adipocyte ROS and adipocytokine production, suggesting that suppression of
calcitriol by dietary calcium may suppress the oxidative and inflammatory stress associated
with obesity (21,22).
In consideration of the multiple effects of dietary calcium and other components of
dairy on adipocyte and muscle metabolism, we used a high density oligonucleotide
microarray approach to identify common and differential pathways related to energy
metabolism, inflammation and oxidative stress in adipose and muscle tissue in response to
milk and milk components in an animal model of diet-induced obesity.

3.3

Material and Methods

3.3.1 Animals and Diets:
aP2-agouti mice have been used in our previous studies of the effects of calcium and
milk on diet-induced obesity. These mice express normal agouti protein under the control of
the aP2 promoter in adipose tissue (23). They are not obese on a standard AIN-93 G diet but
develop mild to moderate obesity when fed high sucrose/high fat diets. Accordingly, we
induced obesity in male 7-week old aP2 agouti mice by feeding a sub-optimal Ca (0.4%),
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high fat, high sucrose diet (Table 3-1) for 6 weeks (Phase I). After this time they were
randomized into an ad libitum control group and four energy-restricted diet groups which
received 70% energy of the ad libitum group (10 animals/diet group). The four 70%
restricted diets contained either soy protein with low Ca (basal restricted (BR), 0.4% Ca),
non-fat dry milk (NFDM, 1.2% Ca), Ca-depleted NFDM (0.4% Ca), or soy protein with low
Ca (0.4% Ca) and supplemental BCAA/ACEi (Table 3-1). Calcium carbonate (CaCO3) was
added to each diet to achieve the individual final level of calcium as indicated. The animals
were kept on these diet groups for 6 weeks (phase II). At the end of this phase they were
terminated by exsanguination under pentobarbital anaesthesia, and fat pads and muscle
tissue were collected for analysis. This study was approved from an ethical standpoint by the
University of Tennessee Institutional Animal Care and Use Committee.

3.3.2 Total RNA extraction:
The Ambion ToTALLY RNA isolation kit (Ambion, Inc., Austin, Texas) was used
to extract total RNA from visceral abdominal adipose tissue and skeletal muscle
(gastrocnemius) from 4 representative animals from each diet group according to the
manufactor‟s instruction. The concentration and purity of the isolated RNA were measured
by using the ND-1000 Spectrophotometer (NanoDrop Technologies Inc., DE).

3.3.3 Quantitative Real-time PCR
Fatty acid synthase (FAS) and 18S expression was measured by real time reverse
transcriptase- polymerase chain reaction (RT-PCR) using the 7300 Real Time PCR system
with TaqMan universal PCR Master Mix, no AmpErase UNG (2X), and reverse
transcriptase and RNAse inhibitor from the TaqMan 1000 Reaction Core Reagent Kit
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Table 3-1: Mouse diet composition

Diet
Low Ca
(Basal)

(0.4% Ca)

Milk
(NFDM)
(1.2% Ca)

Ca-depleted
Milk
(0.4% Ca)

LowCa/
BCAA/ACEi
(0.4% Ca)

Soy protein

161

0

0

164

Milk, non-fat dry

0

400

0

0

Milk, decalcified, dry

0

0

400

0

DL-Methionine

3

0

0

3

Sucrose

637.9

429.7

421

628

Cellulose

50

50

50

50

Soybean oil

100

41.8

41.8

44

Lard

10

65

65

66

Mineral Mix S10022B

7

7

7

7

Calcium carbonate
Potassium phosphate,
monobasic
Potassium Citrate, 1
H2O
ACE inhibitor peptide

9.2

17.4

5.5

9.2

8

8

24

12.7

1.6

1.6

0

0

0

0

0

5.1

Vitamin Mix V10037

10

10

10

10

Choline Bitartrate

2.5

2.5

2.5

2.5

t-butyl hydroqinone

0.014

0.014

0.014

0.014

Ingredient (g/kg)

Macronutrients (g/kg diet)
Protein

143.9

144.8

152.5

152.5

Carbohydrate

647.9

647.7

639.0

639.0

Fat

110.0

110.0

110.0

110.0

Fiber

50

50

50

50
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Table 3-1, Continued.

Diet
Low Ca
(Basal)

(0.4% Ca)

Milk
(NFDM)
(1.2% Ca)

Ca-depleted
Milk
(0.4% Ca)

LowCa/
BCAA/ACEi
(0.4% Ca)

Macronutrients (kcal/kg diet)
Protein

576

579

610

610

Carbohydrate

2592

2591

2556

2556

Fat

990

990

990

990

Total

4157

4160

4156

4156

Protein

14

14

15

15

Carbohydrate

62

62

62

62

Fat

24

24

24

24

Total

100

100

100

100

Calcium, gm

4.0

12.0

4.0

3.99

Phosphorus, gm

3.11

5.7

5.5

5.5

Potassium, gm

3.74

10.81

7.62

4.51

Leucine

11.4

13.8

13.8

13.4

Isoleucine

6.92

8.5

8.5

8.35

Valine

7.08

9.4

9.4

9.22

Leucine

1.14

1.33

1.33

1.34

Isoleucine

0.69

0.82

0.82

0.83

Valine

0.71

0.91

0.91

0.92

Macronutrients (kcal%)

BCAA (g/kg diet)

BCAA (%/kg diet)
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(all from Applied Biosystems, Foster City, CA), according to manufacturers instructions.
Standard curves were made for each gene of interest by pooling 1µl of each sample
(concentration 10 ng/µl), then using ten-fold dilutions for each progressive standard point
ranging from 100 ng to 0.5 pg total RNA. RT-PCR reaction mixture contained TaqMan
universal PCR Master Mix, no AmpErase UNG (2X), murine leukemia virus reverse
transcriptase (50 U/µl), RNAse inhibitor, and 20X Assays-on-Demand Gene Expression
Assay Mix for FAS and 18S (all from Applied Biosystems, Foster City, CA). Polymerase
chain reaction was performed according to instructions of the 7300 Real Time PCR system
(Applied Biosystems) using 50 to 100 ng total RNA per sample plated in Thermo-Fast
96Detection plates (ABgene, Epsom, Surrey, UK). FAS mRNA levels were normalized to
18s levels prior to statistical analysis.

3.3.4 Microarray:
The Affymetrix Gene Chip Mouse Genome 430 Plus Array, release 2.0 (Santa Clara,
Calif., USA) was used and the Affymetrix protocol for One-cycle cDNA synthesis and
labeling was followed. Total RNA (3 μg from abdominal adipose tissue and 1 μg from
gastrocnemius muscle, 4 animals/diet group) was converted into single stranded cDNA. One
cycle cDNA synthesis was followed by cleanup using Affymetrix GeneChip Sample
Cleanup Modules. Biotin-labeled cRNA was prepared using Affy 3‟IVT Kit (Santa Clara,
Calif., USA). After cleanup of the in vitro transcription products using Affymetrix
GeneChip Sample Cleanup Modules for IVT reactions, the purified cRNA was fragmented.
The fragmented cRNA (5 μg from adipose tissue, 1 μg from gastrocnemius) was mixed with
a hybridization cocktail per Affymetrix directions in the Technical Manual. The solution
134

was hybridized to a GeneChip at 45oC for 16 hours. After hybridization, the cocktail was
removed from the GeneChip and stored for potential future analysis. Using an Affymetrix
Fluidics 450 wash station, the GeneChip was washed and stained with streptavidinphycoreythrin (Molecular Probes), followed by a wash with biotinylated antibody (Vector
Labs) and IgG (Sigma) and then another staining with strepatavidin-phycoerythrin. The
GeneChips were immediately scanned with a GeneChip 3000 scanner. The individual
GeneChip scans were quality checked for the presence of image abnormalities, outliers,
control genes and background signal values. The GeneChips were processed at the
University of Tennessee Knoxville Affymetrix Core Facility.

3.3.5 Analysis of Array Data:
The data obtained from the GeneChip scanner were further analyzed using
Affymetrix

®

Microarray Suite 5.0 Algorithm. Hybridization of B2 oligo served as positive

control by the software to place a grid over the scanned image. Noise, which is the pixel-topixel variations of probe cells on the array and the average background (varies between 20
and 100) were subtracted from the signal intensity value. The control genes were analyzed
(poly A controls and hybridization controls) for appropriate signal intensity. The software
uses a detection algorithm to call the expression of each gene as present (P), marginal (M) or
absent (A). This is based on the target-specific intensity of the probe pair relative to the
overall hybridization intensity (i.e., perfect match-mismatch/ perfect match + mismatch).
The genes that are considered as present were selected and their signal intensities were
converted into a signal log base 2 value (log2). Using Partek Genomics Suite (Partek GS)
software (St. Louis, Missouri) for Affymetrix microarray data, differentially expressed genes
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for each treatment groups compared to the control group were obtained with a step-up FDRcorrected statistical significant p-value of ≤0.05 (24). The extracted genes from each diet
group were compared in the Venn diagram to identify genes in common among the
treatment

groups

(25).

The

web-based

tool

David

bioinformatics

(http://david.abcc.ncifcrf.gov/) was used to classify genes according to their biological
pathways in which the gene expression changes occurred (26).
All microarray data were submitted in compliance with Minimal Information about
Microarray Experiments (MIAME) (27). All data can be accessed at the UTMD data
repository under category „Mouse‟.

3.4

Results
To identify gene alterations caused by different milk components, we used three

different diet treatment groups and one control group (low Ca basal group, BR) varying in
the amount of calcium and/or the amount of BCAA/ACEi (Table 3-1). At the end of the
study the animals showed significant differences for weight loss, fat mass and muscle mass
in all three treatment groups compared to the control group, with greatest changes found in
the milk group (Table 3-2). For the microarray data analysis, we identified the genes which
were statistical significantly (FDR corrected p≤ 0.05) altered in each treatment group
compared to the low calcium basal control group and then compared these lists to determine
similarities and differences among the treatment groups (Figure 3-1). Since the level of
BCAA/ACEi is similar in all three treatment groups, the effects of these components can be
identified by comparing common gene alterations among all three treatment groups to the
control group. Specific calcium-mediated effects can be found in the unique gene alterations
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Table 3-2: Effects of the diet groups on weight change, fat pad mass and muscle mass.

Diet
Low Ca (BR)

NFDM

Ca-depleted

LowCa/
BCAA/ACEi

Weight
loss (g)

-8.25 ± 1.06 a

-14 ± 1.06 b

-10.97 ± 0.85 c

-10.52 ± 1.32 c

non-matching superscripts denote
significant different, p<0.01

Fat pad
mass (g)

3.98 ± 0.21 a

1.73 ± 0.18 b

2.52 ± 0.28 c

2.75 ± 0.22 c

non-matching superscripts denote
significant different, p<0.001

soleus
mass (g)

0.017 ± 0.0005 a

0.028 ± 0.0009 b

0.022 ± 0.0.001 c

0.019 ± 0.0001 d

non-matching superscripts denote
significant different, p<0.05
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Adipose tissue

Muscle

Low Ca/BCAA vs BR (1612)

NFDM vs BR (1448)

Low Ca/BCAA vs Br (2158)

Ca depl. vs BR (1704)

NFDM vs BR (2163)

Ca depl. vs BR (1909)

Figure 3-1:
Venn Diagram presenting the number of genes significantly altered by milk (NFDM), Cadepleted milk and LowCa/BCAA/ACEi diets in adipose tissue and muscle relative to a 70% low
calcium basal restricted diet (BR) (step-up FDR corrected p ≤ 0.05).
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in the milk diet group, while changes in common between milk and the other treatment groups
are calcium independent.
Figure 3-1 summarizes the genes differentially regulated by the milk (NFDM), calciumdepleted milk (Ca-depleted) and LowCa/BCAA/ACEi treatments in adipose tissue and skeletal
muscle. There were 1448, 1704 and 1612 genes in adipose tissue altered in the NFDM, Cadepleted milk and LowCa/BCAA/ACEi diet groups, respectively, compared to the 70% low
calcium basal restricted group (BR). Thirty-six of these were in common among all three diet
groups (Table 3-3), including an upregulation of transformation related protein 53.
In muscle, 2163, 2158 and 1909 genes were altered in NFDM, Ca-depleted and
LowCa/BCAA/ACEi diet groups, respectively. 122 of these genes were in common between all
three groups (Table 3-4), including a downregulation of platelet derived growth factor D.
In adipose tissue, 1183 genes were uniquely altered in the NFDM group. The pathway
analysis revealed a significant involvement of insulin signaling, PPAR signaling and pyruvate
metabolism (Table 3-5). Most lipogenic genes in these pathways (e.g. acetyl-coenzyme a
carboxilase beta (ACCβ), stearoyl-coenzyme a desaturase1 (SCD1), acyl-coenzyme a synthetase
(ACS) were downregulated (Table 3-6). Consistent with this, RT-PCR analysis of Fatty acid
synthase (FAS) in adipose tissue showed a significant down regulation in the NFDM diet group
and to a lesser degree in the Ca-depleted and LowCa/BCAA/ACEi group (Fig.3-2).
In muscle, 1571 genes were found uniquely altered by the NFDM group. The pathway
analysis (Table 3-7) identified changes in the adipocytokine signaling pathway; there was a
significant upregulation of adiponectin receptor 1 and AMP-activated protein kinase (AMPK)
(Table 3-8).

139

Table 3-3: List of genes commonly altered among all three diet groups compared to the low calcium basal restricted diet group
(BR) in adipose tissue (step-up FDR corrected p ≤ 0.05).
Column ID
1416977_AT
1419467_AT
1419531_AT
1422224_AT
1422417_AT
1425948_A_AT
1427739_A_AT
1428398_AT
1429351_AT
1430676_AT
1431720_AT
1431870_AT
1436250_AT
1436928_S_AT
1437748_AT
1439303_AT
1439856_AT
1441101_AT
1443238_AT
1445459_AT
1446362_AT
1447103_AT

Name

Fold change
BR/
NFDM

BR/LowCa/
BCAA/ACEi

-1.34046

-1.61335

-1.43847

1.97756
-12.3923
-9.64146
-5.40085
-4.2969

1.61547
-7.75211
-6.7559
-4.54111
-2.93277

1.28154
-14.6248
-14.2911
-4.94442
-2.61668

-1.85564

-1.53007

-1.82481

-6.95665

-4.39804

-4.51513

1.3697
-1.48811
-4.00553
-10.4209
-4.77521
1.59706
-1.51246

1.36996
-1.44295
-4.08327
-10.0796
-7.74733
2.62345
-1.368

1.21694
-1.65256
-3.8094
-7.13554
-4.67203
1.29188
-1.38191

-8.92984

-9.62752

-6.06884

-4.42757
-5.06057
-5.26864
-3.40817

-3.68924
-5.24841
-6.36694
-3.07889

-3.32907
-2.92551
-7.26714
-2.87662

-9.39235

-8.13343

-7.17529

-5.73557

-5.66539

-4.84656

BR/Ca-depl.

|| 1416977_AT || SIGNAL TRANSDUCING ADAPTOR MOLECULE (SH3
DOMAIN AND ITAM MOTIF) 2 || 172086
|| 1419467_AT || RIKEN CDNA 1200003C23 GENE || 203227
|| 1419531_AT || RIKEN CDNA 1700102P08 GENE || 184390
|| 1422224_AT || T-COMPLEX PROTEIN 10B || 167969
|| 1422417_AT || EPIDYMAL SPERM GENE || 197408
|| 1425948_A_AT || SOLUTE CARRIER FAMILY 25, MEMBER 30 || 191699
|| 1427739_A_AT || TRANSFORMATION RELATED PROTEIN 53 || 201660
||
1428398_AT
||
UDP-GAL:BETAGLCNAC
BETA
1,3GALACTOSYLTRANSFERASE, POLYPEPTIDE 5 || 190551
|| 1429351_AT || RIKEN CDNA 4930429H24 GENE || 167678
|| 1430676_AT || PROCOLLAGEN, TYPE XIX, ALPHA 1 || 185892
|| 1431720_AT || RIKEN CDNA 2810404F17 GENE || 197914
|| 1431870_AT || RIKEN CDNA 4930463O16 GENE || 189877
|| 1436250_AT || RIKEN CDNA 5430405G05 GENE || 199709
|| 1436928_S_AT || ADENYLATE CYCLASE 3 || 163001
|| 1437748_AT || FUCOSYLTRANSFERASE 11 || 196868
|| 1439303_AT || 16 DAYS NEONATE CEREBELLUM CDNA, RIKEN FULLLENGTH
ENRICHED
LIBRARY,
CLONE:9630012D08
PRODUCT:UNKNOWN EST, FULL INSERT SEQUENCE || 197336
|| 1439856_AT || ACTIVIN RECEPTOR IIB || 174176
|| 1441101_AT || EST AV273951 || 164974
|| 1443238_AT || TRANSCRIBED SEQUENCES || 166062
|| 1445459_AT || TRANSCRIBED SEQUENCES || 173987
|| 1446362_AT || 10 DAYS NEONATE CEREBELLUM CDNA, RIKEN FULLLENGTH
ENRICHED
LIBRARY,
CLONE:6530421N19
PRODUCT:UNKNOWN EST, FULL INSERT SEQUENCE || 181604
|| 1447103_AT || RIKEN CDNA A330004A13 GENE || 186181
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Table 3-3, continued.
Column ID

Name

1447248_AT

|| 1447248_AT || EXPRESSED SEQUENCE AW046938 || 169265
|| 1449945_AT || PEROXISOME PROLIFERATIVE ACTIVATED RECEPTOR,
GAMMA, COACTIVATOR 1 BETA || 177533
|| 1450547_X_AT || DEUBIQUITINATING ENZYME 2 || 176587
|| 1450552_AT || ATPASE, H+ TRANSPORTING, V1 SUBUNIT E-LIKE 2
ISOFORM 2 || 185482
|| 1450759_AT || BONE MORPHOGENETIC PROTEIN 6 || 202224
|| 1451607_AT || KALLIKREIN 6 || 201006
|| 1453337_AT || RIKEN CDNA 1700013E18 GENE || 170853
|| 1453376_AT || RIKEN CDNA 4921524J06 GENE || 167329
|| 1455797_X_AT || LIGATIN || 182450
|| 1456144_AT || NEURON NAVIGATOR 3 || 167220
|| 1457465_AT || 0 DAY NEONATE KIDNEY CDNA, RIKEN FULL-LENGTH
ENRICHED LIBRARY, CLONE:D630003C04 PRODUCT:UNKNOWN EST,
FULL INSERT SEQUENCE || 179065
|| 1457994_AT || RIKEN CDNA 4930563J15 GENE || 187806
|| 1459012_AT || RIKEN CDNA A730041O05 GENE || 169694
|| 1459160_AT || TRANSCRIBED SEQUENCES || 206099

1449945_AT
1450547_X_AT
1450552_AT
1450759_AT
1451607_AT
1453337_AT
1453376_AT
1455797_X_AT
1456144_AT
1457465_AT
1457994_AT
1459012_AT
1459160_AT

8.65124

Fold change
BR/
NFDM
6.67552

BR/low Ca/
BCAA/ACEi
8.03085

1.49591

1.40401

1.60624

-8.40261

-4.62682

-4.92194

-1.79494

-1.45664

-1.611

1.99759
3.61267
-5.96078
-4.22151
-1.45902
1.27034

3.01482
2.78221
-5.72438
-3.08852
-1.61028
1.36313

1.99564
2.24994
-3.36659
-4.54265
-1.69425
1.29699

1.43248

1.52273

1.60869

-11.4323
-30.385
4.92788

-12.926
-15.3028
3.48275

-8.58853
-11.0091
5.6296

BR/Ca-depl.
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Table 3-4: List of genes commonly altered among all three diet groups compared to the low calcium basal restricted group (BR)
in muscle (step-up FDR corrected p ≤ 0.05).
Fold change

Column ID
1415712_AT
1416383_A_AT
1416851_AT
1417169_AT
1417475_AT
1417679_AT
1418028_AT
1418399_AT
1418853_AT
1419148_AT
1419490_AT
1420144_X_AT
1420355_AT
1420503_AT
1420522_AT
1420556_AT
1420669_AT
1421554_AT
1422588_AT
1422618_X_AT
1422846_AT
1423310_AT

Name
|| 1415712_AT || DNA SEGMENT, CHR 7, WAYNE STATE UNIVERSITY 87,
EXPRESSED || 187001
|| 1416383_A_AT || PYRUVATE CARBOXYLASE || 171605
|| 1416851_AT || SUPPRESSION OF TUMORIGENICITY 13 || 194327
|| 1417169_AT || UBIQUITIN SPECIFIC PROTEASE 2 || 184062
|| 1417475_AT || ATPASE TYPE 13A || 185179
|| 1417679_AT || GROWTH FACTOR INDEPENDENT 1 || 172182
|| 1418028_AT || DOPACHROME TAUTOMERASE || 178332
|| 1418399_AT || POTASSIUM CHANNEL TETRAMERISATION DOMAIN
CONTAINING 9 || 176253
|| 1418853_AT || DNA SEGMENT, CHR 10, UNIVERSITY OF CALIFORNIA AT
LOS ANGELES 2 || 177725
|| 1419148_AT || ADVILLIN || 175347
|| 1419490_AT || EXPRESSED SEQUENCE AW049604 || 187294
|| 1420144_X_AT || RIKEN CDNA D930043C02 GENE || 205205
|| 1420355_AT || G PROTEIN-COUPLED RECEPTOR KINASE 2, GROUCHO
GENE RELATED (DROSOPHILA) || 185080
|| 1420503_AT || SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER
TRANSPORTER), MEMBER 14 || 176389
|| 1420522_AT || RIKEN CDNA 2610529H08 GENE || 197009
|| 1420556_AT || OXYTOCIN || 199913
|| 1420669_AT || ARYL HYDROCARBON RECEPTOR NUCLEAR
TRANSLOCATOR 2 || 167270
|| 1421554_AT || LIM HOMEOBOX TRANSCRIPTION FACTOR 1 ALPHA ||
197332
|| 1422588_AT || KERATIN COMPLEX 2, BASIC, GENE 6B || 190636
|| 1422618_X_AT || CDNA CLONE MGC:74306 IMAGE:6774630, COMPLETE
CDS || 191307
|| 1422846_AT || RETINOL BINDING PROTEIN 2, CELLULAR || 169611
|| 1423310_AT || TROPHOBLAST GLYCOPROTEIN || 202787
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BR/NFDM

BR/Ca-depl.

BR/lowCa/
BCAA/ACEi

-1.35335
-2.00201
-6.63426
-1.28938
-2.36991
-4.44749
-8.46549

-1.41134
-1.82452
-4.76242
-1.39951
-2.22073
-7.02771
-14.4285

-1.49227
-1.56093
-4.5287
-1.40193
-2.51043
-11.2293
-5.23316

1.29951

1.44645

1.34111

1.92403
7.52673
-7.12415
6.26498

3.63223
2.68323
-6.3702
3.90203

2.74606
1.51062
-4.59859
4.06337

11.7003

3.16774

1.85416

-8.88834
1.24124
1.29612

-6.28409
1.65767
1.49924

-5.65696
1.32168
1.86433

-3.20953

-4.90921

-5.87866

2.44334
3.80457

8.32438
5.64882

6.88502
8.11482

-7.37698
4.79857
4.21745

-7.25632
4.12604
4.09507

-7.63256
4.03147
3.99069

Table 3-4, continued.
Fold change

Column ID

Name

1423751_AT
1423788_AT
1423828_AT
1424183_AT
1424265_AT
1424550_AT
1425997_A_AT
1426218_AT
1427331_AT
1427346_AT
1427605_AT
1427617_AT
1427715_A_AT

|| 1423751_AT || ZINC FINGER PROTEIN 162 || 167252
|| 1423788_AT || NUCLEOPORIN 133 || 172999
|| 1423828_AT || FATTY ACID SYNTHASE || 183818
|| 1424183_AT || ACETYL-COENZYME A ACETYLTRANSFERASE 1 || 203679
|| 1424265_AT || N-ACETYLNEURAMINATE PYRUVATE LYASE || 188016
|| 1424550_AT || ZINC FINGER, FYVE DOMAIN CONTAINING 27 || 198523
|| 1425997_A_AT || PHOSPHATIDYLINOSITOL GLYCAN, CLASS N || 189756
|| 1426218_AT || GLUCOCORTICOID INDUCED TRANSCRIPT 1 || 203962
|| 1427331_AT || ADENOSINE A1 RECEPTOR || 193753
|| 1427346_AT || OVARY TESTIS TRANSCRIBED || 169585
|| 1427605_AT || HOMEO BOX B3 || 186655
|| 1427617_AT || FUCOSYLTRANSFERASE 10 || 197429
|| 1427715_A_AT || 5'-NUCLEOTIDASE, CYTOSOLIC IB || 180067
|| 1427781_AT || UPREGULATED DURING SKELETAL MUSCLE GROWTH 2
|| 164172
|| 1427812_AT || IDURONATE 2-SULFATASE || 183142
|| 1427814_AT || ONCOFETAL ANTIGEN || 183782
|| 1427831_S_AT || ZINC FINGER PROTEIN 260 || 171405
||
1428543_AT
||
PHOSPHORIBOSYL
PYROPHOSPHATE
AMIDOTRANSFERASE || 206672
|| 1429254_AT || AQUAPORIN 11 || 165817
|| 1429675_AT || RIKEN CDNA 1700023A16 GENE || 194188
|| 1430340_AT || RIKEN CDNA 4930431B11 GENE || 198460
|| 1430430_AT || RIKEN CDNA 6130401L20 GENE || 172694
|| 1430885_AT || RIKEN CDNA 1110012N22 GENE || 165466
|| 1431501_AT || RIKEN CDNA 1700037C18 GENE || 162790
|| 1431558_AT || RIKEN CDNA 2310016D03 GENE || 172264
|| 1431561_A_AT || DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 34 ||
180508
|| 1431981_AT || HYPOXIA INDUCIBLE FACTOR 1, ALPHA SUBUNIT ||
194391
|| 1432404_AT || RIKEN CDNA 4930505A04 GENE || 170421
|| 1432707_AT || || 170589

1427781_AT
1427812_AT
1427814_AT
1427831_S_AT
1428543_AT
1429254_AT
1429675_AT
1430340_AT
1430430_AT
1430885_AT
1431501_AT
1431558_AT
1431561_A_AT
1431981_AT
1432404_AT
1432707_AT
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BR/NFDM

BR/Ca-depl.

2.97858
3.15111
-1.88581
1.17905
1.76472
-8.28198
-7.8173
-4.27178
2.36482
-5.24395
6.98819
-5.73184
6.93914

4.22042
3.45462
-2.42808
1.2067
1.90653
-3.51495
-3.08041
-4.08387
4.46957
-7.63352
5.27117
-7.50161
5.58697

BR/LowCa/
BCAA/ACEi
7.72445
6.85933
-2.23346
1.23353
1.90852
-8.837
-4.89823
-3.68334
3.79598
-6.70744
9.90109
-6.26794
6.35728

-4.33035
5.50039
-4.55377
1.92638

-7.89799
8.83638
-7.5122
2.30292

-6.05322
5.86947
-3.40696
1.65186

-1.67048
-4.93817
-9.04583
7.2684
-18.5265
1.62095
3.48469
2.03088

-1.85049
-8.75124
-7.57058
12.7997
-20.3426
1.47514
6.19102
4.85741

-1.69324
-9.23874
-4.07078
6.61272
-4.13402
2.40984
8.07013
9.25755

1.58416

1.82636

1.4558

7.79947
-5.65147
3.60213

9.29417
-4.75364
8.90617

4.41806
-5.96371
3.94438

Table 3-4, continued.
Fold change

Column ID

Name

1432914_AT

|| 1432914_AT || RIKEN CDNA 4930413P14 GENE || 203657
|| 1433550_AT || CHECKPOINT WITH FORKHEAD AND RING FINGER
DOMAINS || 197566
|| 1433744_AT || EXPRESSED SEQUENCE AI841794 || 202908
|| 1433918_AT || APG4 (ATG4) AUTOPHAGY-RELATED HOMOLOG D (S.
CEREVISIAE) || 178397
|| 1433958_AT || RIKEN CDNA 9830165K03 GENE || 175166
|| 1434355_AT || ZINC FINGER PROTEIN 617 || 203264
|| 1434535_AT || RIKEN CDNA 6330509G02 GENE || 196799
|| 1434639_AT || KELCH REPEAT AND BTB (POZ) DOMAIN CONTAINING 9
|| 190078
|| 1434689_AT || HYPOTHETICAL PROTEIN LOC232337 || 167554
|| 1434908_AT || EXPRESSED SEQUENCE AI480556 || 204410
|| 1435301_AT || RIKEN CDNA 1110004E09 GENE || 186107
|| 1436552_AT || ADULT MALE TESTIS CDNA, RIKEN FULL-LENGTH
ENRICHED LIBRARY, CLONE:4930402I24 PRODUCT:HYPOTHETICAL
PROTEIN, FULL INSERT SEQUENCE || 199556
|| 1436719_AT || SOLUTE CARRIER FAMILY 35, MEMBER F1 || 181695
|| 1436973_AT || CHAPERONIN SUBUNIT 8 (THETA) || 168680
|| 1437145_S_AT || RIKEN CDNA 2310002J15 GENE || 197482
|| 1437227_AT || RIKEN CDNA 2900073H19 GENE || 161902
|| 1437642_AT || HIV-1 REV BINDING PROTEIN-LIKE || 165187
|| 1437977_AT || SMALL GLUTAMINE-RICH TETRATRICOPEPTIDE REPEAT
(TPR)-CONTAINING, BETA || 206408
|| 1438819_AT || TRANSCRIBED SEQUENCES || 194263
|| 1439052_AT || RIKEN CDNA 5430433G21 GENE || 205079
|| 1439218_AT || ADULT MALE PITUITARY GLAND CDNA, RIKEN FULLLENGTH ENRICHED LIBRARY, CLONE:5330429P03 PRODUCT:UNKNOWN
EST, FULL INSERT SEQUENCE || 179605
|| 1439468_AT || TRANSCRIBED SEQUENCES || 201372
|| 1439931_AT || 190481 Glycogen synthase kinase 3 beta
|| 1440208_AT || TRANSCRIBED SEQUENCES || 205613
|| 1440689_AT || RIKEN CDNA 6230415M23 GENE || 206005

1433550_AT
1433744_AT
1433918_AT
1433958_AT
1434355_AT
1434535_AT
1434639_AT
1434689_AT
1434908_AT
1435301_AT

1436552_AT
1436719_AT
1436973_AT
1437145_S_AT
1437227_AT
1437642_AT
1437977_AT
1438819_AT
1439052_AT

1439218_AT
1439468_AT
1439931_AT
1440208_AT
1440689_AT

10.7795

3.70208

BR/LowCa/
BCAA/ACEi
16.217

1.58106
-9.1872

1.28237
-7.17254

1.45881
-6.35024

-1.68975
1.99615
-1.33503
-4.78067

-1.47852
1.4539
-1.83736
-4.33883

-1.63827
2.07115
-1.547
-6.56723

2.63319
-1.28084
-2.968
-2.97259

3.1387
-1.43372
-1.99812
-3.58944

2.16413
-1.19468
-2.09165
-2.35746

-10.8883
-4.94134
-8.59297
3.05395
-1.51708
-6.79194

-5.17481
-4.0419
-9.9767
3.93001
-2.20731
-9.40643

-3.09718
-5.91077
-5.21228
6.96323
-1.41817
-6.26239

-7.59997
-6.32152
3.47652

-6.80973
-5.2748
3.55648

-6.39455
-8.36567
5.80473

-4.11129
-3.79125
-3.94473
3.73907
1.64773

-5.75808
-5.01008
-4.34706
5.68418
3.59789

-3.10785
-4.64575
-4.19949
1.92974
4.2833

BR/NFDM
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BR/Ca-depl.

Table 3-4, continued.
Fold change

Column ID
1440741_AT

1441037_AT
1441372_AT
1441568_AT
1441954_S_AT
1441996_AT
1442349_AT
1444156_AT
1444555_AT
1445032_AT
1445379_AT
1445381_AT
1445822_AT
1446691_AT
1446795_AT
1447068_AT
1447265_AT
1447890_AT
1448235_S_AT
1448313_AT
1448365_AT
1448731_AT
1449856_AT
1449948_AT
1451138_X_AT
1451262_A_AT
1451849_A_AT

Name
|| 1440741_AT || 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR 1D ||
168815
|| 1441037_AT || ADULT MALE CORPORA QUADRIGEMINA CDNA, RIKEN
FULL-LENGTH
ENRICHED
LIBRARY,
CLONE:B230218K11
PRODUCT:UNKNOWN EST, FULL INSERT SEQUENCE || 168486
|| 1441372_AT || RIKEN CDNA 5930405F01 GENE || 162884
|| 1441568_AT || CDNA SEQUENCE BC010311 || 168842
|| 1441954_S_AT || RIKEN CDNA 1700026P10 GENE || 195127
|| 1441996_AT || RIKEN CDNA E030034P13 GENE || 162754
|| 1442349_AT || RIKEN CDNA C630028N24 GENE || 177471
|| 1444156_AT || RIKEN CDNA 9230112E08 GENE || 175138
|| 1444555_AT || || 203863
|| 1445032_AT || TRANSCRIBED SEQUENCES || 204718
|| 1445379_AT || TRANSCRIBED SEQUENCES || 165129
|| 1445381_AT || POLY(RC) BINDING PROTEIN 2 || 165762
|| 1445822_AT || SIMILAR TO RIKEN CDNA 5730509K17 GENE (LOC212369),
MRNA || 162080
|| 1446691_AT || PLATELET-DERIVED GROWTH FACTOR, D POLYPEPTIDE
|| 182116
|| 1446795_AT || || 168115
|| 1447068_AT || || 175672
|| 1447265_AT || EXPRESSED SEQUENCE AI848615 || 189238
|| 1447890_AT || RETICULOCALBIN || 196714
|| 1448235_S_AT || HIGH MOBILITY GROUP BOX 1 || 192396
|| 1448313_AT || CEROID-LIPOFUSCINOSIS, NEURONAL 2 || 193335
|| 1448365_AT || EXOSOME COMPONENT 7 || 163427
|| 1448731_AT || INTERLEUKIN 10 RECEPTOR, ALPHA || 197545
|| 1449856_AT || REGULATOR OF G-PROTEIN SIGNALING 18 || 194579
|| 1449948_AT || RIKEN CDNA 1300013B24 GENE || 178487
|| 1451138_X_AT || RIKEN CDNA 2700087H15 GENE || 173904
|| 1451262_A_AT || JTV1 GENE || 188119
|| 1451849_A_AT || LAMIN B2 || 167835
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BR/NFDM

BR/Ca-depl.

BR/LowCa/
BCAA/ACEi

-8.61564

-8.08385

-8.69232

5.23709
9.2002
3.84438
-3.63389
-3.75646
1.47798
-6.84308
6.09179
-4.30004
-13.4979
1.50243

4.99003
7.30613
7.33895
-5.617
-4.24349
9.356
-8.35765
5.43162
-2.67333
-5.30494
1.51154

7.62859
5.17671
5.66456
-3.36055
-2.54038
3.95694
-16.5006
6.70045
-3.35349
-10.9984
1.33718

3.89108

10.3419

6.41618

4.17534
3.53002
2.74191
7.9215
-5.36061
1.18006
-1.18153
1.49578
4.02862
-3.89487
12.9982
1.68277
-1.24376
-4.67795

5.61025
8.61071
3.93817
15.3203
-6.01039
1.28624
-1.21734
1.45723
2.17129
-6.36523
6.72961
2.13296
-1.25444
-6.52493

7.33304
1.80826
2.26111
13.3661
-8.76593
1.73583
-1.44428
1.40844
2.27003
-6.81835
10.8192
1.98595
-1.21807
-3.12547

Table 3-4, continued.
Fold change

Column ID
1452070_AT
1452765_AT
1453216_AT
1454088_AT
1454169_A_AT
1454188_AT
1455177_AT
1455346_AT
1456186_AT
1456211_AT

1456230_AT
1457379_AT

1457497_AT
1457581_AT
1458854_AT

1459015_AT
1460068_AT
1460330_AT
1460379_AT

Name
|| 1452070_AT || DEATH EFFECTOR DOMAIN-CONTAINING DNA BINDING
PROTEIN 2 || 174805
|| 1452765_AT || SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER),
MEMBER 9 || 194164
|| 1453216_AT || GLUTAMIC PYRUVIC TRANSAMINASE 1, SOLUBLE ||
164902
|| 1454088_AT || RIKEN CDNA 5330411O13 GENE || 197780
|| 1454169_A_AT || RIKEN CDNA 2310046K10 GENE || 161872
|| 1454188_AT || RIKEN CDNA 4921508D12 GENE || 182487
|| 1455177_AT || ABELSON HELPER INTEGRATION SITE || 163090
|| 1455346_AT || MANNAN-BINDING LECTIN SERINE PROTEASE 1 || 190960
|| 1456186_AT || TRANSCRIBED SEQUENCES || 164626
|| 1456211_AT || NACHT, LEUCINE RICH REPEAT AND PYD CONTAINING 10
|| 164658
|| 1456230_AT || TRANSCRIBED SEQUENCE WITH WEAK SIMILARITY TO
PROTEIN SP:Q14258 (H.SAPIENS) Z147_HUMAN ZINC FINGER PROTEIN
147 || 185268
|| 1457379_AT || EXPRESSED SEQUENCE C78549 || 206080
|| 1457497_AT || ADULT MALE CORPUS STRIATUM CDNA, RIKEN FULLLENGTH
ENRICHED
LIBRARY,
CLONE:C030032K10
PRODUCT:UNCLASSIFIABLE, FULL INSERT SEQUENCE || 166004
|| 1457581_AT || UBX DOMAIN CONTAINING 3 || 183425
|| 1458854_AT || RIKEN CDNA 4931400A14 GENE || 188664
|| 1459015_AT || TRANSCRIBED SEQUENCE WITH WEAK SIMILARITY TO
PROTEIN REF:NP_038603.1 (M.MUSCULUS) L1 REPEAT, TF SUBFAMILY,
MEMBER 23 [MUS MUSCULUS] || 170647
|| 1460068_AT || RIKEN CDNA 1110034C04 GENE || 169594
|| 1460330_AT || ANNEXIN A3 || 172337
|| 1460379_AT || HOMEO BOX B4 || 179283
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BR/NFDM

BR/Ca-depl.

BR/LowCa/
BCAA/ACEi

-3.81644

-2.91332

-3.617

-9.24371

-10.7547

-5.57523

6.64767
3.12934
-9.19905
-9.16763
-5.0662
2.3901
1.43038

3.17801
3.62557
-2.19488
-9.20286
-5.37209
4.10574
1.46722

5.88132
4.9815
-4.05857
-7.5828
-5.04347
2.18403
1.68548

4.62179

7.85207

4.89053

-8.09735
2.33128

-2.59303
1.73971

-2.78549
3.28989

8.10728
13.4241
9.28783

7.50515
5.97589
8.22178

8.47225
7.20791
9.15518

12.9549
-4.39683
1.7872
-6.78036

5.11613
-4.22002
1.32635
-6.39404

4.33649
-4.03103
1.46192
-4.81976

Table 3-5: Pathway analysis from genes uniquely altered (step-up FDR corrected p < 0.05) in
milk diet group in adipose tissue.

Category

Term

Count

%

KEGG_PATHWAY

Pyruvate metabolism

8

0.7

KEGG_PATHWAY

Chronic myeloid leukemia

11

0.9

KEGG_PATHWAY

Insulin signaling pathway

15

1.3

KEGG_PATHWAY

PPAR signaling pathway

10

0.9

KEGG_PATHWAY

Prostate cancer

11

0.9

KEGG_PATHWAY

Endometrial cancer

8

0.7

KEGG_PATHWAY

Glycolysis / Gluconeogenesis

8

0.7

KEGG_PATHWAY

mTOR signaling pathway

8

0.7

KEGG_PATHWAY

Non-small cell lung cancer

8

0.7

KEGG_PATHWAY

Colorectal cancer

10

0.9

KEGG_PATHWAY

Pentose phosphate pathway

5

0.4

KEGG_PATHWAY

Tight junction

13

1.1

KEGG_PATHWAY

Ribosome

10

0.9

KEGG_PATHWAY

Polyunsaturated fatty acid biosynthesis

4

0.3

KEGG_PATHWAY

Acute myeloid leukemia

7

0.6
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Table 3-6: Genes involved within the uniquely altered pathways for milk diet group and their fold change compared to the low
calcium basal restricted diet group (BR) in adipose tissue (step-up FDR corrected p ≤ 0.05).
Mean log base 2 value

NFDM vs. BR (adipose tissue)

BR

NFDM

Fold change
(BR/NFDM)

Insulin signaling pathway (genes)
1452620_AT

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

6.57352

5.91671

1.5766

1452105_A_AT

tuberous sclerosis 2

9.3192

8.72077

1.51407

1448695_AT

protein kinase c, iota

6.00291

3.97955

4.06532

1421954_AT

v-crk sarcoma virus ct10 oncogene homolog (avian)-like

7.02526

5.95862

2.09454

1452281_AT

son of sevenless homolog 2 (drosophila)

10.7275

10.4635

1.20081

1455967_AT

sorbin and sh3 domain containing 1

9.00249

8.52858

1.38887

1427052_AT

acetyl-coenzyme a carboxylase beta

10.3726

8.11331

4.78753

1446390_AT

elk1, member of ets oncogene family

1.02524

3.15126

-4.36511

1443798_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

9.99437

9.72786

1.20289

1450196_S_AT

glycogen synthase 1, muscle

6.83221

4.37409

5.49501

1458472_AT

riken cdna 4932417h02 gene

5.19537

2.99517

4.59544

1450457_AT

casitas b-lineage lymphoma

2.91046

6.18569

-9.68146

1417690_AT

protein kinase, amp-activated, gamma 1 non-catalytic subunit

10.5363

10.938

-1.32111

1421324_A_AT

thymoma viral proto-oncogene 2

8.25732

7.03693

2.33009

1450718_AT

adaptor protein with pleckstrin homology and src

9.40873

7.7783

3.09606

1453466_AT

ribosomal protein s6

6.38798

5.56787

1.76554

1415729_AT

3-phosphoinositide dependent protein kinase-1

10.8689

10.6045

1.20113

1434000_AT

v-ki-ras2 kirsten rat sarcoma viral oncogene homolog

10.322

10.5995

-1.21209

1460326_AT

phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

10.6121

10.2147

1.31707
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Table 3-6, continued.
Mean log base 2 value
BR
NFDM

NFDM vs. BR (adipose tissue)
Pyruvate metabolism (genes):
1424171_A_AT
1452620_AT
1448214_AT
1427052_AT
1423159_AT
1430307_A_AT
1422479_AT
1426264_AT
1416617_AT

hydroxyacyl glutathione hydrolase
phosphoenolpyruvate carboxykinase 2 (mitochondrial)
pyruvate dehydrogenase (lipoamide) beta
acetyl-coenzyme a carboxylase beta
dihydrolipoamide dehydrogenase
malic enzyme, supernatant
acetyl-coa synthetase
dihydrolipoamide s-acetyltransferase (e2 component of
pyruvate dehydrogenase complex)
acyl-coa synthetase short-chain family member 1

Fold change
(BR/NFDM)

10.4408
6.57352
6.92287
10.3726
11.243
12.3805
10.7544

9.57175
5.91671
6.45589
8.11331
10.3944
10.1834
9.4198

1.82642
1.5766
1.38221
4.78753
1.80084
4.58568
2.52204

11.322
9.59437

10.5461
9.94994

1.71223
-1.27949

phosphoenolpyruvate carboxykinase 2 (mitochondrial)
solute carrier family 27 (fatty acid transporter), member 1
sterol carrier protein 2, liver
stearoyl-coenzyme a desaturase 1
3-phosphoinositide dependent protein kinase-1
sorbin and sh3 domain containing 1
acyl-coenzyme a oxidase 1, palmitoyl

6.57352
11.4542
14.2448
12.3516
10.8689
9.00249
12.6655

5.91671
10.5618
13.8489
10.6231
10.6045
8.52858
12.1236

1.5766
1.85625
1.31579
3.31397
1.20113
1.38887
1.45584

acyl-coa synthetase long-chain family member 1
malic enzyme, supernatant
ubiquitin c
glycerol kinase 2

10.4019
12.3805
9.22671
2.39458

9.52782
10.1834
8.74434
4.80585

1.83283
4.58568
1.39703
-5.31942

PPAR signaling pathway (genes)
1452620_AT
1435658_AT
1449686_S_AT
1415965_AT
1415729_AT
1455967_AT
1416408_AT
1422526_AT,
1460316_AT,
1450643_S_AT,
1423883_AT
1430307_A_AT
1454373_X_AT
1416694_AT
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Figure 3-2: Effects of Calcium, ACEi and BCAA on fatty acid synthase (FAS) expression. Nonmatching superscripts denote significant difference (p<0.05).
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Table 3-7: Pathway analysis from genes uniquely altered (step-up FDR corrected p < 0.05) in
milk diet group in muscle.

Category

Term

Count

%

KEGG_PATHWAY

Wnt signaling pathway

25

1.6

KEGG_PATHWAY

Melanogenesis

18

1.1

KEGG_PATHWAY

Thyroid cancer

8

0.5

KEGG_PATHWAY

Endometrial cancer

11

0.7

KEGG_PATHWAY

Tight junction

19

1.2

KEGG_PATHWAY

Insulin signaling pathway

19

1.2

KEGG_PATHWAY

Adipocytokine signaling pathway

12

0.7

KEGG_PATHWAY

B cell receptor signaling pathway

11

0.7

KEGG_PATHWAY

Basal cell carcinoma

10

0.6

KEGG_PATHWAY

Prostate cancer

13

0.8

KEGG_PATHWAY

VEGF signaling pathway

11

0.7

KEGG_PATHWAY

Citrate cycle (TCA cycle)

6

0.4

KEGG_PATHWAY

Long-term depression

11

0.7

KEGG_PATHWAY

Acute myeloid leukemia

9

0.6

KEGG_PATHWAY

Renal cell carcinoma

10

0.6

KEGG_PATHWAY

TGF-beta signaling pathway

12

0.7

KEGG_PATHWAY

Glyoxylate and dicarboxylate metabolism

4

0.2

KEGG_PATHWAY

Colorectal cancer

11

0.7

KEGG_PATHWAY

Long-term potentiation

9

0.6

KEGG_PATHWAY

Hedgehog signaling pathway

8

0.5

KEGG_PATHWAY

Ubiquitin mediated proteolysis

15

0.9

KEGG_PATHWAY

Chronic myeloid leukemia

10

0.6

KEGG_PATHWAY

MAPK signaling pathway

25

1.6
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Table 3-8: Genes involved within the adipocytokine signaling pathway in the milk diet group and their fold change compared to
low calcium basal restricted diet group (BR) in muscle (step-up FDR corrected p< 0.05).
Mean log base 2 value

Genes involved in Adipocytokine signaling
1420088_AT
1423104_AT
1444480_AT
1421324_A_AT,
1424480_S_AT
1456156_AT
1425711_A_AT,
1440950_AT

Fold change
(BR vs NFDM)

BR

NFDM

12.3429

12.0147

1.25539

insulin receptor substrate 1
protein kinase, amp-activated, gamma 3 noncatatlytic subunit

11.0837

10.4648

1.53565

13.0262

13.3445

-1.2468

thymoma viral proto-oncogene 2

10.2967

10.7973

-1.41483

leptin receptor

7.07321

5.47355

3.03071

nuclear factor of kappa light chain gene enhancer in
b-cells inhibitor, alpha

thymoma viral proto-oncogene 1
tumor necrosis factor receptor superfamily, member
1a

8.05

6

4.15

10.1378

10.5312

-1.3135

1428386_AT
1424312_AT,
1451311_A_AT

acyl-coa synthetase long-chain family member 3

8.50904

8.02886

1.39491

12.17

12.67

-1.42

1433800_A_AT

pro-opiomelanocortin-alpha
protein kinase, amp-activated, alpha 2 catalytic
subunit
protein kinase, amp-activated, gamma 1 noncatalytic subunit

8.45222

9.1206

-1.58929

12.4988

12.7497

-1.18995

4.46506

3.1242

2.53302

1417291_AT

1429463_AT
1457803_AT

adiponectin receptor 1
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Since the small number of genes in common among all treatment groups could identify
only few pathways, we also compared in addition the pathways revealed from using all
significant altered genes in each treatment group. In muscle, the LowCa/BCAA/ACEi and Cadepleted group exhibited significant alterations of the mTOR pathway (Table 3-9). In adipose
tissue, pathways found in Ca-depleted and LowCa/BCAA/ACEi were involved in inflammatory
or cell regulatory processes such as MAPK signaling, JAK-STAT signaling, and TGF-beta
signaling pathway (Table 3-10). The genes involved in these pathways are listed in Appendix
Table A1 and A2. In muscle we found involvement of insulin signaling, VEGF signaling, B cell
receptor signaling and GnRH signaling pathway among all three treatment groups; the genes are
shown in Appendix Table A3 to A6.

3.5

Discussion
In this study, two different approaches were used to compare the gene expression changes

caused by the three different diet groups: the Venn Diagram, which is a simple but effective
procedure to examine the overlap of large gene lists differentially expressed between different
sample sets (25), and a comparison of pathways identified by significantly altered genes in each
diet group.
The results of both approaches identified several gene expression patterns and pathways
consistent with our previous findings. We have demonstrated that dietary calcium stimulates
lipolysis and decreases lipogenesis in adipocytes in vivo and in vitro, with dairy products
exerting greater effects than supplemental calcium (4,28,29). These additional effects are partly
caused by the BCAA leucine, contained in the whey fraction of dairy products (7). Leucine is
153

Table 3-9: Genes involved within the mTOR pathway in Ca-depleted and LowCa/BCAA/ACEi diet group and their induction fold
change compared to basal restricted diet group (BR) in muscle (step-up FDR corrected p< 0.05).
Mean log base 2 value
BR
Ca-depl.

Genes involved within mTOR pathway (muscle)
Ca-depleted vs. BR
1428188_AT
1437539_AT
1444831_AT
1447940_A_AT
1431981_AT
1453281_AT
1455252_AT,
1422043_AT
1438954_X_AT
1429434_AT

Fold change
(BR/Ca-depl.)

riken cdna 2610019a05 gene
protein kinase, amp-activated, alpha 1 catalytic subunit
thymoma viral proto-oncogene 3
braf transforming gene
hypoxia inducible factor 1, alpha subunit
phosphatidylinositol 3-kinase catalytic delta polypeptide

7.34586
7.65128
7.79715
5.49872
7.41284
8.76758

8.4323
7.17523
5.37593
7.37856
4.19651
8.02663

-2.1235
1.39093
5.35622
-3.68034
9.29417
1.67127

tuberous sclerosis 1
c-fos induced growth factor

10.1581
9.1695

10.7441
8.58222

-1.50108
1.50242

phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

8.38313
7.65034
Mean log base 2 value
LowCa/
BR
BCAA/ACEi

LowCa/BCAA/ACEi vs. Br
1453069_AT
phosphatidylinositol 3-kinase, catalytic, beta polypeptide
1441311_AT
ribosomal protein s6 kinase, related sequence 1
1442044_AT
ribosomal protein s6
phosphatidylinositol 3-kinase, regulatory subunit,
1425514_AT
polypeptide 1 (p85 alpha)
1444831_AT
thymoma viral proto-oncogene 3
1415842_AT
g protein beta subunit-like
1431981_AT
hypoxia inducible factor 1, alpha subunit
1453281_AT
phosphatidylinositol 3-kinase catalytic delta polypeptide
1439989_AT
tuberous sclerosis 1
1446185_AT
fk506 binding protein 12-rapamycin associated protein 1
1419568_AT
mitogen activated protein kinase 1
1457562_AT
ribosomal protein s6 kinase, polypeptide 1
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1.66186
Fold change
(BR/LowCa/
BCAA/ACEi)

5.1568
5.84424
6.70554

7.60749
3.4635
4.72864

-5.46678
5.20803
3.93645

7.83016
7.79715
9.06191
7.41284
8.76758
6.65765
7.97048
9.26914
4.27528

8.52621
5.0313
8.24947
5.26942
8.13474
3.65317
6.33475
8.58738
7.28731

-1.62007
6.80146
1.75617
4.41806
1.55061
8.02488
3.10744
1.6041
-8.06699

Table 3-10: Pathway analysis from genes altered in lowCa/BCAA/ACEi and Ca-depleted
compared to the low calcium basal restricted diet group (BR) in adipose tissue (step-up FDR
corrected p < 0.05).

Category
Term
LowCa/BCAA/ACEi vs. BR
KEGG_PATHWAY Basal cell carcinoma
KEGG_PATHWAY Wnt signaling pathway
Dentatorubropallidoluysian atrophy
KEGG_PATHWAY
(DRPLA)
KEGG_PATHWAY MAPK signaling pathway
KEGG_PATHWAY Adipocytokine signaling pathway
KEGG_PATHWAY Melanogenesis
KEGG_PATHWAY Jak-STAT signaling pathway
KEGG_PATHWAY Toll-like receptor signaling pathway
KEGG_PATHWAY Pancreatic cancer
KEGG_PATHWAY Hedgehog signaling pathway
KEGG_PATHWAY Streptomycin biosynthesis
KEGG_PATHWAY Ubiquitin mediated proteolysis
KEGG_PATHWAY Small cell lung cancer
Ca-depleted vs BR
KEGG_PATHWAY Endometrial cancer
KEGG_PATHWAY GnRH signaling pathway
KEGG_PATHWAY MAPK signaling pathway
KEGG_PATHWAY Regulation of actin cytoskeleton
KEGG_PATHWAY TGF-beta signaling pathway
KEGG_PATHWAY ErbB signaling pathway
KEGG_PATHWAY Leukocyte transendothelial migration
KEGG_PATHWAY Long-term potentiation
KEGG_PATHWAY Folate biosynthesis
KEGG_PATHWAY Calcium signaling pathway
KEGG_PATHWAY Olfactory transduction
KEGG_PATHWAY Long-term depression
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Count

%

12
19

0.8
1.2

5

0.3

28
11
13
18
13
10
8
3
15
11

1.8
0.7
0.8
1.1
0.8
0.6
0.5
0.2
0.9
0.7

11
15
31
26
14
13
16
10
7
21
6
11

0.6
0.9
1.8
1.5
0.8
0.8
0.9
0.6
0.4
1.2
0.3
0.6

well known for its effects on protein synthesis and maintenance of muscle mass (10,11).
However, this is an anabolic process and requires the addition of energy. Interestingly, there is
evidence that leucine alters energy partitioning between adipose tissue and muscle (8). The
decrease in fat storage and the increase in fat oxidation in muscle which is seen after leucine
treatment suggest that adipose tissue fat stores are utilized by muscle to fuel the energeticallyexpensive process of protein synthesis. The results of this analysis support this concept. The
insulin and PPAR signaling pathways were highly impacted in adipose tissue by the milk diet
group, resulting in downregulation of genes affecting lipogenesis such as ACC, SCD1, and FAS.
ACC and FAS are key enzymes of fatty acid synthesis and highly regulated by hormonal and
transcriptional control (30,31). The fact that these results are mostly found in the milk diet
groups implies that these effects are mainly calcium dependent. In addition, we found in muscle
an upregulation of adiponectin receptor I in the milk diet group. AdipoRI is the main adiponectin
receptor expressed in skeletal muscle, and adiponectin binding leads to stimulation of AMPK.
Both an increase in AdipoRI expression and an increase in AMPK activity are associated with
improved insulin sensitivity, enhanced glucose uptake and fatty acid oxidation (32,33). On the
other hand, the mTOR pathway was altered in muscle in both the lowCa/BCAA/ACEi and Cadepleted diet group, suggesting a leucine effect. The fact that AMPK activation results in
inhibition of mTOR pathway may explain that the pathway was less impacted in the milk diet
group (34).
Other pathways that were altered in adipose tissue in the low Ca/BCAA/ACEi and Ca
depleted diet group were JAK-STAT signaling pathway, MAPK signaling pathway, and TGFbeta signaling. These pathways are involved in inflammation, proliferation and cell cycle
regulation (35-38). Adipose tissue is a major production site of both pro-inflammatory cytokines
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such as TNFα and IL-6, and anti-inflammatory factors such as adiponectin and IL-15. However,
excess in body fat, especially visceral adiposity, is associated with a dysregylation of
adipocytokines leading to a low-grade systemic inflammation (39.40). In addition, adipose tissue
is recognized as a significant source of angiotensin II (41), and the local renin-angiotensinsystem (RAS) plays a significant role in the development of inflammatory and atherogenic
diseases linking obesity to hypertension, diabetes and CVD (42). Accordingly, ACEi peptides in
dairy products may contribute to an anti-inflammatory and antithrombotic effect in these diet
groups. We also note a significant downregulation of platelet-derived growth factor D in all three
diet groups (PDGF-D). Overactivity of PDGFs has been implicated in conditions characterized
by increased cell proliferation such as tumor growth but also in atherosclerosis and fibrotic
diseases (43).
Interestingly, we found an upregulation of transformation related protein 53 (p53) in all
three treatment groups in adipose tissue. p53, first identified as tumor suppressor gene, regulates
cellular response such as apoptosis, cell cycle arrest and senescence to a broad array of stress
types (44). However, p53 activation has also been found in adipocytes of obese mice, where it
results in negative regulation of SREBP-1 and thereby of lipogenic genes such as FAS (45).
Accordingly, the observed downregulation of adipose tissue FAS expression in all three
treatment groups may be due to upregulation of p53.
In conclusion, we have identified several roles for dairy components in modulating
expression pattern and pathways involved in energy metabolism and inflammation in adipose
and muscle tissue. Our results demonstrate calcium-dependent effects as well as calciumindependent effects of BCAAs and ACEis on lipid metabolism, protein synthesis and
suppression of inflammation.
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4
Part Four
Dietary Calcium and Dairy Modulation of Oxidative
Stress and Life Span in aP2-Agouti and Wild-type
Mice
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4.1

Abstract

Dietary Ca reduces oxidative and inflammatory stress, while milk exerts a greater effect than
supplemental Ca.

To examine the effects on lifespan and related biomarkers, aP2-agouti

transgenic (model of diet-induced obesity) and wild-type mice were fed a low Ca (0.4% Ca),
high-Ca (1.2% Ca from CaCO3), or milk (1.2% Ca from non-fat dry milk) obesigenic diet until
their death. Randomized subgroups were sacrificed at 28, 52 and 78 weeks of age for biomarker
analysis. The milk diet attenuated weight and adiposity gain, prevented muscle loss (p<0.04),
and the age-related rise in reactive oxygen species (ROS) production in adipose tissue (p=0.05).
This was associated with an increase in SOD3 (in wild-type, p=0.04) and glutathione peroxidase
gene expression (p<0.02) in soleus muscle, and liver SOD activity (p<0.04). In male mice, the
milk diet decreased IL6 (p<0.05) and TNFα (p<0.03) gene expression in adipose tissue. The
survival analysis showed an overall shorter lifespan in transgenic vs. wild-type mice. Although
no diet effect was found on maximal lifespan, the milk diet resulted in a significant increase in
the 75% survival rate in wild-type mice (p<0.05). These data demonstrate that milk diet
attenuates adiposity, protects against muscle loss and reduces oxidative and inflammatory stress.
Although these effects seem not to influence the maximum lifespan, they may suppress early
mortality.

4.2

Introduction
Oxidative stress and inflammatory stress have been implicated as a cause of tissue

damage in multiple organ systems leading to the development of chronic diseases such as
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obesity, diabetes, hypertony and atherosclerosis (1-3). They are also recognized as one of the
major factors contributing to the physiological process of aging (4, 5). Dietary calcium appears
to play a significant role in regulating ROS production and inflammation in adipocytes (6) and
may therefore contribute to a reduction of metabolic disorders and a prolonged lifespan.
The major intracellular source of ROS production and free radicals in mammalian cells
are mitochondria (7). Under normal physiological conditions, mitochondria generate ROS only
at very low levels. However, several conditions, including obesity, hyperglycemia and
hyperlipidemia can promote ROS production leading to oxidative damage to DNA, lipids and
proteins. The resulting mitochondrial dysfunction can lead to increased ROS production with
subsequent further damage and progressive decline of cellular and tissue functions due to energy
depletion (7). Supporting evidence shows a strong correlation between aging, increased
mitochondrial ROS production and mitochondrial dysfunction (8-11). In addition, inflammatory
mediators such as tumor necrosis factor alpha (TNF-α) can induce oxidative stress by upregulating NADPH oxidase and altering the mitochondrial redox state (12, 13).
As a cellular defense against oxidative stress, mammalian cells have developed an array
of antioxidant enzymes and proteins to dispose ROS under normal physiological conditions.
These include superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase.
However, the age associated decline of the enzyme activities coupled with an increase in
intracellular ROS production can overwhelm the capacity of this defense system, resulting in
increased oxidative stress (4, 7, 14).
Previous work from our laboratory has demonstrated an anti-obesity effect of calcium
rich diets, which we have proposed to be mediated, in part, by calcium suppression of circulating
1α, 25-Dihydroxyvitamin D (Calcitriol) (15-17). Calcitriol promotes glucocorticoid production
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in adipocytes, favoring fat storage in visceral rather than subcutaneous depots (18). Visceral
adiposity is characterized by a low-grade systemic inflammation and is associated with the
development of metabolic disorders (19). Calcitriol also regulates ROS production by adipocytes
(6). Consequently, we have shown that suppression of calcitriol by dietary calcium inhibits
adipocyte-derived inflammatory cytokine expression (20) and reduces oxidative stress in murine
and humane adipocytes (6, 21). We also demonstrated that dairy products exert greater effects
than supplemental calcium, and have proposed that this increased effect is due to additional
components in dairy such as branched-chain amino acids (BCAA) and angiotensin converting
enzyme inhibitor (ACEi) peptides (22, 23).
Considering the protective role of dietary calcium and other dairy components against
oxidative and inflammatory stress, which otherwise accelerate the process of aging, the present
study was designed to evaluate the effects of dietary calcium from both non-dairy and dairy
sources on mouse lifespan and on lifespan-related biomarkers. We utilized aP2-agouti transgenic
mice because we have already demonstrated effects of calcium on adiposity, oxidative stress and
inflammatory stress in this model and because these mice are susceptible to diet-induced obesity.
These mice express normal agouti protein under the control of the aP2 promoter in adipose tissue
(24), thereby mimicking the human pattern of agouti expression. They are not obese on a
standard AIN-93 G diet but develop mild to moderate obesity when fed high sucrose/high fat
diets. In order to gain a more complete understanding of the effect of this genotype, this study
was also done in wild type littermates.
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4.3

Materials and Methods

4.3.1 Animals and Diets
Six to eight week old aP2-agouti mice of both genders (n=197) and their littermate
controls (n=186) from our colony were randomly divided into three diet groups. Group 1 (control
group) was fed a modified AIN93G diet with suboptimal calcium (calcium carbonate, 0.4%) and
with sucrose as sole carbohydrate source, providing 64% of energy. Fat was increased to 25 % of
energy with lard. Group 2 (high calcium group) and group 3 (milk group, NFDM) received the
same diet as group 1, however modified to contain 1.2% calcium in form of calcium carbonate or
to contain 50% of protein replaced by non-fat dry milk with 1.2% calcium, respectively. Diet
composition is shown in Table 4-1. There were similar numbers of both genders and genotypes
in each group (31-35 animals/subgroup). Three to four animals of same gender and diet group
were kept together in polypropylene cages at room temperature of 22+/- 20C and a regime of 12h
light/dark cycle until their death. The animals had free access to water and their experimental
food throughout the experiment. All animals were checked daily for any signs of diseases or
death and moribund animals (as defined by the facility veterinarian) were humanely euthanized.
Weight was measured to the nearest gram at the beginning of the experiment and then at the
beginning of each month until the death of the animals. Small subgroups (4 males and 4 females)
of each diet group and breed (48 animals per age group) were terminated under CO2 anesthesia at
28, 52 and 78 weeks of age to determine biochemical markers in adipose tissue, liver, muscle
and blood. Blood was collected by cardiac puncture. The excised tissues were immediately
weighed and used for further studies, as described below. This study was approved from an
ethical standpoint by the University of Tennessee Institutional Animal Care and Use Committee.
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Table 4-1: Diet composition of the control, high calcium and non-fat dry milk (NFDM) diet
groups.
Diet
Control (0.4% Ca)

High Ca (1.2% Ca)

NFDM (1.2% Ca)

Casein, 80 Mesh

160

160

0

DL-Methionine

3

3

0

Sucrose

637.9

638.3

429.7

Cellulose

50

50

50

Soybean oil

100

100

41.8

Lard

10

10

65

Mineral Mix S10022B

7

7

7

Calcium carbonate

10

30

17.4

Potassium phosphate,
monobasic

8

8

8

Potassium Citrate, 1 H2O

1.6

1.6

1.6

Vitamin Mix V10037

10

10

10

Choline Bitartrate

2.5

2.5

2.5

t-butyl hydroqinone

0.014

0.014

0.014

Milk, Nonfat, Dry

0

0

400

Total

1000.014

1020.414

1033.014

Protein

143.8

143.8

144.8

Carbohydrate

647.9

648.3

647.7

Fat

110

110

110

Fiber

50

50

50

Protein

14.4

14.1

14

Carbohydrate

64.8

63.5

62.7

Fat

11

10.8

10.6

Fiber

5

4.9

4.8

Ingredient (gm)

Macronutrients (g/kgdiet)

Macronutrients (gm %)
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Table 4-1, continued.
Diet
Control (0.4% Ca)

High Ca (1.2% Ca)

NFDM (1.2% Ca)

Protein

575

575

579

Carbohydrate

2592

2593

2591

Fat

990

990

990

TOTAL

4157

4158

4160

Protein

14

14

14

Carbohydrate

62

62

62

Fat

24

24

24

TOTAL

100

100

100

Calcium, gm

4.03

12.03

12.03

Phosphorus, gm

3.1

3.1

5.7

Potassium, gm

3.61

3.61

10.81

Macronutrients (kcal/kg diet)

Macronutrients (kcal %)
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4.3.2 Measurement of blood chemistry markers
Blood glucose was determined in whole blood by using a glucometer. Insulin and
adiponectin plasma levels were assessed by using Mouse Insulin and Adiponectin ELISA Kits,
respectively (Linco Research, St. Charles, MO). The levels of TNFα, IGF-I, IL6 and IL15 in
plasma were measured by using the specific Mouse TiterZyme ELISA Kits from Assay Designs
Inc. (Ann Arbor, MI). Plasma CRP levels were calculated by using the Mouse C-reactive protein
ELISA Kit (Life Diagnostics, Inc., West Chester, PA). MDA in plasma was assessed by using
the TBARS Assay Kit from ZeptoMetrix Corporation (Buffalo, NY).

4.3.3 Measurement of Cortisol release
Perirenal fat tissue was incubated in KRB buffer for 2 hours. Cortisol release in the
medium was determined by using the Cortisol Enzyme Immunoassay Kit from Assay Designs,
Inc (Ann Arbor, MI).

4.3.4 Determination of intracellular ROS generation in white adipose tissue
(perirenal and retroperitoneal fat pads)
Adipose tissue (retroperitoneal and perirenal) digestion and adipocytes preparation was
prepared as described in [Ca2+]i measurement (6). Adipose tissue was washed several times with
Hank‟s balanced salt solution, then minced into small pieces and digested with 0.8 mg/ml type I
collagenase in a shaking water bath at 37oC for 30 min. Adipocytes were then filtered through
sterile 500-μm nylon mesh and cultured in KRB buffer supplemented with 1% fetal bovine
serum (FBS). Cells were cultured in suspension and maintained in a thin layer at the top of
culture media for 2h for cell recovery. Intracellular ROS generation was assessed by using 6170

carboxy-2‟, 7‟-dichlorodihydrofluorescein diacetate (H2-DCFDA) as described (25). Cells were
loaded with H2-DCFDA (2 μmol/L) for 30 minutes. After washing twice with KRB,
Fluorescence (emission 520 nm) and protein content were measured. The intensity of
fluorescence is expressed as arbitrary units per μg protein.

4.3.5 Measurement of enzyme activities in liver
The Superoxide Dismutase activity (SOD) was measured by using an assay kit from
Cayman Chemical Company, Ann Arbor, MI. Tissue samples were prepared according to
manufacture‟s instructions. 200 µl of diluted radical detector (tetrazolium salt) was added to 10
µl of sample or standard. The reaction was started by adding 20 µl of diluted xanthine oxidase.
After 20 min of incubation the absorbance was read at 450 nm using a plate reader. One unit of
SOD is defined as the amount of enzyme needed to exhibit 50 % dismutation of the superoxide
radical. All three types of SODs (Cu/Zn-, Mn-, and Fe-SOD) were measured by the assay.
The Catalase activity was measured as described (26). Tissues were rinsed with
phosphate buffered saline three times to remove any red blood cells, and then homogenized in 510 vol. of cold buffer (50 mM potassium phosphate, pH 7.0). 1% Triton X-100 was added to the
stock homogenate (1 + 9) and then further diluted with phosphate buffer (1:200). The reaction
was started by adding 1ml H2O2 at 20oC to 2 ml homogenate. The decrease of absorbance at 240
nm against a blank (1ml of phosphate buffer instead of substrate) was recorded for about 30s.
The Glutathione peroxidase (GPx) activity was measured using an assay kit from
Oxford Biomedical Research, Oxford, MI. Liver tissue was prepared according to manufacture‟s
instructions. 350 µl of Assay buffer, 350 µl of NADPH Reagent and 70 µl of sample were
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pipetted into a cuvette. The reaction was started by adding 350 µl of diluted Tert-Butyl
Hydroperoxide. The change in absorbance at 340 nm was recorded for three minutes.
The NADPH oxidase activity was measured using the modified Quantitative Photometric
Assay as described (27). Freshly excised tissue was homogenized in 5 vol. of homogenization
buffer (Krebs-Ringer-Phosphate buffer containing 50 mM HEPES, 100 mM NaCl, 5 mM KCl, 1
mM MgCl2/H2O, 1 mM NaH2PO4, 1 mM CaCl2, and 2 mM glucose, pH 7.4). 50 µl of sample
was incubated with 50 µl of PBS and 50 µl of phorbol myristate acetate (PMA) (1.625 µmol/l;
Sigma Diagnostics) to initiate the respiratory burst. After 10 min of mixing, 50 µl of Nitroblue
tetrazolium (NBT) (2.4 mmol/l; Sigma Diagnostics) was added to each individual well. The rate
of NBT reduction was monitored at 490 nm for 30 min and optical density was recorded every 5
min by a photometer for microplates, starting immediately after the addition of NBT. The
NADPH oxidase activity is expressed as the mean of absorbance (A) values in the 30-min
period.
AMPK activity was measured as described in (28). Freshly excised tissue was
immediately homogenized in 2 vol. of homogenization buffer (50 mM Tris/HCL, 250 mM
Mannitol, 50 mM NaF, 5 mM Sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
0.1 mM Phenylmethylsulphonylfluoride, 1 mM Benzanidine, 1 μg/ml Soybean trypsin inhibitor).
Homogenate was centrifuged at 5000 x g for 10 min and supernatant was aliquoted and stored at
-80oC until further use. Reaction mixtures were prepared containing 5 µl of 1 mM [γ-32P] ATP, 5
µl of 1 mM AMP in HEPES-Brij buffer, 5 µl of 1 mM SAMS peptide in HEPES-Brij buffer and
5 µl of HEPES-Brij buffer. The reaction was initiated by the addition of 5 µl AMPK sample.
After 30 min of incubation at 30oC, 15 µl was removed and spotted onto a P81 paper square.
After washing the paper squares twice with 1 % (v/v) phosphoric acid and once with acetone,
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they were laid out on a paper towel and allowed to dry. Dried filters were counted after
immersing in 5 ml of scintillation cocktail. The AMPK activity is expressed as nanomoles of
phosphate incorporated into substrate peptide per minute.

4.3.6 Measurement of mRNA expression
Total RNA extraction: A total cellular RNA isolation kit (Ambion, Austin, TX) was
used to extract total RNA from abdominal (inguinal and retroperitoneal) fat (3 animals/
subgroup), liver and soleus muscle (4 animals/ subgroup) according to manufacturer‟s
instruction. The concentration, purity and quality of the isolated RNA were assessed by
measuring the 260/280 ratio (1.7 – 2.1) and 260/230 ratio (close to 2.0) by using the ND-1000
Spectrophotometer (NanoDrop Technologies Inc., DE).
Quantitative real time PCR: Gene expression of SOD (1 to 3), Glutathione peroxidase,
Catalase, NADPH oxidase, TNFα, IL6, IL15, UCP2, UCP3, Adiponectin, 11β-HSD, NFкB,
PPARα, PPARγ, PPARσ, AMPK, Telomerase, SIRT1 and SIRT3 in retroperitoneal fat, soleus
muscle and liver was quantitatively measured by using an ABI 7300 Real Time PCR System
(Applied Biosystem, Branchburg, NJ) with a TaqMan 1000 Core Reagent Kit (Applied
Biosystem, Branchburg, NJ). The primers and probes sets were obtained from Applied
Biosystems TaqMan® Assays-on-Demand TM Gene Expression primers and probe set
collection according to manufacturer‟s instruction. Pooled adipocyte total RNA was serialdiluted and used to establish a standard curve; total RNAs of unknown samples were also diluted
in the same range. Reactions of quantitative RT-PCR for standards and unknown samples were
performed according to the instructions of the ABI 7300 Real Time PCR System and TaqMan
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1000 Core Reagent Kit (Applied Biosystem, Branchburg, NJ). The mRNA quantitation for each
sample was further normalized using the corresponding 18S quantitation.

4.3.7 Statistical analysis:
Data were evaluated by Multivariate Analysis of Variance (MANOVA) for statistical
significant main effects of gender, genotype, diet and age and possible interactions between
groups. Statistical significantly different means in subgroups were separated by the least
significant difference test (p≤0.05) using ANOVA. Data points were identified as outliers
graphically with box plots and removed when they were extreme (out of 3 IQ range). Survival
analysis was done by using the Kaplan Meier survival analysis. All data analysis was done with
SPSS software (SPSS inc., Chicago, IL). Data are expressed as mean ± standard error (SE).

4.4

Results
Because of the complex design of this experiment we used a MANOVA approach in the

first step of analysis. This approach permits to assess main effects of diets while holding the
other factors (genotype, gender, age) constant as well as to identify interactions between factors.
Accordingly, the following section presents the main effects of diet on the combined subgroups,
and only presents other main effects and interactions when statistically significant.

4.4.1 Body weight and composition
Figure 4-1 shows the mean of body weight for each subgroup over the study duration.
Tables 4-2 and 4-3 list the percentage of total body fat (calculated from the sum of abdominal,
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A

B

Figure 4-1:
Mean weight distribution (A: males, B: females of all aP2-agouti transgenic and wild-type mice
fed control, high calcium or NFDM diets over the study duration.
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Table 4-2: Percentage of total body fat calculated from inguinal, retroperitoneal, perirenal, subscapular and epididymal (in male)
fat pads per body weight in aP2-agouti transgenic and wild-type mice fed control, high calcium or NFDM diets at 28, 52 and 78
weeks of age.1

Gender
female

Genotype
wild

transgenic

male

both
wild

transgenic

both

1

Age
28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all

control
mean ± SE
6.53 ± 2.89
18.53 ± 2.18
19.42 ± 1.49
14.41 ± 2.26
19.27 ± 1.69
19.24 ± 4.39
23.07 ± 2.94
20.72 ± 1.76
17.83 ± 1.53 a
12.43 ± 0.87
15.33 ± 1.84
17.47 ± 1.96 a
15.07 ± 1.05 a
12.54 ± 1.11
16.67 ± 1.25 a
19.97 ± 0.73
16.00 ± 1.23 a
15.50 ± 0.79 a

n
4
4
3
11
4
4
5
13
24
4
4
4
12
4
3
3
10
22

Diet
high calcium
mean ± SE
12.10 ± 1.57
14.37 ± 1.07
17.84 ± 3.73
14.77 ± 1.44
16.90 ± 4.72
22.13 ± 1.15
23.84 ± 4.61
21.07 ± 1.98
17.64 ± 1.36 ab
12.73 ± 0.66
15.06 ± 0.19
11.46 ± 2.05 b
13.08 ± 0.79 ab
12.38 ± 0.49
12.88 ± 1.08 b
13.98 ± 4.94
12.94 ± 1.13 b
13.02 ± 0.68 ab

n
4
4
4
12
3
4
3
10
22
4
4
4
12
5
4
3
12
24

NFDM
mean ± SE
9.24 ± 2.22
12.16 ± 3.07
12.98 ± 1.44
11.32 ± 1.39
12.99 ± 0.65
16.52 ± 1.20
18.62 ± 3.33
16.05 ± 1.29
13.79 ± 1.05 b
10.08 ± 0.75
13.65 ± 0.36
13.44 ± 1.11 ab
12.39 ± 0.64 b
12.87 ± 0.94
13.18 ± 0.51 b
13.56 ± 0.92
13.20 ± 0.43 ab
12.79 ± 0.39 b

n
4
4
3
11
4
4
4
12
23
4
4
4
12
4
4
4
12
24

Values are expressed as mean ± SE. Non-matching superscripts denote significant differences between diet groups, p < 0.05.
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Table 4-2, continued.

Gender
both

Genotype
wild

transgenic

both

1

Age
28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all

control
mean ± SE
9.48 ± 1.79
16.93 ± 1.46 a
18.30 ± 1.25 a
14.76 ± 1.18 a
15.90 ± 1.60
18.14 ± 2.42
21.90 ± 1.92
18.67 ± 1.21 a

n
8
8
7
23
8
7
8
23

Diet
high calcium
mean ± SE
12.42 ± 0.79
14.72 ± 0.52 ab
14.62 ± 2.30 ab
13.93 ± 0.83 ab
14.07 ± 1.78
17.50 ± 1.89
18.91 ± 3.74
16.64 ± 1.38 ab

28 wk
52 wk
78 wk
all

12.69
17.49
20.22
16.72

16
15
15
46

13.24
16.11
16.47
15.23

±
±
±
±

1.42
1.32 a
1.24 a
0.88 a

±
±
±
±

0.96
1.01 ab
2.07 ab
0.81 ab

n
8
8
8
24
8
8
6
22

NFDM
mean ± SE
9.66 ± 1.09
12.91 ± 1.46 b
13.24 ± 0.84 b
11.88 ± 0.74 b
12.93 ± 0.52
14.85 ± 0.87
16.09 ± 1.86
14.63 ± 0.73 b

n
8
8
7
23
8
8
8
24

16
16
14
46

11.29
13.88
14.76
13.28

16
16
15
47

±
±
±
±

0.72
0.86 b
1.09 b
0.55 b

Values are expressed as mean ± SE. Non-matching superscripts denote significant differences between diet groups, p < 0.05.
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Table 4-3: Percentage of total muscle mass calculated from gastrocnemius and soleus muscle per body weight in aP2-agouti
transgenic and wild-type mice fed control, high calcium or NFDM diets at 28, 52 and 78 weeks of age.11
Diet
high calcium

control
Gender

Genotype

Age

female

wild

28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all

transgenic

male

both
wild

transgenic

both

1

28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all

mean ± SE

n

mean ± SE

NFDM
n

mean ± SE

n

0.33
0.25
0.35
0.31
0.28
0.22
0.18
0.22
0.26
0.29
0.13

±
±
±
±
±
±
±
±
±
±
±

0.05
0.04
0.06
0.03
0.02
0.02
0.02
0.02 a
0.02 a
0.05
0.01 a

4
4
3
11
4
4
5
13
24
4
4

0.40
0.28
0.32
0.33
0.35
0.24
0.27
0.28
0.31
0.28
0.22

±
±
±
±
±
±
±
±
±
±
±

0.04
0.02
0.05
0.02
0.10
0.04
0.08
0.04 ab
0.02 ab
0.05
0.03 b

4
4
4
12
3
4
3
10
22
4
4

0.32
0.41
0.36
0.36
0.38
0.30
0.33
0.34
0.35
0.43
0.25

±
±
±
±
±
±
±
±
±
±
±

0.04
0.09
0.03
0.03
0.05
0.04
0.08
0.33 b
0.02 b
0.06
0.03 b

4
4
3
11
4
4
4
12
23
4
4

0.15
0.19
0.23
0.15
0.19
0.19
0.19

±
±
±
±
±
±
±

0.05 a
0.03 a
0.05
0.02
0.005
0.02
0.02 a

4
12
4
3
3
10
22

0.19
0.23
0.26
0.16
0.29
0.24
0.23

±
±
±
±
±
±
±

0.04 a
0.02 ab
0.02
0.03
0.04
0.02
0.02 ab

4
12
5
4
3
12
24

0.42
0.36
0.23
0.24
0.23
0.24
0.30

±
±
±
±
±
±
±

0.05 b
0.04 b
0.01
0.03
0.08
0.03
0.03 b

4
12
4
4
4
12
24

Values are expressed as mean ± SE. Non-matching superscripts denote significant differences between diet groups, p < 0.05.
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Table 4-3, continued.
Diet

control
Gender

Genotype

Age

both

wild

28 wk
52 wk

transgenic

both

1

78 wk
all
28 wk
52 wk
78 wk
all
28 wk
52 wk
78 wk
all

high calcium
n
8

mean ± SE

0.31
0.19
0.24
0.25
0.25
0.19
0.18
0.20
0.28
0.19
0.20
0.23

±
±
±
±
±
±
±
±
±
±
±
±

0.03
0.03

a
a

0.05
0.024 a
0.02
0.02 a
0.01
0.01 a
0.02
0.02 a
0.02 a
0.01 a

mean ± SE

0.34 ± 0.04

8
7
23
8
7
8
23
16
15
15
46

0.25 ± 0.02

ab

0.25
0.28
0.29
0.20
0.28
0.26
0.32
0.23
0.27
0.27

a

±
±
±
±
±
±
±
±
±
±

0.04
0.02 ab
0.04
0.03 ab
0.04
0.02 ab
0.03
0.02 a
0.03 ab
0.01 ab

NFDM
n
8

0.38

±

0.04

8

0.33

±

0.05 b

±
±
±
±
±
±
±
±
±
±

b

8
24
8
8
6
22
16
16
14
46

n
8

mean ± SE

0.39
0.36
0.31
0.27
0.29
0.29
0.34
0.30
0.34
0.33

0.03
0.02 b
0.04
0.03 b
0.06
0.02 b
0.03
0.03 b
0.04 b
0.02 b

8
7
23
8
8
8
24
16
16
15
47

Values are expressed as mean ± SE. Non-matching superscripts denote significant differences between diet groups, p < 0.05.
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perirenal, subscapular and epididymal (in male mice) fat pads divided by body weight) and the
percentage of muscle tissue (calculated from the sum of soleus and gastrocnemius muscle
divided by body weight), respectively.
4.4.1.1

Males:
Transgenic. The milk diet group showed a lower weight compared to the high calcium

group continuously over the first year and to the control group starting at month 6. Although, no
difference in weight was found between high calcium and control group, there was a significant
reduction in adipose tissue mass (Table 4-2).
Wild-type. The weight in the milk diet was continuously lower compared to the control
and high calcium diet group. This difference was associated with a reduction in adiposity (Table
4-2) and a prevention of muscle loss with age (Table 4-3) which was significantly different from
the control group, but not the high calcium group. Although body weight in the high calcium
group was not significantly different from the control group, there was a significant reduction in
adiposity and a prevention of muscle loss compared to the control group at 78 weeks and 52
weeks of age, respectively.
4.4.1.2

Females:
Transgenic.

The high calcium diet group exhibited the highest weight, and this

difference reached statistical significance in older animals. There was a trend for lower adiposity
and higher percentage of muscle tissue in the milk diet group compared to the control diet group,
however, it did not reach statistical significance.
Wild-type. No difference in weight, fat mass and muscle mass was found among the diet
groups.
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4.4.1.3

Summary:
There was a significant gender–diet interaction reflected in a significant weight

difference in the male mice for both genotypes in the milk diet group compared to control and
high calcium diet group but not in female mice. In addition, the milk diet prevented the increase
in fat mass and the loss in muscle mass with age compared to the control group when genotypes
and genders were combined,

4.4.2 Oxidative stress
ROS production in white adipose tissue (Fig. 4-2). The age-related rise in ROS
production was significantly blunted in the high calcium and milk diet groups compared to the
control group.
GPx gene expression in soleus (Table 4-4). There were no diet interactions found;
therefore data are collapsed for genotype, gender and age. The milk diet group had a
significantly higher level of GPx gene expression than the control and high calcium diet groups.
SOD 3 gene expression in soleus (Table 4-4). There was a significant diet-genotype
interaction. Wild type mice showed increased levels of SOD 3 expression in the milk diet group
while no diet effect was found in the transgenic mice.
SOD 3 gene expression and SOD enzyme activity in liver (Table 4-4 and 4-5). There
were no diet interactions found; therefore only main effects of diet are reported. There was an
overall increase in SOD enzyme activity in liver in the milk diet group compared to high calcium
and control group; however, this was not associated with a significant difference in gene
expression.
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Figure 4-2:
ROS production (expressed as fluorexcence intensity/

g protein) in white adipose tissue

(retroperitoneal and perirenal fat) in aP2-agouti transgenic and wild-type mice (gender and
genotype combined) fed control, high calcium or NFDM diets at 28, 52 and 78 weeks of age.
Values are expressed as mean

SE, (n= 4-5). * Significant different from control, p < 0.05.
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Table 4-4: Glutathione Peroxidase ((GPx), soleus muscle) and Superoxide Dismutase 3 (SOD3) gene expression (soleus muscle
and liver) of aP2-agouti transgenic and wild-type mice fed control, high calcium or NFDM diets, all three age groups combined.1
Diet
control
Gene
expression
GPx
soleus

Genotype

female

wild
transgenic
both
wild
transgenic
both

0.77
0.81
0.79
0.83
0.83
0.83

±
±
±
±
±
±

0.06 a
0.08 a
0.05 a
0.07
0.14
0.07

12
12
24
11
11
22

0.93
0.84
0.89
0.74
0.81
0.77

±
±
±
±
±
±

0.09 ab
0.08 a
0.06 a
0.07
0.10
0.06

12
11
23
12
13
25

1.06
1.20
1.14
1.22
0.82
1.01

±
±
±
±
±
±

0.09 b
0.14 b
0.08 b
0.20
0.11
0.12

12
12
24
12
13
25

wild
transgenic
both
wild
transgenic
both
wild
transgenic
both
wild
transgenic
both

0.80
0.82
0.81
0.73
0.81
0.77
0.96
0.80
0.88
0.84
0.81
0.82

±
±
±
±
±
±
±
±
±
±
±
±

0.05 a
0.08
0.04 a
0.09 a
0.10
0.07 a
0.08
0.07
0.06
0.07 a
0.06
0.05

23
23
46
12
12
24
11
11
22
23
23
46

0.83
0.83
0.83
0.88
0.84
0.86
0.90
0.89
0.90
0.89
0.87
0.88

±
±
±
±
±
±
±
±
±
±
±
±

0.06 a
0.07
0.05 a
0.12 a
0.13
0.09 ab
0.17
0.09
0.10
0.11 ab
0.08
0.07

24
24
48
12
11
23
12
13
25
24
24
48

1.14
1.02
1.07
1.31
0.88
1.09
1.27
0.85
1.06
1.30
0.87
1.07

±
±
±
±
±
±
±
±
±
±
±
±

0.10 b
0.10
0.07 b
0.19 b
0.10
0.12 b
0.26
0.14
0.15
0.16 b
0.09
0.09

24
25
49
12
12
24
12
13
25
24
25
49

both
both
both
female

male

both
both
both

1

mean ± SE

n

mean ± SE

NFDM

Gender

male

SOD3
soleus

high calcium
n

mean ± SE

n

Gene expression data are normalized to 18S expression. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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Table 4-4, continued.1
Diet
high calcium

control
Gene expression
SOD3 liver

Gender
female

male

both
both
both

1

Genotype
wild
transgenic
both
wild
transgenic
both
wild
transgenic
both

mean ± SE
0.48 ± 0.07
0.62 ± 0.11
0.56 ± 0.07
0.48 ± 0.10
0.52 ± 0.13
0.51 ± 0.08
0.49 ± 0.06
0.58 ± 0.09
0.53 ± 0.05

n
12
12
24
11
11
22
23
23
46

mean ± SE
0.79 ± 0.22
0.52 ± 0.13
0.66 ± 0.13
0.50 ± 0.12
0.38 ± 0.06
0.44 ± 0.07
0.65 ± 0.13
0.45 ± 0.07
0.55 ± 0.08

NFDM
n
12
11
23
12
12
24
24
23
47

mean ± SE
0.86 ± 0.27
0.78 ± 0.26
0.83 ± 0.19
0.97 ± 0.52
0.41 ± 0.08
0.67 ± 0.25
0.92 ± 0.28
0.59 ± 0.14
0.75 ± 0.15

n
12
12
24
11
13
24
23
25
48

Gene expression data are normalized to 18S expression. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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Table 4-5: Liver SOD enzyme activity of aP2-agouti transgenic and wild-type mice fed control, high calcium or NFDM diets, all
three age groups combined.1

Diet
control
Enzyme activity
SOD liver

Gender
female

male

1

Genotype

high calcium

mean ± SE

n

wild

0.59

±

0.07

transgenic

0.55

±

both

0.57

wild

ab

mean ± SE

12

0.35

±

0.08

0.16

12

0.65

±

±

0.90

24

0.49

0.54

±

0.16

11

transgenic

0.34

±

0.08

both

0.44

±

0.09

both

wild

0.56

±

0.09

both

transgenic

0.45

±

both

both

0.50

±

ab

NFDM
n

a

mean ± SE

n
b

12

0.83

±

0.17

0.14

11

0.63

±

0.12

12

±

0.08

23

0.73

±

0.10

24

0.48

±

0.10

12

0.76

±

0.18

11

11

0.37

±

0.07

12

0.59

±

0.14

13

22

0.42

±

0.06

24

0.68

±

0.11

23

0.42

±

0.06

0.09

23

0.50

±

0.06 a

46

0.46

±

a

24
b

24

0.79

±

0.12

0.08

23

0.61

±

0.09

25

0.05 a

47

0.70

±

0.07 b

48

Enzyme activity is normalized to protein content. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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12

23

4.4.2.1

Summary:
The age-related rise in ROS production was significantly attenuated by calcium rich

diets. This was associated in the milk diet group with an increase in GPx and SOD3 gene
expression in soleus muscle as well as an increase in liver SOD enzyme activity. We also
examined other markers such as Catalase and NADPH oxidase gene expression and liver
activity, AMPK liver activity, and serum MDA levels; however, no significant differences
among the diet groups were found (data not shown).

4.4.3 Inflammatory Stress
There was a statistically significant diet-gender interaction for adipocytokines (Table 46). Male mice showed lower levels of TNFα and IL6 gene expression in abdominal fat tissue in
the milk diet, consistent with previous data from our laboratory. Levels in females were quite
low compared to males and were unaffected by diet. Cytokines and other markers in serum were
unchanged (data not shown).

4.4.4 Survival
The survival analysis showed a longer lifespan in wild-type compared to transgenic mice
for the milk diet group (Fig. 4-3B). There was no overall diet effect on maximal lifespan (Fig. 43A), although the milk diet significantly reduced the early mortality rate in wild-type mice as
demonstrated by a significant increase in 75% survival rate (Fig. 4-3C).
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Table 4-6: Gene expression of IL6, IL15, TNFα and NFкB in inguinal fat tissue in aP2-agouti transgenic and wild-type mice fed
control, high calcium or NFDM diets, all three diet groups combined.1
Diet
high calcium

control
Gene expression
IL6

Gender
female

Genotype
wild
transgenic
both

mean ± SE
0.21 ± 0.04
0.38 ± 0.08
0.31 ± 0.05

n
8
11
19

mean ± SE
0.40 ± 0.13
0.38 ± 0.08
0.39 ± 0.07

n
8
9
17

mean ± SE
0.42 ± 0.16
0.26 ± 0.32
0.35 ± 0.08

n
9
8
17

male

wild
transgenic
both
wild
transgenic
both

1.45
6.23
3.84
0.83
2.85
1.93

±
±
±
±
±
±

0.86
2.12
1.27 a
0.44
1.09
0.64

8
8
16
16
19
35

2.18
2.87
2.49
1.39
1.56
1.47

±
±
±
±
±
±

0.67
1.15
0.62 a
0.43
0.61
0.36

10
8
18
18
17
35

0.57
0.51
0.53
0.49
0.39
0.44

±
±
±
±
±
±

0.22
0.07
0.48 b
0.13
0.05
0.07

8
9
17
17
17
34

female

wild
transgenic
both

0.33
0.47
0.41

±
±
±

0.06
0.08
0.05

8
11
19

0.69
0.68
0.69

±
±
±

0.30
0.16
0.16

8
9
17

0.24
0.50
0.37

±
±
±

0.04
0.16
0.08

9
9
18

male

wild
transgenic
both

1.49
3.83
2.49

±
±
±

0.47
0.74 a
0.51 a

8
6
14

2.39
2.53
2.46

±
±
±

0.39
0.64 ab
0.35 a

10
9
19

0.73
1.17
0.95

±
±
±

0.13
0.20 b
0.13 b

9
9
18

both
both
both

wild
transgenic
both

0.91
1.65
1.29

±
±
±

0.27 ab
0.47
0.28

16
17
33

1.64
1.60
1.62

±
±
±

0.32 a
0.39
0.25

18
18
36

0.49
0.84
0.66

±
±
±

0.09 b
0.15
0.09

18
18
36

both
both
both
TNFα

1

NFDM

Gene expression data are normalized to 18S expression. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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Table 4-6, continued.
Diet
high calcium

control
Gene
expression
IL15

Gender

Genotype

female

both
both

wild
transgenic
both
wild
transgenic
both
wild
transgenic

0.43
0.84
0.66
0.85
1.18
1.02
0.62
0.98

±
±
±
±
±
±
±
±

0.09
0.19
0.13
0.22 a
0.26
0.18
0.12
0.16

8
11
19
7
8
15
15
19

0.64
0.88
0.77
1.45
1.26
1.36
1.09
1.07

±
±
±
±
±
±
±
±

0.14
0.26
0.15
0.22 b
0.31
0.18
0.16
0.20

8
9
17
10
9
19
18
18

0.69
0.93
0.81
0.61
1.07
0.84
0.65
1.00

±
±
±
±
±
±
±
±

0.18
0.27
0.16
0.09 a
0.21
0.12
0.10
0.17

9
9
18
9
9
18
18
18

both

both

0.82

±

0.11

34

1.08

±

0.13

36

0.83

±

0.10

36

female

wild
transgenic
both

0.84
0.86
0.85

±
±
±

0.25
0.17
0.14

8
11
19

0.85
0.96
0.91

±
±
±

0.20
0.21
0.14

8
9
17

0.72
1.03
0.88

±
±
±

0.17
0.23
0.15

9
9
18

male

wild
transgenic
both

1.27
1.49
1.38

±
±
±

0.38
0.47
0.29

8
7
15

1.58
1.09
1.35

±
±
±

0.22
0.26
0.17

10
9
19

0.83
1.17
1.01

±
±
±

0.16
0.22
0.14

9
9
18

both
both
both

wild
transgenic
both

1.05
1.13
1.09

±
±
±

0.22
0.23
0.16

16
18
34

1.26
1.03
1.14

±
±
±

0.17
0.17
0.12

18
18
36

0.77
1.11
0.94

±
±
±

0.12
0.16
0.10

18
18
36

male

NFкB

1

mean ± SE

n

mean ± SE

NFDM
n

mean ± SE

n

Gene expression data are normalized to 18S expression. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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Figure 4-3:
Survival curves of all aP2-agouti transgenic and wild-type mice fed control, high calcium or
NFDM diets. A: Diet effect on survival independent of gender and genotype.
B: Genotype effect on survival independent of diet. C: Diet effect for each genotype on
survival. * Significant different, p < 0.05.
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4.4.5 Additional findings
Interestingly, we found a reduction of Sirt1 gene expression in abdominal fat (at 78
weeks) and in soleus muscle (Table 4-7). Also liver PPARα gene expression was reduced in the
milk diet compared to the control group (Table 4-7).

4.5

Discussion
Our data demonstrate that age-related changes in body composition were blunted by

calcium-rich diets. This is consistent with our previous short-term findings, which show that
calcium rich diets contribute to a reduction in body fat mass in both humans and mice under
eucaloric and hypocaloric conditions (15, 29-31). We have also noted that dairy foods exert
significantly greater effects than supplemental sources of calcium, and have attributed this
observation to other bioactive components in dairy products, such as branched-chain amino acids
(BCAA) and angiotensin-converting enzyme inhibitor (ACEi) peptides (32). Leucine is well
recognized to stimulate muscle protein synthesis, and leucine supplementation decreases agerelated loss in muscle mass in both rodents and humans (33-35). Our previous data also indicate
that leucine alters energy partitioning between adipose tissue and muscle by augmenting lipolysis
in adipose tissue and stimulating fatty acid oxidation in muscle to supply the energy demand of
the anabolic process of protein synthesis (22). Consistent with these observations, data from this
study show a greater effect of the milk diet than of the high calcium diet in preventing the agerelated increase in adiposity and the age-related loss of muscle mass.
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Table 4-7: Sirt1 (inguinal fat and soleus muscle) and PPARα (liver) gene expression in aP2-agouti transgenic and wild-type mice
fed a control, high calcium or NFDM diet.1
Diet
high calcium

control
Gene expression
Sirt1
abdominal fat

Gender
female

male

both

Sirt1
soleus

both
female

male

both

both

1

Genotype
wild
transgenic
both
wild
transgenic
both
wild
transgenic
both

both
wild
transgenic
both
wild
transgenic
both
wild
transgenic
both

both

Age
all
all
all
all
all
all
all
all
28 wk
52 wk
78 wk
all
all
all
all
all
all
all
all
all
28 wk
52 wk
78 wk
all

mean ± SE
0.88 ± 0.28
0.12 ± 0.22
1.02 ± 0.17
1.17 ± 0.38 a
1.28 ± 0.24
1.23 ± 0.22
1.03 ± 0.23 ab
1.19 ± 0.16
0.53 ± 0.10
0.87 ± 0.12 ab
2.02 ± 0.19 a
1.12 ± 0.13
0.86 ± 0.12
1.07 ± 0.08 a
0.97 ± 0.08
0.96 ± 0.07
0.98 ± 0.11
0.97 ± 0.04 ab
0.91 ± 0.07
1.03 ± 0.05 a
0.79 ± 0.05
1.04 ± 0.09 ab
1.07 ± 0.06
0.97 ± 0.04 a

n
8
11
19
8
8
16
16
19
12
12
11
35
11
11
22
10
11
21
22
21
14
15
14
43

mean ± SE
0.97 ± 0.17
1.28 ± 0.25
1.13 ± 0.15
1.43 ± 0.16 b
1.02 ± 0.25
1.24 ± 0.15
1.23 ± 0.13 b
1.15 ± 0.17
0.66 ± 0.13
1.09 ± 0.12 b
1.81 ± 0.11 a
1.18 ± 0.11
1.02 ± 0.11
0.86 ± 0.08 ab
0.94 ± 0.07
1.13 ± 0.10
1.01 ± 0.10
1.07 ± 0.07 b
1.07 ± 0.07
0.94 ± 0.06 ab
0.76 ± 0.05
1.20 ± 0.10 b
1.07 ± 0.07
1.00 ± 0.05 a

NFDM
n
8
9
17
10
9
19
18
18
12
12
12
36
11
11
22
11
11
22
22
22
15
13
16
44

mean ± SE
0.82 ± 0.16
0.91 ± 0.21
0.86 ± 0.13
0.77 ± 0.12 a
1.10 ± 0.22
0.94 ± 0.13
0.79 ± 0.09 a
1.00 ± 0.15
0.69 ± 0.16
0.56 ± 0.08 a
1.43 ± 0.08 b
0.90 ± 0.09
0.78 ± 0.08
0.82 ± 0.08 b
0.80 ± 0.06
0.98 ± 0.13
0.78 ± 0.08
0.88 ± 0.08 a
0.88 ± 0.08
0.80 ± 0.05 b
0.69 ± 0.06
0.88 ± 0.07 a
0.93 ± 0.10
0.84 ± 0.05 b

n
8
9
17
9
9
18
17
18
11
12
12
35
12
12
24
11
12
23
23
24
15
16
16
47

Gene expression data are normalized to 18S expression. Values are expressed as mean ± SE. Non-matching superscripts denote

significant differences between diet groups, p < 0.05.
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Table 4-7, continued.
Diet
high calcium

control
Gene expression
PPARα
liver

1

Gender
female

Genotype
wild
transgenic
both

Age
all
all
all

mean ± SE
0.62 ± 0.11
0.83 ± 0.14 a
0.73 ± 0.09

n
12
12
24

0.65
0.79
0.72

male

wild
transgenic
both

both

wild
transgenic
both

both

both

mean ± SE
± 0.13
± 0.14 a
± 0.10

all
all
all

0.86
0.86
0.86

±
±
±

0.18
0.18
0.12 a

11
11
22

0.40
0.57
0.49

±
±
±

all
all
28 wk
52 wk
78 wk
all

0.74
0.84
0.88
0.47
1.04
0.79

±
±
±
±
±
±

0.10
0.11 a
0.10 a
0.06
0.17 a
0.08 a

23
23
15
16
15
46

0.53
0.68
0.57
0.55
0.70
0.61

±
±
±
±
±
±

NFDM
n
12
11
23

mean ± SE
0.70 ± 0.10
0.42 ± 0.07 b
0.56 ± 0.07

n
12
12
24

0.08
0.11
0.07 b

11
12
23

0.41
0.56
0.49

± 0.08
± 0.07
± 0.05 b

11
13
24

0.08
0.09 ab
0.09 b
0.11
0.12 ab
0.06 ab

23
23
16
15
15
46

0.56
0.49
0.56
0.45
0.56
0.53

±
±
±
±
±
±

23
25
17
15
16
48

0.07
0.05 b
0.08 b
0.07
0.07 b
0.04 b

Gene expression data are normalized to 18S expression, enzyme activity to protein content. Values are expressed as mean ± SE.

Non-matching superscripts denote significant differences between diet groups, p < 0.05.
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The free radical theory of aging, originally proposed by Harman (36), postulates that the
aging process is caused by accumulation of free radicals over time, resulting in oxidative damage
and progressive deterioration of biological systems. Since mitochondria are the major production
site of free radicals, this theory was extended to the mitochondrial theory of aging (37), which
proposes that cumulative oxidative damage to mtDNA leads to a decline in bioenergetic function
of mitochondria with a progressive decline of cellular and tissue functions. Other major sources
of oxidative stress are ROS generating enzymes such as calcium-dependent NADPH oxidase
which plays a crucial role in developing vascular diseases (38). Furthermore, there is
bidirectional interaction between intracellular calcium signaling and ROS with calcium
activating ROS production by cellular enzymes and mitochondria, and ROS increasing
intracellular calcium levels by activating calcium channels on plasma membrane and
endoplasmatic reticulum (39, 40). Accordingly, our previous data demonstrate that decreasing
intracellular [Ca]2+ by dietary calcium can diminish ROS production. We have shown that
suppression of calcitriol results in an inhibition of cellular NADPH oxidase gene expression (6),
and in an increase in UCP production which diminishes mitochondrial membrane potential,
thereby resulting in decreased ROS production (41). In addition, dairy products further enhances
this anti-oxidant effect (23), most likely mediated by the inhibition of the local adipocyte reninangiotensin-system (RAS) by ACEi peptides in dairy products (42-44). Data from this long-term
study also demonstrate that dietary calcium significantly reduced the age-related rise in ROS,
and that dairy exerted a greater effect than calcium carbonate. However, in contrast with our
previous data, this reduction was not found in younger mice (28 weeks old) and was not
associated with alterations of NADPH oxidase and UCP expression. Instead, we found an
increase in antioxidant enzyme activity and associated gene expression in the milk diet. Since
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aging is associated with a decline in anti-oxidant enzyme activity (14, 45), our observation that
dairy components appear to attenuate this decline is likely to play a role in reducing ROS
formation with aging.
Oxidative stress can cause a dysregulation of adipocytokines (2, 46), and data from this
study indicate that this effect is attenuated by high calcium diets, as demonstrated by decreases in
adipose tissue TNFα and IL6 expression. Consistent with this, we previously demonstrated that
calcitriol can stimulate inflammatory cytokine expression in human and murine adipocytes (20)
and that suppression of calcitriol by high calcium diets attenuates the inflammatory response in
shorter-term studies (23). An additional reduction is seen with dairy products; this is most likely
mediated by ACEi peptides (47).
There was a significant gender-diet interaction for body weight and abdominal
adipocytokine production. The milk diet significantly reduced body weight gain over the first
year and reduced expression of TNFα and IL6 in visceral abdominal fat in male mice, while
these effects were not found in females. Multiple studies have shown that sex hormones are
responsible for gender specific differences in fat distribution and adipose metabolism (48, 49).
Premenopausal females tend to accumulate fat in non visceral areas such as hip and thighs while
men develop visceral adiposity with a higher risk for metabolic disorders, as visceral fat is the
major production site of adipocytokines (50-52). Moreover, estrogens can cause an antiinflammatory effect with inhibition of TNFα and IL6 in macrophages (53, 54). We have
demonstrated that the response of visceral fat to dietary calcium is higher than that of
subcutaneous fat (20). In support of these concepts, the male mice showed markedly higher
levels of adipocytokines compared to females.
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Since oxidative and inflammatory stress is a major contributor to aging, we hypothesized
that a reduction of both by dietary calcium could influence the lifespan in mice. In support of this
hypothesis, studies in short-lived animals such as nematodes and flies have shown that a
reduction in oxidative stress increased the lifespan (55-57). In addition, the senescence
accelerated mouse (SAM) model is associated with many characteristic features of mammalian
aging, increased oxidative stress and a shortened lifespan (58), and administration of a free
radical scavenger prolonged the lifespan in this model (59). On the other hand, modifying the
antioxidant defense system resulted in contradicting findings in some models of aging. While
over-expression of catalase in mice extended the life span (60, 61), a reduction in SOD activity
increased oxidative stress and cancer incidence but did not accelerate aging in mice (62).
Although the age-related increase of oxidative stress was reduced by the milk diet in our animals,
we did not find any overall diet effect on mean and maximal survival; however, the milk diet
decreased the early mortality in wild-type mice, as demonstrated by a significant increase in 75%
survival rate. At this point, it is not clear why this effect is seen only in the wild-type mice. Since
the agouti transgene is only locally expressed in adipose tissue, no systemic alterations were
expected. However, the survival analysis revealed a shorter survival rate of the transgenic mice
compared to the wild-type mice in the milk diet group. Therefore, it is possible that this overall
genotype effect could have overwhelmed any possible diet interaction.
Interestingly, we found a decrease of sirtuin 1 (Sirt1) gene expression in abdominal
adipose tissue and soleus muscle as well as a reduction of peroxisome proliferation activating
receptor (PPAR) α gene expression in liver in the milk diet group. The sirtuins belong to a
conserved family of deacetylases and have been linked to prevention of mitochondrial
dysfunction, aging and metabolic disease (63, 64). In addition, the NAD+-dependent histone
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deacetylase Sirt1 regulates energy metabolism such as glucose homeostasis and fat metabolism
(65). PPAR α, a ligand-activated transcription factor and mainly expressed in muscle and liver, is
also involved in lipid metabolism and inflammation (66). At this point, it is not clear how to
interpret these findings. We speculate that the overall reduction in adiposity, oxidative and
inflammatory stress by the milk diet acts as a negative feedback loop and counteracts Sirt1 and
PPAR α up-regulation.
In conclusion, data from the present study demonstrate that milk diet attenuates adiposity
under eucaloric conditions and protects against age-related muscle loss. Consistent with previous
findings, we show that dietary calcium reduces oxidative and inflammatory stress. Although
these effects did not to influence the maximum lifespan, they did suppress early mortality.
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The hypothesis that increased oxidative and inflammatory stress contributes to the
process of aging, leading to the development of chronic diseases and to reduced life span and
quality of life is well accepted. Obesity is associated with increased ROS production and
systemic low-grade inflammation, and is consequently one of the major risk factor for the
development of metabolic diseases. Dietary calcium and dairy products have been shown to exert
anti-obesity effects and to reduce ROS and inflammatory cytokine production in mice and
humans. The present studies support this concept. We have demonstrated greater weight and fat
loss as well as prevention of age-related changes in adiposity and lean tissue mass for high
calcium diets under hypocaloric and eucaloric conditions, respectively. In addition, both studies
indicated a role of dietary calcium in reducing oxidative and inflammatory stress. Further, we
have elucidated the common and distinct pathways of calcium and other dairy components
explaining at least in part the greater efficacy of dairy products on these effects. Although overall
these effects were not able to extend absolute lifespan, they did reduce early mortality.
In conclusion, these data demonstrate that dietary calcium, particularly in form of dairy
products, is an effective strategy to reduce adiposity, oxidative and inflammatory stress. These
effects attenuated age-related changes in body composition and are predicted to maintain
physical strength with age, and to reduce morbidity risk. Eventually this may lead to a
„successful aging process‟ and to a reduction of the early mortality risk.
The finding that Sirt1 gene expression was up-regulated by the milk diet group in the
lifespan study was unexpected since sirtuins are linked to longevity, and invites further
investigations, especially regarding a possible interaction between situins and oxidative stress.
Further, the observed up-regulation of the tumor suppressor gene p53 by dairy components
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presents new questions about its possible role in lipid metabolism and may provide a link
between obesity and carcinogenesis.
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Table A1: Genes from Ca-depleted diet group involved in MAPK and TGF-beta signaling pathway in adipose tissue (step-up
FDR corrected p≤ 0.05).
Mean log base 2 value
BR
Ca-depl.

Ca-depleted vs BR (adipose tissue)

Fold change
(BR/Ca-depl.)

MAPK signaling pathway (genes)
1449901_A_AT
1445786_AT
1446390_AT
1441521_AT
1422250_AT
1427739_A_AT
1422078_AT
1449545_AT
1450096_AT
1452525_A_AT
1448558_A_AT
1421297_A_AT
1443115_AT
1439828_AT
1435196_AT
1450698_AT
1418786_AT

mitogen-activated protein kinase kinase kinase 6
braf transforming gene
elk1, member of ets oncogene family
calcium channel, voltage-dependent, beta 2 subunit
mitogen activated protein kinase kinase kinase 2
transformation related protein 53
thymoma viral proto-oncogene 3
fibroblast growth factor 18
guanine nucleotide binding protein, alpha 12
neurofibromatosis 1
phospholipase a2, group iva (cytosolic, calcium-dependent)
calcium channel, voltage-dependent, l type, alpha 1c subunit
transforming growth factor, beta receptor ii
map kinase-activated protein kinase 5
neurotrophic tyrosine kinase, receptor, type 2
dual specificity phosphatase 2
mitogen-activated protein kinase 8 interacting protein 2

9.16606
6.38478
0.459504
3.42586
4.94582
6.87725
6.59676
5.25803
3.85947
5.25062
9.84588
6.39772
5.06088
6.54279
8.51684
7.42911
4.02391

8.72352
7.08513
2.6056
2.48783
5.86342
7.76916
7.20295
3.47341
6.13253
6.41262
9.55461
5.40047
5.96757
7.18772
7.93628
6.94081
6.08048

1.359
-1.62491
-4.42628
1.9159
-1.88897
-1.85564
-1.52224
3.44527
-4.8335
-2.23768
1.22372
1.99619
-1.87474
-1.56366
1.49543
1.40279
-4.15994

1421376_AT

tnf receptor-associated factor 6

6.72878

7.61592

-1.84951

7.16588

8.16064

-1.99275

11.2233
10.1422
9.48114
3.01589
4.97692

10.7157
9.52584
9.2165
3.73843
6.02046

1.42162
1.53299
1.20134
-1.65008
-2.06128

1456720_AT
1427162_A_AT
1415974_AT
1417542_AT
1427582_AT
1426108_S_AT

protein phosphatase 3, regulatory subunit b, alpha isoform
(calcineurin b, type i)
elk4, member of ets oncogene family
mitogen activated protein kinase kinase 2
ribosomal protein s6 kinase, related sequence 1
fibroblast growth factor 6
calcium channel, voltage-dependent, beta 1 subunit
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Table A1, continued.
Mean log base 2 value
BR

Ca-depl.

Fold change
(BR/Ca-depl.)

5.03057
1.37588
3.00307
7.80812
3.79031
3.13064
6.60535

6.62853
3.36466
1.89113
8.39522
5.92261
3.85915
7.2731

-3.02715
-3.96901
2.16137
-1.50222
-4.38417
-1.65692
-1.58859

transforming growth factor, beta receptor ii
activin receptor iib
protein phosphatase 2 (formerly 2a), catalytic subunit, beta
isoform
mad homolog 7 (drosophila)

5.06088
5.15205

5.96757
7.29856

-1.87474
-4.42757

5.33567

6.41794

-2.11737

7.21287

7.52469

-1.24127

inhibitor of dna binding 4
protein phosphatase 2 (formerly 2a), regulatory subunit a (pr 65),
alpha isoform
nodal
protein phosphatase 2, regulatory subunit b, delta isoform
mad homolog 5 (drosophila)
bone morphogenetic protein 6
inhibitor of dna binding 2
latent transforming growth factor beta binding protein 1
trans-acting transcription factor 1
bone morphogenic protein receptor, type ii (serine/threonine
kinase)

9.06812

8.28231

1.72406

13.5936

13.3733

1.16499

6.22734
10.9998
9.85841
8.51295
6.31961
2.8265
11.3672

6.71284
10.8097
9.46701
7.51469
7.22302
4.66182
10.9986

-1.40007
1.14087
1.31166
1.99759
-1.87048
-3.56851
1.29114

12.3331

11.9679

1.28804

Ca-depleted vs BR (adipose tissue)
MAPK signaling pathway (genes)
1447823_X_AT
1451882_A_AT
1459029_AT
1422999_AT
1440442_AT
1420596_AT
1449955_AT

mitogen-activated protein kinase 12
fibroblast growth factor 8
p21 (cdkn1a)-activated kinase 1
mitogen-activated protein kinase kinase kinase 14
mitogen activated protein kinase kinase 7
calcium channel, voltage-dependent, gamma subunit 2
calcium channel, voltage-dependent, alpha 1f subunit

TGF beta signaling pathway (genes)
1443115_AT
1439856_AT
1421822_AT
1440952_AT
1423259_AT
1438991_X_AT,
1455929_X_AT
1422058_AT
1420033_S_AT
1433641_AT
1450759_AT
1453596_AT
1419786_AT
1454852_AT
1434310_AT
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Table A2: Genes from lowCa/BCAA/ACEi diet group compared to the low calcium basal restricted diet group (BR) involved in
MAPK and JAK-STAT signaling pathway in adipose tissue (step-up FDR corrected p≤ 0.05).
Mean log base 2 value
LowCa/
BR
BCAA/ACEi

Low Ca/BCAA/ACEi vs BR (adipse tissue)

Fold Change
(BR/LowCa/
BCAA/ACEi)

MAPK signaling pathway (genes)
1449901_A_AT
1427739_A_AT
1422078_AT
1425902_A_AT
1450975_AT
1450096_AT
1440343_AT
1435747_AT
1443630_AT
1453171_S_AT
1443115_AT
1460296_A_AT
1438325_AT
1454313_AT,
1457563_AT
1425330_A_AT
1447667_X_AT
1418943_AT
1449073_AT
1426165_A_AT
1427162_A_AT
1438031_AT
1427582_AT
1449283_A_AT
1442949_AT
1422999_AT
1451927_A_AT

mitogen-activated protein kinase kinase kinase 6
transformation related protein 53
thymoma viral proto-oncogene 3
nuclear factor of kappa light polypeptide gene enhancer in b-cells 2,
p49/p100
calcium channel, voltage-dependent, gamma subunit 4
guanine nucleotide binding protein, alpha 12
ribosomal protein s6 kinase, polypeptide 5
fibroblast growth factor 14
protein phosphatase 3, catalytic subunit, alpha isoform
protein phosphatase 1a, magnesium dependent, alpha isoform
transforming growth factor, beta receptor ii
fibroblast growth factor 22
ecotropic viral integration site 1

9.16606
6.87725
6.59676

8.30664
7.74499
7.33573

1.81431
-1.82481
-1.66899

7.35802

8.40014

-2.05925

5.4792
3.85947
7.94383
2.56013
6.41964
11.0325
5.06088
7.13396
8.80928

3.83728
6.18042
7.28855
0.714246
5.65832
10.6321
5.79602
4.58583
8.02728

3.12081
-4.99663
1.57492
3.59472
1.69505
1.31984
-1.66457
5.84875
1.71951

epidermal growth factor receptor

7.08212

6.31746

1.69897

protein phosphatase 1b, magnesium dependent, beta isoform
mitogen activated protein kinase kinase kinase 4
riken cdna b230120h23 gene
filamin c, gamma (actin binding protein 280)
caspase 3
elk4, member of ets oncogene family
ras, guanyl releasing protein 3
fibroblast growth factor 6
mitogen-activated protein kinase 12
nuclear factor of kappa light chain gene enhancer in b-cells 1, p105
mitogen-activated protein kinase kinase kinase 14
mitogen activated protein kinase 14

8.20206
8.0985
7.0025
5.4219
6.21513
11.2233
6.84792
3.01589
9.00084
2.47938
7.80812
5.27681

8.70774
7.67661
7.61462
7.48902
7.01698
10.8152
4.57383
5.61369
8.27147
4.20891
8.24107
7.39961

-1.41979
1.33967
-1.5285
-4.19049
-1.74334
1.32692
4.83693
-6.05361
1.65792
-3.31622
-1.34999
-4.35537
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Table A2, continued.
Mean log base 2 value
LowCa/
BR
BCAA/ACEi

Low Ca/BCAA/ACEi vs BR (adipse tissue)

Fold Change
(BR/LowCa/
BCAA/ACEi)

JAK-STAT signaling pathway (genes):
1416977_AT

signal transducing adaptor molecule (sh3 domain and itam motif) 2

6.92884

7.45337

-1.43847

1450564_X_AT

interferon alpha family, gene 1

4.42874

6.4487

-4.05571

1450565_AT

interleukin 9

4.56361

5.86908

-2.47165

1450033_A_AT

signal transducer and activator of transcription 1

8.81717

9.12516

-1.23799

1442890_AT

suppressor of cytokine signaling 5

7.31111

5.61024

3.25096

1426587_A_AT

signal transducer and activator of transcription 3

10.6534

11.3806

-1.65536

1415874_AT

sprouty homolog 1 (drosophila)

10.0444

9.41377

1.54826

1449026_AT

interferon (alpha and beta) receptor 1

9.33899

9.76613

-1.34456

1448681_AT

interleukin 15 receptor, alpha chain

9.80652

8.85758

1.93045

1425750_A_AT

janus kinase 3

7.15899

7.96689

-1.75067

1422078_AT

thymoma viral proto-oncogene 3

6.59676

7.33573

-1.66899

1450297_AT

interleukin 6

2.73611

5.31157

-5.96061

1438492_AT

suppressor of cytokine signaling 7

6.73446

4.60217

4.38414

1440867_AT
1437808_X_AT,
1456173_AT
1450207_AT
1427165_AT,
1451775_S_AT
1433804_AT

sprouty homolog 4 (drosophila)

7.8384

7.06622

1.70785

interleukin 10 receptor, alpha

6.83032

6.08398

1.67754

leukemia inhibitory factor receptor

6.59455

6.13913

1.37118

interleukin 13 receptor, alpha 1

7.8582

8.42551

-1.48177

janus kinase 1

7.18736

8.07229

-1.84667
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Table A3: List of genes in insulin signaling pathway altered in all three diet groups compared to low calcium basal restricted diet
group (BR) in muscle (step-up FDR corrected p≤ 0.05).

Genes involved in Insulin signaling pathway (muscle)

Mean log base 2 value
LowCa/
BR
BCAA/ACEi

Fold change
(BR/LowCa/
BCAA/ACEi)

LowCa-BCAA-ACEi vs BR
1423828_AT
1447635_AT
1453069_AT
1421146_AT
1445693_AT
1453281_AT
1439989_AT
1446185_AT
1439931_AT
1419568_AT
1421275_S_AT
1457562_AT
1460336_AT
1433694_AT
1443436_AT
1442044_AT
1444831_AT
1425514_AT
1442147_AT
1426710_AT
1430634_A_AT
1420841_AT

fatty acid synthase
protein kinase, camp dependent regulatory, type i, alpha
phosphatidylinositol 3-kinase, catalytic, beta polypeptide
rap guanine nucleotide exchange factor (gef) 1
v-raf murine sarcoma 3611 viral oncogene homolog
phosphatidylinositol 3-kinase catalytic delta polypeptide
tuberous sclerosis 1
fk506 binding protein 12-rapamycin associated protein 1
glycogen synthase kinase 3 beta
mitogen activated protein kinase 1
suppressor of cytokine signaling 4
ribosomal protein s6 kinase, polypeptide 1
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha
phosphodiesterase 3b, cgmp-inhibited
mitogen activated protein kinase kinase 2
ribosomal protein s6
thymoma viral proto-oncogene 3
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85
alpha)
riken cdna 6330505c01 gene
calmodulin 1
phosphofructokinase, platelet
protein tyrosine phosphatase, receptor type, f
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10.7655
7.69327
5.1568
8.44919
5.10713
8.76758
6.65765
7.97048
5.43039
9.26914
5.9779
4.27528
9.83756
9.73867
8.17892
6.70554
7.79715

11.9248
5.1575
7.60749
7.14477
7.12827
8.13474
3.65317
6.33475
7.50061
8.58738
3.19968
7.28731
8.90874
10.239
6.25341
4.72864
5.0313

-2.23346
5.79889
-5.46678
2.46985
-4.05902
1.55061
8.02488
3.10744
-4.19949
1.6041
6.86003
-8.06699
1.90372
-1.41449
3.79869
3.93645
6.80146

7.83016

8.52621

-1.62007

6.11827
10.8448
6.09196
5.55126

3.40306
10.3555
4.23833
7.51591

6.56692
1.40374
3.6141
-3.90318

Table A3, continued.

Genes involved in Insulin signaling pathway (muscle)

Mean log base 2 value
BR

Ca-depl.

Fold change
(BR/Ca-depl.)

Ca-depleted vs BR
1423828_AT

fatty acid synthase

10.7655

12.0453

-2.42808

1422108_AT

protein phosphatase 1, regulatory (inhibitor) subunit 3a

8.08744

6.73376

2.55563

1440856_AT

mitogen activated protein kinase 8

9.71473

9.39732

1.24609

1437539_AT

protein kinase, amp-activated, alpha 1 catalytic subunit

7.65128

7.17523

1.39093

1427006_AT

rap guanine nucleotide exchange factor (gef) 1

10.3813

10.8088

-1.34494

1447940_A_AT

braf transforming gene

5.49872

7.37856

-3.68034

1421897_AT

elk1, member of ets oncogene family

6.99614

4.30068

6.47763

1453281_AT
1422043_AT,
1455252_AT
1439931_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

8.76758

8.02663

1.67127

tuberous sclerosis 1

10.1581

10.7441

-1.50108

glycogen synthase kinase 3 beta

5.43039

7.55043

-4.34706

1417308_AT

pyruvate kinase, muscle

14.5938

14.8747

-1.21493

1424132_AT
1433504_AT,
1445397_AT
1443436_AT

harvey rat sarcoma virus oncogene 1

10.0517

9.80534

1.18617

brain glycogen phosphorylase

4.7391

6.60962

-3.65665

mitogen activated protein kinase kinase 2

8.17892

7.61227

1.48107

1444831_AT

thymoma viral proto-oncogene 3

7.79715

5.37593

5.35622

1433691_AT

protein phosphatase 1, regulatory (inhibitor) subunit 3c

15.0011

15.4731

-1.38706

1422414_A_AT

calmodulin 1

12.8256

12.4328

1.3129

1416069_AT

phosphofructokinase, platelet

8.78388

7.85036

1.90993

1429434_AT

phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

8.38313

7.65034

1.66186
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Table A3, continued.

Genes involved in Insulin signaling pathway (muscle)

Mean log base 2 value

Fold change
(BR/NFDM)

BR

NFDM

fatty acid synthase
v-crk sarcoma virus ct10 oncogene homolog (avian)-like
suppressor of cytokine signaling 2
flotillin 2
phosphorylase kinase gamma 1
protein kinase, amp-activated, alpha 2 catalytic subunit
protein kinase, amp-activated, gamma 1 non-catalytic subunit

10.7655
3.64653
5.91189
9.94438
12.1868
12.4988
4.46506

11.6807
6.37529
7.71666
10.3156
12.3306
12.7497
3.1242

-1.88581
-6.62884
-3.49372
-1.29343
-1.10479
-1.18995
2.53302

glycogen synthase kinase 3 beta

5.43039

7.41032

-3.94473

insulin receptor substrate 1
pyruvate kinase, muscle
protein kinase, amp-activated, gamma 3 non-catatlytic subunit

11.0837
4.6179
13.0262

10.4648
6.86393
13.3445

1.53565
-4.74378
-1.2468

thymoma viral proto-oncogene 2

10.2967

10.7973

-1.41483

adaptor protein with pleckstrin homology and src
mitogen activated protein kinase kinase 2
harvey rat sarcoma virus oncogene 1
brain glycogen phosphorylase

4.16515
10.7307
11.166
8.12467

7.2041
11.2635
11.5517
8.91569

-8.21891
-1.44672
-1.3065
-1.7303

thymoma viral proto-oncogene 1

8.0511

5.99692

4.1531

riken cdna 6330505c01 gene
putative phosphatase
v-ki-ras2 kirsten rat sarcoma viral oncogene homolog

8.35457
9.95815
9.09361

8.87864
10.3197
9.82235

-1.43801
-1.28478
-1.65718

calmodulin 1

4.07028

6.04404

-3.9279

NFDM vs BR
1423828_AT
1425604_AT
1441476_AT
1438164_X_AT
1422315_X_AT
1429463_AT
1457803_AT
1439931_AT,
1454958_AT
1423104_AT
1443186_AT
1444480_AT
1421324_A_AT,
1424480_S_AT
1450718_AT
1415974_AT
1422407_S_AT
1433504_AT
1425711_A_AT,
1440950_AT
1434518_AT
1416195_AT
1454060_A_AT
1417365_A_AT,
1438825_AT,
1455571_X_AT
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Table A4: List of genes in VEGF signaling pathway altered in all three diet groups compared to low calcium basal restricted diet
group (BR) in muscle (step-up FDR corrected p≤ 0.05).
Mean log base 2 value

Genes involved in VEGF signaling pathway (muscle)

BR

LowCa/
BCAA/ACEi

Fold change
(BR/lowCa/
BCAA/ACEi)

LowCa/BCAA/ACEi vs. BR
1453069_AT

phosphatidylinositol 3-kinase, catalytic, beta polypeptide

5.1568

7.60749

-5.46678

1426401_AT

protein phosphatase 3, catalytic subunit, alpha isoform

11.9474

12.2035

-1.19423

1452026_A_AT

phospholipase a2, group xiia

9.52965

8.52051

2.01272

1440208_AT

ras-related c3 botulinum substrate 2

7.60771

6.65931

1.92974

1451596_A_AT

sphingosine kinase 1

3.97605

6.87431

-7.45528

1453281_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

8.76758

8.13474

1.55061

1417814_AT

phospholipase a2, group v

5.38723

3.78561

3.03485

1419568_AT

mitogen activated protein kinase 1

9.26914

8.58738

1.6041

1440426_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 2

7.88457

5.63267

4.7631

1443436_AT

mitogen activated protein kinase kinase 2

8.17892

6.25341

3.79869

1444831_AT

thymoma viral proto-oncogene 3

7.79715

5.0313

6.80146

1425514_AT

phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1
(p85 alpha)

7.83016

8.52621

-1.62007

1431278_S_AT

phospholipase a2, group vi

4.40704

7.42211

-8.08403

1426104_AT

mitogen activated protein kinase 14

6.80826

3.16278

12.5141

1423380_S_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 4

6.74705

8.45292

-3.26224
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Table A4, continued.
Mean log base 2 value

Genes involved in VEGF signaling pathway (muscle)

BR

Ca-depl.

Fold change
(BR/Ca-depl.)

Ca-depleted vs. BR
1423478_AT,
1460419_A_AT

protein kinase c, beta 1

4.34773

6.29499

-3.85641

1440208_AT

ras-related c3 botulinum substrate 2

7.60771

5.$10076

5.68418

1451596_A_AT

sphingosine kinase 1

3.97605

6.35566

-5.20395

1453281_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

8.76758

8.02663

1.67127

1417814_AT

phospholipase a2, group v

5.38723

4.0432

2.53859

1453914_AT

heat shock protein 1

3.49707

6.45746

-7.78334

1418987_AT

phospholipase a2, group iid

8.08689

7.09444

1.98955

1443436_AT

mitogen activated protein kinase kinase 2

8.17892

7.61227

1.48107

1424132_AT

harvey rat sarcoma virus oncogene 1

10.0517

9.80534

1.18617

1444831_AT

thymoma viral proto-oncogene 3

7.79715

5.37593

5.35622

1416703_AT

mitogen activated protein kinase 14

11.4772

11.7312

-1.19245

1429434_AT

phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

8.38313

7.65034

1.66186

1438999_A_AT

nuclear factor of activated t-cells 5

8.75395

7.71459

2.05531
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Table A4, continued.
Mean log base 2 value

Genes involved in VEGF signaling pathway (muscle)

BR

NFDM

Fold change
(BR/NFDM)

NFDM vs. BR
1448558_A_AT

phospholipase a2, group iva (cytosolic, calcium-dependent)

8.24018

7.28951

1.93277

1440208_AT

ras-related c3 botulinum substrate 2

7.60771

5.70503

3.73907

1447084_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 1

7.30594

6.09695

2.31175

1453914_AT

heat shock protein 1

3.49707

6.92506

-10.7629

1425990_A_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 2

6.7824

7.4935

-1.63705

1421324_A_AT,
1424480_S_AT

thymoma viral proto-oncogene 2

10.2967

10.7973

-1.41483

1426085_A_AT

paxillin

6.01678

8.32559

-4.95475

1425711_A_AT,
1440950_AT

thymoma viral proto-oncogene 1

8.0511

5.99692

4.1531

1415974_AT

mitogen activated protein kinase kinase 2

10.7307

11.2635

-1.44672

1422407_S_AT

harvey rat sarcoma virus oncogene 1

11.166

11.5517

-1.3065

1431278_S_AT

phospholipase a2, group vi

4.40704

6.91574

-5.69107

1454060_A_AT

v-ki-ras2 kirsten rat sarcoma viral oncogene homolog

9.09361

9.82235

-1.65718

1420743_A_AT

protein phosphatase 3, catalytic subunit, gamma isoform

9.42015

10.0058

-1.50076

1416703_AT

mitogen activated protein kinase 14

11.4772

11.7035

-1.1698

1432821_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 4

3.61167

5.19948

-3.00593

218

Table A5: List of genes in B-cell receptor signaling pathway altered in all three diet groups compared to low calcium basal
restricted diet group (BR) in muscle (step-up FDR corrected p≤ 0.05).
Mean log base 2 value

Genes involved in B cell receptor signaling pathway (muscle)

BR

LowCa/
BCAA/ACEi

Fold change
(BR/LowCa/
BCAA/ACEi)

LowCa/BCAA/ACEi vs. BR
1456694_X_AT

protein tyrosine phosphatase, non-receptor type 6

9.7332

8.98414

1.6807

1453069_AT

phosphatidylinositol 3-kinase, catalytic, beta polypeptide

5.1568

7.60749

-5.46678

1426401_AT

protein phosphatase 3, catalytic subunit, alpha isoform

11.9474

12.2035

-1.19423

1440208_AT

ras-related c3 botulinum substrate 2

7.60771

6.65931

1.92974

1425902_A_AT

nuclear factor of kappa light polypeptide gene enhancer in
b-cells 2, p49/p100

5.56488

7.14272

-2.98522

1444831_AT

thymoma viral proto-oncogene 3

7.79715

5.0313

6.80146

1425514_AT

phosphatidylinositol 3-kinase, regulatory subunit,
polypeptide 1 (p85 alpha)

7.83016

8.52621

-1.62007

1453281_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

8.76758

8.13474

1.55061

1425797_A_AT

spleen tyrosine kinase

7.5153

4.06872

10.9025

1439931_AT

glycogen synthase kinase 3 beta

5.43039

7.50061

-4.19949

6.74705

8.45292

-3.26224

7.88457

5.63267

4.7631

1423380_S_AT
1440426_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 4
nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 2
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Table A5, continued.
Mean log base 2 value

Genes involved in B cell receptor signaling pathway (muscle)

BR

Ca-depl.

Fold Change
(BR/Ca-depl.)

Ca-depleted vs. BR
1423478_AT,
1460419_A_AT

protein kinase c, beta 1

7.12077

7.63148

-1.42475

1440208_AT

ras-related c3 botulinum substrate 2

7.60771

5.10076

5.68418

1453281_AT

phosphatidylinositol 3-kinase catalytic delta polypeptide

8.76758

8.02663

1.67127

1439931_AT

glycogen synthase kinase 3 beta

5.43039

7.55043

-4.34706

1456694_X_AT

protein tyrosine phosphatase, non-receptor type 6

9.7332

8.79087

1.92163

1435244_AT

vav2 oncogene

5.04971

3.08612

3.90031

1435476_A_AT,
1455332_X_AT

fc receptor, igg, low affinity iib

7.81359

8.69101

-1.83709

1424132_AT

harvey rat sarcoma virus oncogene 1

10.0517

9.80534

1.18617

1444831_AT

thymoma viral proto-oncogene 3

7.79715

5.37593

5.35622

1418262_AT

spleen tyrosine kinase

5.03188

7.06925

-4.10498

1446718_AT

nuclear factor of kappa light chain gene enhancer in b-cells
inhibitor, beta

5.6978

3.65303

4.12606

1429434_AT

phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

8.38313

7.65034

1.66186

1438999_A_AT

nuclear factor of activated t-cells 5

8.75395

7.71459

2.05531
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Table A5, continued.
Mean log base 2 value
BR

NFDM

Fold Change
(BR/NFDM)

nuclear factor of kappa light chain gene enhancer in b-cells
inhibitor, alpha

12.3429

12.0147

1.25539

thymoma viral proto-oncogene 2

10.2967

10.7973

-1.41483

fc receptor, igg, low affinity iib

9.34774

8.49187

1.80986

harvey rat sarcoma virus oncogene 1

11.166

11.5517

-1.3065

thymoma viral proto-oncogene 1

8.0511

5.99692

4.1531

ras-related c3 botulinum substrate 2
nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 1
v-ki-ras2 kirsten rat sarcoma viral oncogene homolog

7.60771

5.70503

3.73907

7.30594

6.09695

2.31175

9.09361

9.82235

-1.65718

protein phosphatase 3, catalytic subunit, gamma isoform

9.42015

10.0058

-1.50076

glycogen synthase kinase 3 beta

10.1668

9.67241

1.4087

3.61167

5.19948

-3.00593

6.7824

7.4935

-1.63705

Genes involved in B cell receptor signaling pathway (muscle)
NFDM vs. BR
1420088_AT
1421324_A_AT,
1424480_S_AT
1435477_S_AT
1422407_S_AT
1425711_A_AT,
1440950_AT
1440208_AT
1447084_AT
1454060_A_AT
1420743_A_AT
1439931_AT,
1454958_AT
1432821_AT
1425990_A_AT

nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 4
nuclear factor of activated t-cells, cytoplasmic, calcineurindependent 2
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Table A6: List of genes in GnRH signaling pathway altered in all three diet groups compared to low calcium basal restricted diet
group (BR) in muscle (step-up FDR corrected p≤ 0.05).

Genes involved in GnRH signaling pathway (muscle)
Low Ca/BCAA/ACEi vs. BR
1443540_AT
mitogen activated protein kinase kinase kinase 1
1452026_A_AT
phospholipase a2, group xiia
calcium/calmodulin-dependent protein kinase ii
1452453_A_AT
alpha
1424932_AT
epidermal growth factor receptor
1417814_AT
phospholipase a2, group v
1434653_AT
ptk2 protein tyrosine kinase 2 beta
1442679_AT
mitogen activated protein kinase kinase 4
1416572_AT,
matrix metallopeptidase 14 (membrane-inserted)
1440920_AT
1419568_AT
mitogen activated protein kinase 1
1425739_AT
phospholipase d1
1443436_AT
mitogen activated protein kinase kinase 2
guanine nucleotide binding protein, alpha q
1455729_AT
polypeptide
1431278_S_AT
phospholipase a2, group vi
calcium/calmodulin-dependent protein kinase ii
1423941_AT
gamma
1426710_AT
calmodulin 1
1426104_AT
mitogen activated protein kinase 14
1421416_AT
mitogen activated protein kinase kinase 7
1449955_AT
calcium channel, voltage-dependent, alpha 1f subunit
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Mean log base 2 value
LowCa/
BR
BCAA/ACEi

Fold change
(BR/LowCa/
BCAA/ACEi)

6.3317
9.52965

5.06658
8.52051

2.40348
2.01272

7.54691

5.2291

4.98573

8.33145
5.38723
7.56944
7.01674

9.02714
3.78561
5.29283
8.27152

-1.61966
3.03485
4.84538
-2.3863

8.5956

7.73907

1.81068

9.26914
7.28787
8.17892

8.58738
4.07639
6.25341

1.6041
9.26297
3.79869

9.01062

9.98417

-1.96366

4.40704

7.42211

-8.08403

11.4742

11.9042

-1.34725

10.8448
6.80826
8.19301
5.50168

10.3555
3.16278
7.31861
7.93108

1.40374
12.5141
1.83324
-5.38671

Table A6, continued.
Mean log base 2 value
BR

Ca-depl.

Fold change
(BR/Ca-depl.)

inositol 1,4,5-triphosphate receptor 1
calcium channel, voltage-dependent, l type, alpha 1c
subunit
mitogen activated protein kinase 8

10.6323

10.1688

1.37882

6.72737

4.49144

4.71068

9.71473

9.39732

1.24609

protein kinase c, beta 1

7.12077

7.63148

-1.42475

elk1, member of ets oncogene family

6.99614

4.30068

6.47763

1417814_AT

phospholipase a2, group v

5.38723

4.0432

2.53859

1418987_AT
1416572_AT,
1440920_AT
1437113_S_AT

phospholipase a2, group iid

8.08689

7.09444

1.98955

matrix metallopeptidase 14 (membrane-inserted)

8.5956

7.87546

1.64733

phospholipase d1

8.27096

9.02738

-1.68929

1424132_AT

harvey rat sarcoma virus oncogene 1

10.0517

9.80534

1.18617

1443436_AT

mitogen activated protein kinase kinase 2

8.17892

7.61227

1.48107

1445112_AT

adenylate cyclase 1

8.08973

6.95162

2.20093

1422414_A_AT

calmodulin 1

12.8256

12.4328

1.3129

1416703_AT

mitogen activated protein kinase 14

11.4772

11.7312

-1.19245

1451714_A_AT

mitogen activated protein kinase kinase 3

12.3122

12.7175

-1.32437

1439364_A_AT

matrix metallopeptidase 2

10.6965

10.1032

1.50874

Genes involved in GnRH signaling pathway (muscle)
Ca-depleted vs. BR
1417279_AT
1421297_A_AT
1440856_AT
1423478_AT,
1460419_A_AT
1421897_AT
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Table A6, continued.
Mean log base 2 value

Genes involved in GnRH signaling pathway (muscle)

BR

NFDM

Fold change
(BR/NFDM)

8.24018

7.28951

1.93277

8.98407

9.9863

-2.0031

4.79118

2.87368

3.77769

9.025

9.44725

-1.34002

NFDM vs. BR
1448558_A_AT
1442707_AT
1434653_AT,
1442437_AT
1422847_A_AT

phospholipase a2, group iva (cytosolic, calciumdependent)
calcium/calmodulin-dependent protein kinase ii alpha
ptk2 protein tyrosine kinase 2 beta
protein kinase c, delta

1437112_AT

phospholipase d1

4.48281

6.93238

-5.46254

1415974_AT

mitogen activated protein kinase kinase 2

10.7307

11.2635

-1.44672

1422407_S_AT

harvey rat sarcoma virus oncogene 1

11.166

11.5517

-1.3065

1431278_S_AT

phospholipase a2, group vi
calcium/calmodulin-dependent protein kinase ii
gamma
v-ki-ras2 kirsten rat sarcoma viral oncogene homolog

4.40704

6.91574

-5.69107

11.4742

12.1699

-1.6197

9.09361

9.82235

-1.65718

phospholipase c, beta 4

5.98812

7.60448

-3.066

calmodulin 1

4.07028

6.04404

-3.9279

1450186_S_AT

gnas (guanine nucleotide binding protein, alpha
stimulating) complex locus

14.7867

15.2217

-1.35187

1416703_AT

mitogen activated protein kinase 14

11.4772

11.7035

-1.1698

1451714_A_AT

mitogen activated protein kinase kinase 3

12.3122

12.5296

-1.16263

1423941_AT
1454060_A_AT
1441531_AT
1417365_A_AT,
1438825_AT,
1455571_X_AT
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